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Following sciatic nerve transection in adult rats, a proportion of injured dorsal root 
ganglion (DRG) neurons die, through apoptosis, over the following 6 months. Axotomy 
also has effects on expression of neurotrophins (NGF, BDNF, and NT-3) and their 
receptors (trkA, trkB, trkC, and p75NTR) in DRG as shown by in situ hybridisation or 
Northern blotting. Previous groups showed that administration of neurotrophin-3 (NT-3) to 
the proximal stump or intrathecally appears to prevent neuronal loss and functional 
impairment after axotomy.
This thesis tests the hypothesis that
(1) Axotomy may cause certain cells to differentiate into DRG neurons and NT-3 
may stimulate this process.
(2) Systemic NT-3 may produce morphological and biochemical changes in DRG 
that may assist regeneration.
During the course of the study, the 4th and 5th lumbar DRGs were examined up to 8 
weeks after right sciatic nerve transection and ligation. Stereology was used to estimate 
neuronal numbers, and morphological and immunohistochemical techniques were used to 
examine the incidence of neuronal apoptosis. Antibodies for p-III tubulin, trkA, trkC and 
CGRP were applied to characterise nestin-immunoreactive cells. Real-time quantitative 
PCR was used to investigate the effects of axotomy and systemic NT-3 on the mRNA 
expression of neurotrophins, their receptors and nestin in injured DRGs at various time 
points. In addition, the effects of axotomy and NT-3 treatment on neuronal genes were 
investigated by microarray.
The results obtained suggest that:
2(1) Axotomy led to 16% neuronal loss in L4 and L5 DRGs 4 weeks after injury; 
administration of NT-3 systemically for 4 weeks prevented neuronal loss, but 
did not reduce neuronal apoptosis. The appearance of nestin- and p-III tubulin- 
immunoreactive cells in these DRGs suggests an axotomy-initiated replacement 
mechanism, which was enhanced by systemic NT-3 treatment.
(2) The changes of neurotrophin and neurotrophin receptor mRNA suggest a higher 
overall responsiveness of DRG neurons to neurotrophins after axotomy and NT- 
3 treament.
(3) Microarray data showed the up-regulation of a few genes relevant to neuronal 
lineage commitment of progenitor cells following axotomy and that some 
signalling pathways were activated after axotomy and NT-3 administration. NT- 
3 may stimulate axonal regeneration after axotomy.
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17CHAPTER 1: REVIEW OF THE LITERATURE1.1  Normal appearance and structure
1.1.1  Classes of  sensory neuron in dorsal root ganglia
When dissected L4 and L5 dorsal root ganglia (DRGs) of rats appear as yellow 
fusiform swellings of the dorsal roots, measuring 2-3 mm in length. They are mainly 
composed of sensory neuron perikarya, each of them surrounded by satellite cells; in 
addition, they contain axons, myelinating and non-myelinating Schwann cells, fibroblasts, 
few mast cells, scanty extracellular matrix and blood vessels (Friede et al.,  1967; Pannese 
et al., 1995; Lieberman, 1976). The capillaries penetrating the ganglia have fenestrated 
endothelia and come from the vascular plexus within its capsule (Jacobs,  1976). Due to the 
lack of known neuron-to-neuron connections and the apparent simplicity of the tissue, 
many studies have used DRG to investigate the effects of sensory nerve injury and they 
have also been my choice to study the injury-regulated genes against the background of 
constitutive gene expression.
The DRG neurons can be divided into subpopulations by biochemical, molecular or 
physiological phenotypes each of them thought to transmit different modalities of sensory 
information (Lawson,  1992). Commitment to different neuronal lineages occurs during 
neural crest cell migration (Rifkin et al., 2000); however the molecular signals that are 
responsible for this are starting to be understood. In this review, I will concentrate on the 
functional and biochemical aspects of adult lumbar DRG neurons as they have been 
extensively studied and are particularly relevant for my study, which deals with the 
interaction between DRG cells and neurotrophins.
19Using histological DNA/RNA stains, such as cresyl fast violet and toluidine blue, to 
show Nissl (rough endoplasmic reticulum) substance clearly, DRG neurons were originally 
divided into large light cells (L neurons, 10-60 pm in diameter) with myelinated axons, 
which make up around 20-30% of the DRG neurons and the small dark cells (SD neurons, 
10-25 pm in diameter) with unmyelinated axons (see Lieberman,  1976; Lawson,  1992; 
Tandrup,  1993,  1995). L neurons contain clumped Nissl substance, which leaves lightly 
staining spaces of cytoplasm filled with neurofilaments and microtubules. The darker 
staining of the SD neurons is due to the higher density of ribosomes in their cytoplasm with 
a more homogeneous distribution. Despite the labelling “Large” and “Small” there is a 
considerable overlap between these two groups (Lawson et al.,  1984; Tandrup,  1993). L 
neurons express high levels of neurofilament protein, including the 200kD subunit NF-H, 
the 150-kD subunit NF-M and the 6 8-kD subunit NF-L. in both myelinated and 
unmyelinated axons, the axon calibre correlated well with the amount of neurofi laments 
(Friede and Samorajski, 1970). In addition, SD neurons contain peripherin, a type III 
intermediate filament protein. There is coexistence of peripherin and neurofilament-L in 
around 5.6% DRG neurons (Portier et al.,  1983; Lawson et al.,  1984; Goldstein et al.,  1991). 
DRG cells that synthesise large amounts of neurofilament proteins have more 
neurofilaments in their axons as well as in their cell bodies, and have larger diameters of 
cell bodies and axons (Portier et al.,  1983; Hoffman et al., 1987). In L5 DRG, around 70% 
of DRG neurons are SD neurons and approximately 28% are L neurons with 2% being 
unclassifiable (Tandrup, 1993). L4 DRG is probably similar, although there is no 
information about the distribution of these two types of neurons within other individual 
ganglia.
20Anatomical and electrophysiological evidence for the correlation of SD neurons 
with unmyelinated axons and L neurons with myelinated axons in the periphery has been 
described (Yoshida and Matsuda, 1979; Sugiura et al.,  1988); however,thinly myelinated 
A8 fibres may show features of either group, such as RT97 immunoreactivity (Lawson and 
Waddell, 1991). The majority of the small sensory neurons with unmyelinated axons are 
generally nociceptive (heat, cold, inflammation etc.); small, thinly myelinated axons are 
generally mechanosensory (light touch, vibration, high threshold mechanoreceptors). Those 
with myelinated axons are larger neurons; they are involved in heterogeneous functions 
such as proprioception, mechanoception and touch sensation (Lawson and Waddell, 1991, 
1993). Peripherally, proprioceptive afferents terminate on muscle spindles (la afferents) 
and Golgi tendon receptors (lb afferents) in the muscle and provide information about 
muscle length and tension to the CNS. Centrally, both la and lb afferents send projections 
to the spinal cord and synapse with interneurons; some axons ascend in the spinal cord and 
finally synapse at the medulla. In adult rats, the expression of tropomyosin-related kinase 
(trk) family receptors in DRG neurons correlates well with functions of sensory neurons 
(McMahon et al.,  1994). Most of the DRG proprioceptive neurons express trkC and only 
around 20% of them express trkA (McMahon et al.,  1994).
1.1.2  Contribution of  L4 and L5 DRGs to the sciatic nerve
The adult rat sciatic nerve at mid-thigh level, where we induced permanent damage 
by transection in this study, is composed of about 23,700-27,000 axons (Jenq and 
Coggeshall,  1985; Schmalbruch,  1986), including 19,000 sensory axons originating from 
around 10,500-11,000 ± 2,000 L4 and L5 DRG neurons, motor axons from 2,000 motor
21neurons in spinal cord segments L3-L6 (Schmalbruch, 1986; Swett et al.,  1986) and around 
6,200 sympathetic axons (Schmalbruch, 1986). The total number of L4 and L5 DRG 
neurons in an adult rat is around 27,000 (Schmalbruch,  1987b; Groves et al.,  1999; Groves 
et al., 2003), which is much more than the number of sensory neurons whose axons extend 
through the mid-thigh level; therefore the axons of remaining neurons may exit before they 
enter the sciatic nerve and go to areas such as the viscera, the pia (Risling et al.,  1994), the 
muscles and the skin above the cut. It is calculated that mid-thigh sciatic nerve transection 
axotomises around 50-70% of L5 DRG neurons (Devor et al.,  1985; Himes and Tessler, 
1989). An increasing number of postnatal DRG neurons has been reported in 3 studies 
(Devor et al., 1985; Popken and Farel, 1997; Farel, 2002); therefore the ratio of right: left 
was used in my study to avoid the uncertainty of comparing the absolute number of 
neurons at different ages. However, the relative individual contribution of L4 and L5 DRG 
neurons to the sciatic nerve is unclear.
Using WGA-HRP/HRP labelling method, Swett et al. (1991) reported that 98.4 % 
of sciatic sensory axons are contributed to by L4 and L5 DRGs in the rat whereas L3 and 
L6 DRGs contribute 0.3 and 1.2% respectively. Therefore, L4 and L5 DRG neuron counts 
are pooled together in this study instead of looking at individual ganglion neuron numbers.
1.1.3  Interaction with other components in DRG
In DRG, sensory neurons are surrounded by a perineuronal microenvironment 
(Pannese et al., 1994), which mainly consists of satellite cells, Schwann cells and the 
extracellular matrix. The satellite and Schwann cells are known to provide trophic support 
to sensory neurons with which they are associated (Heumann et al.,  1987), induce neuronalmaturation in vitro (Mudge, 1984) and affect the axon diameter (de Waegh et al., 1992). In 
turn, DRG neurons are also able to influence these supporting neuroglial cells, and regulate 
their proliferation, differentiation and maturation (Wood and Bunge, 1975; Jessen et al., 
1987).
1.2  Characteristics of neurotrophins and their receptors
In mice and rats, four members of neurotrophin family have been identified: nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
and neurotrophin-4/5 (NT-4/5) (Levi-Montalcini and Cohen,  1960; Barde et al.,  1982;
Hohn et al.,  1990; Berkemeier et al., 1991). Neurotrophin genes are translated into pro­
proteins that are a little longer than 2 0 0 amino acids, which are then cleaved by proteases, 
such as plasmin and selective matrix metalloproteinases, and released as a mature C- 
terminal biologically active peptide. These form neurotrophin dimers by non-covalent 
bonds, slightly shorter than 120 amino acids long in mammals; approximately 50% of the 
amino acids are conserved in all neurotrophins. These factors act largely through trk family 
receptors, each of them expressed in a subpopulation of DRG neurons, with NGF 
interacting with its preferred receptor trkA, BDNF and NT-4 with trkB, and NT-3 with trkC. 
NT-3 also binds to trkA and trkB, although with significantly lower affinity, and NT-3 has 
been shown to initiate trkA signalling and cellular responses, and is required to maintain 
trkB-expressing neurons during neurogenesis in development (Clary and Reichardt, 1994; 
Davies et al., 1995; Farinas et al., 1998). Truncated isoforms of trkB and trkC have been 
characterised which lack most of the sequence for the cytoplasmic region, including the
23protein tyrosine kinase domain, of the full-length isoforms (Klein et al.,  1990a; Middlemas 
et al.,  1991; Tsoulfas et al., 1993; Valenzuela et al.,  1993).
The low affinity neurotrophin receptor p75N TR can also interact with all of these 
neurotrophins and regulate intracellular signalling pathways. The two classes of 
neurotrophin receptors, high- and low-affinity, are physico-chemically distinguished by 
their dissociation constants of 10'n/10' 10 MM and 10'9 M, respectively (Sutter et al.,  1979). 
ProNGF also binds to p75N TR and trkA with higher and lower affinity respectively than that 
exhibited by mature NGF, and can induce apoptosis (Lee et al., 2001), but whether other 
pro-neurotrophins can activate p75N TR  and trigger apoptosis is not well known.
These neurotrophins are secreted by target organs, internalised by interacting with 
trk receptors, and retrogradely transported to the cell soma, in which activating intracellular 
signalling pathways, such as the ras/raf/mitogen-activated protein (MAP) kinase pathways, 
the phosphatidylinositol 3’(PI-3)-kinase/Akt pathways and the phospholipase C-y (PLCy) 
pathway, regulate adult sensory neurons (Vetter et al.,  1991; Obermeier et al.,  1993; Baxter 
et al.,  1995; Goldberg and Barres, 2000). NGF, BDNF and NT-3 mRNAs are also 
expressed in uninjured DRG neurons (Zhou et al.,  1999b), and are essential for the survival 
and phenotypic differentiation of sensory neurons during development.
Most of the early studies on neurotrophins in development were performed in 
chicken and mouse. During embryonic development in these animals, neural crest cells 
migrate, proliferate, aggregate and coalesce lateral to the neural tube to form the nascent 
DRG. Neurons are then derived from neuronal crest stem cells in the DRG (Weston,  1963; 
Sharma et al.,  1995), with larger diameter neurons, including proprioceptive neurons, born 
and differentiated prior to the smaller neurons (Lawson et al.,  1974; Carr and Simpson,
241978); a majority undergo programmed cell death after the postmitotic stage, when 
differentiating neurons project axons toward their cutaneous, muscle and visceral targets 
and both birth and death of neurons happens simultaneously in nascent DRG (Farinas et al., 
2002). In mice, null mutants of the genes encoding all neurotrophins and their receptors 
have been generated to analyse their effects on neuronal development (Snider and Silos- 
Santiago, 1996).
1.2.1  Early sensory development and neurotrophic hypothesis
The mouse DRG neurons derive from the neural crest cells that migrate to a 
dorsolateral position along the neural tube at E9 and coalesce into somite-related clusters to 
form the discernible ganglia at E10 (Farinas et al., 2002). Subsequent cell proliferation, 
studied by BrdU incorporation, and addition of new migrating neural crest cells result in 
the rapid enlargement of ganglia. Nearly all the DRG neurons are generated between E10 
and El 3 with the peak rate of neurogenesis between El 2-El 3 (Lawson and Biscoe,  1979). 
In the developing peripheral nervous system of mice, DRG neurons initiate axon elongation 
immediately after they are generated at as early as E10. Many neurons die shortly after 
their axons have reached their target fields, possibly because the limiting amounts of 
neurotrophic factors in target organs which new neurons innervate select only the specific 
neuronal subpopulations which obtain enough substance and eliminate the remaining 
through programmed cell death (Barde et al., 1989; Barde, 1994; Purves et al.,  1996). This 
is known as the neurotrophic hypothesis and was formulated to account for the behaviour 
of sensory and motor neurones during the latter stages of development during which the 
total population was reduced by approximately 50%. However, the epidermis in trunk and
25proximal limbs are innervated at around E l3 and distal limbs are innervated at as late as 
E l8; furthermore, trkC knockout mutants have elevated apoptosis in lumbar DRGs at El 1  
before their axons approach their target organs support (Coggeshall et al.,  1994; Farinas et 
al., 1996). Therefore, the neurotrophic hypothesis can only describe a small part of 
neurotrophin action on sensory neurons; even during development neurotrophins have 
function that exceeds their role in assuring neuronal survival, and they may act on the 
differentiation of precursor cells and continue to act on sensory function in the adult 
(Farinas et al.,  1996). The neurotrophic hypothesis implies that neurotrophins are derived 
from the target organ, but it has been shown that a broader distribution of these 
neurotrophins exists also in sensory nervous system (Shen et al.,  1999a; Zhou et al.,  1999b).
1.2.2  Nerve growth factor (NGF)
Nerve growth factor (NGF), the best characterised member of the neurotrophin 
family, was first identified by Levi-Montalcini (1960) and plays an important role in the 
development and survival of sympathetic and a subpopulation of sensory neurons in DRG 
(Levi-Montalcini and Cohen,  1960; Levi-Montalcini and Angeletti,  1963). It may function 
as a mediator of some persistent pain and controls the “activity” of trkA-expressing 
nociceptive neuron; trkA-IgG administration has been shown to produce a sustained 
thermal and chemical hypoalgesia (McMahon et al.,  1995; Malcangio et al., 2000). Some of 
its actions are mediated by its high affinity receptor trkA, and it plays a role in the 
maintenance and regeneration of mature peripheral neurons (Kaplan et al., 1991). NGF also 
mediates its effects via the low affinity neurotrophin receptor p75N TR (Johnson et al.,  1986). 
NGF is mainly synthesised in skin, a major target of nociceptive sensory neurons, and also
26in a subpopulation of DRG neurons (Zhou et al., 1999b). At El 1.5 in the mouse, NGF 
mRNA starts to be detectable in the surface ectoderm of the developing hindlimb 
(Schecterson and Bothwell,  1992; White et al.,  1996). The expression of NGF transcripts 
increases from E13.5 to El 5.5, when NGF is strongly expressed in the epithelium of the 
hindlimb epidermis and subjacent mesenchyme (White et al.,  1996). Increased cell death 
from E ll to E l3 in both NGF and trkA null mutant mice shows the synchronous onset of 
NGF and trkA survival dependence in the developing DRGs (Farinas et al., 2002).
In the adult, NGF mRNA expression can be detected in DRG (Shelton and 
Reichardt, 1986; Zhou et al., 1999b). The fact that antiserum to NGF does not result in 
further decrease of cell number in DRGs after postnatal day 2 shows that NGF is required 
for survival of lumbar DRG neurons mostly during development, but not in the adult 
(Tonraand Mendell, 1998). However, 5-week NGF antiserum administration starting from 
postnatal days 4 to 11 switches many A6- high nociceptive afferents to be high-threshold 
D-hair afferents, thus revealing the functional importance of NGF in neonatal rats (Lewin 
et al., 1992).
1.2.3  Brain-derived growth factor (BDNF) and NT-4/5
BDNF was first purified from mammalian brain (Barde et al.,  1982) and its amino 
acid sequence shows about 40% homology with that of NGF. BDNF, which acts through 
the trkB and p75N TR receptors, is synthesised in a small subpopulation of sensory neurons, 
predominantly NGF-responsive, trkA-expressing neurons, both during development and 
adulthood. (Ernfors et al.,  1990; Schecterson and Bothwell,  1992; Apfel et al.,  1996; 
Michael et al.,  1999); this neurotrophin may maintain the survival of a subpopulation of
27sensory neurons through an autocrine or paracrine loop; in addition it is anterogradely 
transported, probably to provide trophic support for peripheral sensory organs and 
postsynaptic neurons within the spinal cord (Acheson et al., 1995; Zhou and Rush, 1996; 
Michael et al., 1999). At El 1   in murine embryos, expression of BDNF mRNA can be 
detected in dermal mesenchyme, which is a target of sensory neurons, but not within the 
mesenchyme immediately adjacent to DRG cells (Schecterson and Bothwell,  1992). BDNF 
promotes the survival of a subpopulation of neurons at El 1, but exerts no effects at E 12- 
El 8 in vitro’ , it appears to have survival promoting property at postnatal day 7 (P7), when 
35% of DRG neurons in culture are rescued by BDNF (Lindsay et al.,  1985; Acheson et al., 
1995). NT-4/5, also acting through trkB, is a survival factor for a specialised type of 
mechanoreceptive neuron, called a D-hair receptor, in the adult DRG (Stucky et al., 2002).
1.2.4  Neurotrophin-3 (NT-3)
In mice, NT-3 mRNA is expressed in mesenchymal cells in the dermamyotome 
immediately adjacent to the DRG and in muscle precursors in the proximal limb bud 
between E10 and E12 before their axons have reached their peripheral targets (Farinas et al., 
1996; White et al., 1996); later in development at E l3.5, it appears in all developing 
paraxial and hindlimb muscle precursors along the growing nerves, and it is expressed in 
the intrafusal muscle fibres of the muscle spindles, Golgi tendon organs, Merkel cells and a 
subpopulation of DRG neurons after muscle spindle innervation (ElShamy and Ernfors, 
1996; Farinas et al., 1996; White et al., 1996; Copray and Brouwer, 1997); knockout of 
NT-3 gene leads to the excessive death of proliferating sensory precursor cells as early as 
El 1  (ElShamy and Ernfors,  1996; White et al.,  1996), and prevents sensory precursor cells
28from differentiating into NT-3 dependent neurons, instead overriding the G1  phase 
restriction point and dying by apoptosis in S phase (ElShamy et al.,  1998). In vitro, El 1  
DRG neurons can survive without exogenous NT-3 for at least 1  day, but anti-NT-3 
antiserum or NT-3 null mutation can lead to their death (Vogel and Davies,  1991; ElShamy 
and Ernfors, 1996); this shows that in early development DRG neurons may synthesise NT- 
3 to support their own survival. Not only affecting postmitotic neurons, NT-3 knock-out 
mice show premature differentiation of precursor cells between E ll and E12 without 
changes in rates of their proliferation or apoptosis, resulting in early depletion of the pool 
of precursor cells (Farinas et al., 1996). In migrating murine neural crest cells, trkC mRNA 
can be detected by radioactive in situ analysis (Tessarollo et al.,  1993); however, these cells 
do not express detectable levels of any trk receptor protein due to proposed translational 
repression (Farinas et al., 1998). Therefore, actions of any neurotrophin on precursor cells 
are suggested to be indirect.
In NT-3 homozygous knockout mutant mice, around 60-70 % of DRG neurons are 
lost between E10.5 and El 3, involving all subpopulations of neurons (Ernfors et al.,  1994; 
Farinas et al.,  1996), but trkC knockout mutant mice only results in  17-30% loss (Klein et 
al.,  1994; Minichiello et al.,  1995). These discrepancies suggest that NT-3 can support 
survival of embryonic sensory neurons via trkA or trkB signalling rather than through its 
preferred receptor trkC (Davies et al.,  1995). However, when trkA and trkB are expressed 
in P12 cells, they can only be activated by NT-3 at concentrations  100-fold higher than 
their preferred ligands, NGF and BDNF (Ip et al.,  1993; Farinas et al.,  1998).
Application of exogenous NT-3 during the formation of sensory ganglia in chick 
embryos results in a marked decrease in neuronal numbers, possibly due to the premature
29cessation of sensory precursor cell proliferation and initiation of differentiation (Ockel et 
al.,  1996b; ElShamy et al., 1998). However, administration ofNT-3 at later developmental 
stages increases neuronal number, presumably by preventing programmed cell death in 
DRG (Ockel et al.,  1996a). In rats, administration of antiserum against NT-3 for 2 weeks 
from postnatal day 1  results in a 20% reduction of the number of L5 DRG neurons, a 25% 
decrease of the DRG weight, a 19% reduction in the number of myelinated axons in the 
saphenous nerve, and a significant shift toward the left in the size distribution histogram of 
neurons. However number or appearances of muscle spindles is not affected; it is not clear 
which subpopulation of sensory neurons is lost (Zhou et al.,  1998).
In adult animals, NT-3 is synthesised both in muscle and skin (Copray and Brouwer, 
1994; Kennedy et al.,  1998; Botchkarev et al., 2000). In addition, NT-3 protein and mRNA 
is expressed in a subpopulation of large neurons, as well as in some small sensory neurons, 
without any detectable signal in non-neuronal cells in uninjured DRGs (Zhou and Rush, 
1995; Zhou et al., 1999b).
1.2.5  Tyrosine kinase receptors: trkA, trkB and trkC
TrkA was originally identified as a proto-oncogene isolated from colon carcinoma 
cells, and was then found to mediate the biological effects of NGF (Martin-Zanca et al.,
1986; Klein et al., 1991). Activation of high-affinity trk receptors (KD~10'n/10' 10 M) by 
neurotrophins was later found to lead to the initiation of signal transduction cascades 
involved with proliferation, survival and differentiation of PNS and CNS neurons (Segal 
and Greenberg,  1996).
30During development, neurogenesis in nascent DRGs is initiated shortly before E10 
and shows a burst of neuron formation between E12 and E13 in mice (Farinas et al.,  1996). 
Although mRNAs for trkB and trkC were observed in migrating neural crest cells in the 
mouse, their proteins seem to be synthesised concomitantly with neuronal differentiation 
(Klein et al., 1990b; Tessarollo et al.,  1994). At El 0.5-El 1   in mice, when more than 60% 
of DRG cells are precursors, trkC protein is expressed by most of the DRG neurons, 
whereas trkB is present in a modest subpopulation of cells and only low levels of trkA are 
present (Farinas et al.,  1998). Lack of neuronal precursors or neuronal loss at El 0 in 
neurotrophin knockout mutant mice is consistent with the absence of expression of 
detectable trk proteins by migrating neural crest cells, which are therefore not affected by 
the lack of neurotrophins at that time point (Farinas et al.,  1996; White et al., 1996; Liebl et 
al.,  1997). In NT-3 null mutant mice at El 1, a reduction of 35% and 6 8% of trkB and trkC - 
expressing neurons, respectively, was observed without any loss of trkA-expressing 
neurons (Farinas et al., 1998). Therefore, the direct activation of trkB by NT-3 in vivo has 
been suggested to explain their finding. From El 1-13.5, trkA expression increases steadily 
and appears in the majority of cells; however trkC decreases to be only expressed in a 
minority of DRG cells (Figure 1.1) (Farinas et al.,  1998). At E 11.5 in mice, trkA-positive 
axons start penetrating into the central region of the proximal hindlimb, approaching 
cutaneous targets in proximal hindlimb at E l3.5, when the central projections are still 
limited to the dorsal root entry zone (White et al.,  1996). By El 5.5, some of the trkA- 
expressing axons reach the most distal portion of the hindlimb and the central axons also 
reach grey matter in the spinal cord (White et al.,  1996). The onset of trkA and NGF 
dependence by El 3.5 is synchronous and of equal magnitude, suggesting that the samepopulation of DRG cells requires both molecules (White et al.,  1996). By El 5, 
approximately 80% of DRG neurons express trkA mRNA and protein (White et al.,  1996). 
After birth, trkC is mainly expressed in large DRG neuron. TrkB expression undergoes no 
obvious changes during this period of development, being expressed only by very few (6%) 
DRG neurons at E l8 (Mu et al.,  1993). The factors regulating the shift of trk expression 
during development are not clear. Using BDNF null mutant mice, it has been shown that 
endogenous BDNF is not required for the developmental induction of trkB expression and 
the onset of BDNF dependence in sensory neurons (Huber et al., 2000).
In adult, trkA is expressed in 35-45% of neurons, trkB in 20-33%, and trkC in 20- 
43% lumbar DRG neurons (Verge et al., 1992; McMahon et al.,  1994), these receptors are 
also expressed on afferent fibres. Some of the trkC-expressing neurons are small cells, but 
primarily are medium to large sized cells (McMahon et al., 1994; Wetmore and Olson, 
1995; Karchewski et al., 1999). Around 45% of the lumbar DRG neurons, mostly small 
neurons with unmyelinated axons that express calcitonin gene-related peptide (CGRP) and 
substance P, express trkA (McMahon et al.,  1994; Averill et al.,  1995). Chemical, thermal, 
and mechanical stimuli may all evoke pain when applied to the skin. Noxious stimuli are 
translated into electrical activity at the sensory endings of nerves and then the impulses are 
propagated throughout the sensory nervous system. CGRP and substance P, two important 
neuropeptides in the transduction of pain in the spinal cord, are synthesised in a subset of 
DRG neurons and released from the peripheral terminals of sensory nerves to induce 
inflammation by stimulating vasodilatation, inducing plasma extravasation and stimulating 
mast cell degranulation to release inflammatory mediators such as histamine and serotonin 
(Maggi et al.,  1993).
32Analysis of neuronal profiles shows that trkA, trkB and trkC can be expressed in 
neurons of all size categories. Co-localisation studies show that approximately 10% of 
DRG neurons co-express trkA and trkB mRNA;  18% coexpress trkB and trkC mRNA, and 
19% coexpress trkA and trkC mRNA (McMahon et al.,  1994; Wright and Snider,  1995). 
Localisation of all three trk mRNAs is seen only in 3-4% of neurons (Karchewski et al.,
1999). Only 16%, 9% and 10% of the DRG population express one trk receptor (trkA, trkB 
and trkC respectively) to the exclusion of the others (Karchewski et al.,  1999). The trkA- 
expressing neurons have a mean cross-section area 5-10% smaller than the mean value of 
the total population in lumbar DRGs; however, trkB and trkC-expressing cell profiles have 
a 5% and 25-50% larger than average area, respectively (Bergman et al.,  1999).
In the DRGs of NGF or trkA knockout mutant mice, approximately 70-82 % of the 
DRG neurons are missing, including those which express trkA postnatally (Crowley et al., 
1994; Smeyne et al.,  1994; Silos-Santiago et al.,  1995) and the subpopulation of non- 
peptidergic small-diameter neurons, which bind the Bandeiraea simplicifolia isolectin (IB4), 
with unmyelinated axons which may mediate non-nociceptive thermal and low threshold 
mechano-receptive stimuli (Silos-Santiago et al.,  1995), but it is clear that many of them 
express TRP VI and are therefore likely to be nociceptors. The latter neurons, accounting 
for a third of adult DRG neurons, depend on NGF transiently during embryonic 
development, and then switch their dependence from NGF to glial cell line-derived 
neurotrophic factor (GDNF) postnatally (Bennett et al.,  1996b; Molliver et al.,  1997).
These cells start to express Ret during perinatal development (Molliver et al.,  1997), which 
is part of a common receptor complex for GDNF and neurturin (Bennett et al.,  1998).
33Physiologically, conduction velocity (CV) of sensory axons significantly slowed by 
1  week after peripheral axotomy, affecting all fibre sizes, especially those of larger 
diameter (Munson et al.,  1997). Treatment with trkB-IgG or trkC-IgG fusion proteins at the 
dose of 12 pg/d into the region of the gastrocnemius muscles for 2 weeks in normal rats to 
sequester BDNF and NT-3 does not reduce CV of gastrocnemius sensory neurons, but a 
higher dose of trkC-IgG at 60 pg/d results in a significant reduction in CV (Munson et al.,
1997). NT-3 administration to the proximal stump of tibial nerve (60 pg/d) for two weeks 
after 3 week axotomy partly rescues the decrease of CV. These results imply that NT-3 
continues to play a role in physiological functions of a subpopulation of DRG neurons in 
adult rat (Munson et al.,  1997).
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Figure 1.1: Numbers and percentages of trkA, trkB, trkC protein-expressing neurons in 
early LI  DRG in mice (Farinas et al.,  1998). Virtually all cells expressing any trk receptor 
were also labelled by antibodies to the  150kDa neurofilament, and no proliferating 
precursors, labelled by bromodeoxyuridine (BrdU), coexpressed a trk receptor.
1.2.6  Intracellularly-spliced trk receptor isoforms
By alternative splicing, the trkB and trkC loci additionally encode a few isoforms 
which lack the intracellular catalytic tyrosine kinase domain, but either include instead 
alternative cytoplasmic domains, or have insertions in the tyrosine kinase domains (Klein et 
al.,  1990a; Tsoulfas et al.,  1993; Valenzuela et al..  1993). These, named “non-catalytic” or 
“truncated”, domains are highly conserved across species; the intracellular truncated 
domains in trkB isoforms are different from those in trkC isoforms (Gamer and Large,
1994; Armanini et al.,  1995). 8 isoforms of trkC have been identified in the chick and 
mammal (Tsoulfas et al.,  1993; Valenzuela et al.,  1993; Garner and Large,  1994), and
35different isoforms may mediate distinct activities in immature and mature DRGs. Although 
no signalling molecules downstream have been identified, the importance of these 
truncated isoforms in signalling pathways is suggested due to the highly conserved 
intracellular domains in human, mouse, rat and chicken (Garner and Large,  1994; Baxter et 
al.,  1997). The truncated trkC isoforms are widely expressed in normal mouse development, 
throughout the CNS and PNS, including the DRGs. Overexpression of truncated trkC 
transgene in the mouse results in DRG neuronal loss between El 1.5-El3.5 as cells are 
prematurely driven out of the cell cycle with differentiation of neural progenitor cells; this 
effect resembles that of early depletion of precursor cells in the NT-3 null mutants. The 
overexpressed truncated trkC may promote neural differentiation, with the collaboration of 
p75N TR, in some cells (Hapner et al.,  1998; Palko et al.,  1999). Other isoforms with peptide 
insertions in the tyrosine kinase domain are still phosphorylated by their ligands, but are 
limited in their signalling potential (Garner and Large,  1994). Targeted deletion of the 
entire gene for trkC in mice leads to a more severe defect of the nervous system than in 
mice in which only the catalytic isoform has been deleted (Liebl et al.,  1997; Tessarollo et 
al.,  1997). The exact functions of these trk isoforms during neural development and in the 
adult are not completely known.
Outside the nervous systems, the trk receptors, mostly truncated isoforms, are also 
expressed during development, in lymphocytes, spleen, tooth, salivary gland, lung, heart, 
thyroid gland, kidney, muscle, testis and hair follicle, suggesting that they may not be 
transducing neurotrophin signals but rather acting as scavenger or dominant negative 
receptors (Middlemas et al.,  1991; Tessarollo et al.,  1993; Eide et al.,  1996; Menn et al.,
1998). Truncated trkC isoform is important in the morphogenesis of the cardiac outflow
36tract, and the differentiation, maintenance and function of monocytes, lymphocytes and 
mast cells (Burgi et al., 1996; Hiltunen et al., 1996; Levi-Montalcini et al., 1996); indeed 
NT-3 knockout mutant mice were found to have cardiac defects (Donovan et al.,  1996; 
Srivastava and Olson,  1996).
1.2.7  Extracellularly-spliced trk receptor isoforms
Alternative splicing of an exon can occur in the extracellular domain of trkA and 
trkB, resulting in isoforms (Barker et al., 1993). These are only present in chick and man, 
not in rodents (Strohmaier et al., 1996). The trkB isoform, which can bind BDNF with 
similar affinity to its full-length receptor, has reduced affinities for NT-4/5 and NT-3; in 
contrast, the trkA isoform has a higher affinity for NT-3 (Clary and Reichardt,  1994).
1.2.8Low-affinity neurotrophin receptor:p75N TR
The low-affinity neurotrophin receptor p75NTR, which is the prototypic member of 
the tumour necrosis factor (TNF) receptor family, is a transmembrane glycoprotein of 75k 
Da which exhibits lower affinity binding (Kd=10‘9 M) for all neurotrophins than their 
preferred trk receptors. Its expression is widespread in most dividing progenitor and post­
mitotic neurons in developing DRG with a peak at El 1.5-E12.5 in mice (Schecterson and 
Bothwell,  1992; Snider et al.,  1992). It does not have a known intrinsic ligand-inducible 
enzymatic function, but it is able to induce signalling independently and modify the binding 
and signalling capabilities of trk receptors (see Roux and Barker, 2002). The coexpression 
of p75N TR exerts conformational changes in trkA and enhances the affinity of trkA- 
expressing neurons for NGF binding at low concentrations (Hempstead et al.,  1991;
37Hantzopoulos et al., 1994). p75NTR affects the retrograde axonal transport of neurotrophins 
and may be functionally important during normal development, when tissue levels of 
neurotrophins are a limiting factor (Bothwell, 1995; Curtis et al.,  1995). NGF and BDNF 
binding is more affected by p75N TR expression than NT-3 binding. On the majority of 
migrating neural crest cells, p75NTR, both in mRNA and protein, is broadly and strongly 
expressed (Rifkin et al., 2000).
In vitro studies show that p75N TR suppresses the ability of trkA to respond to NT-3 
(Clary and Reichardt, 1994; Mischel et al., 2001); NT-3 only activates trkA signalling in 
PC 12 rat pheochromocytoma cells, which extend neurites and differentiate into neuron-like 
cells upon exposure to NGF (Greene and Tischler,  1976), when p75N TR levels are reduced 
(Benedetti et al., 1993). In p75N TR'ANGF+/' mutant mice, endogenous NT-3 can activate 
trkA receptors to compensate for reduced levels of NGF in sympathetic neurons and there 
is no reduction of neuron number in superior cervical ganglia (SCG) of these mice 
(Brennan et al.,  1999). However, controversial findings from two groups leaves open the 
question of whether the coexpression of p75N TR and trkB decreases trkB phosphorylation in 
response to NT-3 or other neurotrophins (Bibel et al., 1999; Vesa et al., 2000).
In adult rodents, approximately 50% of trkC-expressing neurons express p75N TR 
(Wright and Snider, 1995), and 55-79% of neurons of all sizes express p75N TR (Zhou et al., 
1996; Bergman et al., 1999; Karchewski et al., 1999). p75N TR is also present in some 
satellite cells (Zhou et al.,  1996). Co-localisation of p75N TR with trks is higher during 
development, when both trkC and p75N TR receptors are more widespread and p75N TR 
expression reaches a peak at El 1.5-El2.5 (Schecterson and Bothwell,  1992). p75N TR 
receptor is not essential for the development of proprioceptive neurons to fast, but not slow
38(e.g. soleus muscle), hindlimb muscle in mice when NT-3 is expressed at normal levels. 
However, when NT-3 expression decreases, p75N TR may act in synergy with NT-3 to 
enhance the survival of proprioceptive neurons (Fan et al.,  1999). Other potential roles for 
p75N TR include the modulation of trk signalling capabilities (Verdi and Anderson, 1994), 
inhibition or promotion of apoptosis (Rabizadeh et al., 1993), and activation of a signal 
transduction pathway by neurotrophins that involves the hydrolysis of sphingomyelin 
(Dobrowsky et al.,  1995). This versatile receptor uses different ligands in distinct cell types, 
embryonic development, or following injury to mediate cell motility, proliferation, survival 
and death (Ibanez, 2002; Roux and Barker, 2002).
1.2.9 Spliced p75NTR isoform
Alternative splicing of exon III in the p75N TR gene, which encodes the extracellular 
cysteine-rich domains essential for the binding of neurotrophins, occurs in human, mouse, 
rat and chick (Dechant and Barde, 1997). This short isoform, called s-p75NTR, shares 
identical transmembrane and cytoplasmic domains with the full-length p75N TR and may act 
as a modulator of the full-length receptor.
1.2.10 Molecular interactions between trk receptors andp75N TR
Biochemical experiments show that neurotrophin receptors may form three kinds of 
complexes: homodimers of trk receptors, homomeric p75N TR complexes and heteromeric 
complexes containing both trk and p75N TR receptors. These complexes coexist in some 
neurons and transduce independent, synergistic or antagonistic signalling. In vitro studies 
indicate that p75N TR interacts differently with different types of trk receptors. Co­
39expression with p75N TR in PC 12 rat pheochromocytoma cells enhances NGF signalling via 
trkA by increasing trkA tyrosine autophosphorylation, and desensitises trkA to NT-3 
(Benedetti et al.,  1993; Verdi and Anderson,  1994).  However, p75NTR has either a negative 
or positive effect on BDNF and NT-4/5 signalling via TrkB depending on the cellular 
system (Bibel et al., 1999; Vesa et al., 2000). Coexpression of p75NTR does not change the 
autophosphorylation of trkC by binding of NT-3 in an MG87 fibroblast cell line (Vesa et al.,
2000). In addition to the interactions between trk receptors and p75NTR at the level of 
physical association of the proteins, interactions between p75N TR and trk signalling 
cascades are also indicated (Bilderback et al., 2001).
1.2.11 Interaction of neurotrophins with their receptors
After binding to trk receptors, neurotrophins and their phosphorylated receptors are 
taken up via clathrin-dependent mechanisms into intracellular small vesicles, forming 
complexes. Endocytosed complexes, which differ according to the cell-type and 
neurotrophin involved, are retrogradely transported to cell body and induce signal 
transduction (Ehlers et al.,  1995; Bhattacharyya et al.,  1997; Grimes et al.,  1997). p75N TR 
may modulate trkA internalisation and change its signalling spectrum (Gargano et al.,
1997). Other than being retrogradely transported, the receptors in complexes may reappear 
back to the membrane surface or be degraded. Therefore, the trk receptors that respond to 
neurotrophins can either be newly synthesised or recycled from the signal transducing 
vesicles (Eveleth and Bradshaw, 1988).
1.2.12 Signal transduction
40The effects of neurotrophins binding to their receptors are believed to involve the 
activation of intracellular protein kinases. Multiple parallel signalling pathways have been 
found to be involved in neuronal survival. Particularly, three intracellular pathways seem to 
be important in mediating survival, differentiation and neurite growth of sensory neurons 
(Obermeier et al., 1993; Baxter et al.,  1995; Goldberg and Barres, 2000):
1) The ras/raf/mitogen-activated protein (MAP) kinase pathway
2) The phosphatidyl inositol 3’-kinase (PI-3 kinase)/Akt pathway
3) The phospholipase C-y (PLCy) pathway
MAP kinase signal transduction seems essential for NGF-stimulated outgrowth of 
adult DRG nociceptive neurons (Thomas et al.,  1992; Jaiswal et al.,  1994) and this effect is 
blocked by PD98059, which inhibits the MAP kinase activator MEK (Wiklund et al., 2002). 
■  In contrast, inhibition of MAP kinase enhances NT-3-stimulated outgrowth, which suggests 
differences in the trkA and trkC intracellular signalling pathways.
In the MAP kinase pathway, activated trk receptors on cell bodies induce GTP- 
loading and activation of Ras. Ras-GTP recruits a three-tiered enzyme cascade in which a 
Raf phosphorylates and activates Erk-1/2, which then translocates from the cytoplasm to 
the nucleus and activates ribosomal S6 kinase (Rsk). Activated Rsk then phosphorylates the 
transcription factor Ca2+/cAMP response element binding protein (CREB) at Ser 133 
subsequently activating cAMP response element (CRE)-mediated gene expression, leading 
to alterations in gene expression (English et al.,  1999; Finkbeiner, 2000; Chang and Karin,
2001). Rsk also phosphorylates Bad, which is a member of bcl-2 family that blocks cell 
survival by binding to another member of bcl-2 family, Bcl-xL, in its unphosphorylated 
form, to inhibit its pro-apoptotic activity. In addition to Rsk, other neurotrophin-induced
41CREB kinases have been identified, including MAPK-activated protein kinase-2, Ca2+- and 
calmodulin-dependent kinase IV and protein kinase B (Finkbeiner, 2000). Ras activity is 
necessary for the survival of sensory neurons (Borasio et al.,  1993), but the activities of its 
downstream effectors, Raf, Mek and Erk are not (Creedon et al.,  1996). The Erk-5 pathway 
is also activated by neurotrophins and leads to CREB activation. These MAP kinases 
activate different groups of transcription factors; Erk-1/2 phosphorylates Elk-1 and c-Myc, 
whereas Elk-5 activates MEF2. However, using neuron culture in compartmented chambers 
with the cell body in one chamber and axon terminals in an adjacent chamber, neurotrophin 
stimulation of axon terminals resulted in localised activation of Erkl/2 and Erk5, but only 
activated Erk5 mediates retrograde signalling to the nucleus, which also leads to nuclear 
translocation of Erk5, phosphorylation of CREB, activation of MEF2 transcription factor 
and enhanced neuronal survival (Mao et al., 1999; Watson et al., 2001). In PC 12 cells, the 
Ras cascade is necessary and sufficient for neurite outgrowth induced by NGF, but the 
cascade mediating differentiation of primary neurons from PC 12 cells is still not clear 
(Creedon et al., 1996).
The PI-3 kinase/Akt intracellular pathways regulate NGF-stimulated neuronal 
survival (Yao and Cooper, 1995). PI-3 kinase is composed of a SH2-containing 85 kDa 
regulatory subunit and a 1  lOkDa catalytic domain. Activated PI-3 kinase catalyses the 
formation of lipid second messengers, which activate the serine-threonine kinase Akt 
(Burgering and Coffer,  1995; Franke et al.,  1997). Akt leads to cell survival via two 
possible pathways. One is through phosphorylation of Bad, which decreases its capability 
to bind to bcl-2 and bclxL and that promotes cell survival (Finkbeiner, 2000); another 
possible mechanism includes inactivation of caspase-9 (Yao and Cooper,  1995). PI-3
42kinase activity is also required for neurotrophin-induced survival of sensory neurons 
(Crowder and Freeman,  1998), consequently it has been proposed that the PI-3 kinase 
cascade is downstream of Ras in primary sensory neurons (Rodriguez-Viciana et al.,  1994). 
Both the MAP kinase and PI-3 kinase pathways converge on two proteins, Bad and CREB, 
to inhibit apoptosis and promote survival.
Activation of trks also triggers other signalling pathways such as the PLCy pathway 
(Vetter et al., 1991). PLCy binds to the phosphorylated trk receptors through src-homology 
domain 2 (SH2) and catalyses the breakdown of phosphoinositol 4,5-bisphosphate to 
diacylglycerol and inositol triphosphate, which then activate protein kinase C and also lead 
to an increase of intracellular calcium.
It is still an open question whether all of the neurotrophins signal through conserved 
intracellular cascades and if the cross talk between trk receptors and p75N TR determines the 
intracellular signalling mechanism. p75N TR has been shown to signal independently through 
activation of a sphingomyelin-based pathway to activate nuclear factor-kappa B (NFkB), 
jun-N terminal kinase (JNK), and ceramide to induce cell apoptosis (Carter et al., 1996; 
Casaccia-Bonnefil et al., 1996), although the signalling appears to be inhibited by trkA 
activation (Dobrowsky et al., 1995).
A limitation of the studies on signal transduction is that most of the biochemical 
studies of trk-related signalling pathways were performed in PC 12 cells, instead of primary 
sensory neurons. PC 12 cells are derived from a rat pheochromocytoma and are used as a 
model of a neuronal system because NGF induces differentiation of PC 12 cells to resemble 
neurons, stimulates PC 12 cells to stop division, extend neurites, express neuronal markers 
and become electrically excitable, and differentiated PC 12 cells undergo apoptosis in
43serum-free conditions without NGF (Tischler and Greene,  1975; Greene and Tischler,  1976; 
Greene,  1978). It is not clear how relevant PC 12 studies are to events in true neurons. How 
neurotrophins exert their effects via their receptors in intact or injured DRG is not clear.
1.3  Morphological changes following axotomy
Axonal damage by crush, axotomy, ischemia, or inflammation leads to interruption 
of axonal integrity and initiates Wallerian degeneration in the distal stump (WD). This is 
characterised by axon degeneration, myelin sheath detachment and degradation, activation 
and proliferation of Schwann cells, to form bands of Bungner, and invading macrophages 
(Salzer et al., 1980). WD begins with degradation of axoplasm and axolemma induced by 
the activation of axonal proteases and calcium influx (Schlaepfer and Bunge,  1973; George 
et al., 1995). The proliferation of Schwann cells continues for approximately 2 weeks, 
eventually forming conduits that guide the regenerating axons to their peripheral targets 
and are a source of neurotrophic factors, such as NGF, BDNF and ciliary neurotrophic 
factor (CNTF) (Heumann et al.,  1987; Acheson et al.,  1991; Sendtner et al.,  1992; Son and 
Thompson, 1995). In the proximal stump, the axons degenerate retrogradely to the first 
node of Ranvier and subsequently start to form regenerating neuronal sprouts within a few 
hours (Wong and Mattox, 1991).
1.3.1  Neuronal loss
In the peripheral nervous system, nerve transection (neurotmesis) and nerve crush 
are different models used to study the injury-induced degeneration and regeneration
44responses. There are many reports of DRG neuron death after peripheral nerve lesion in 
adults, but the results are quite variable (Table 1.1). Nerve transection results in loss of 
continuity of all nerve elements; on the other hand, in crush injuries the integrity of the 
basal lamina of nerve fibres is maintained. It has been shown that crushing of the peripheral 
axons results in less severe neuronal loss in the affected ganglia than permanent transection 
because of highly effective regeneration due to continuity of basal laminae (Risling et al., 
1983; Swett et al.,  1995; Groves et al., 2003); crush-related functional deficit can 
completely recover in 2-3 months (Bridge et al.,  1994). In addition to the type of nerve 
damage, the distance from the lesion to the DRG is also a factor in the rate and magnitude 
of neuronal death, which may be related to the loss of larger amount of axoplasm and the 
decreased trophic support from the proximal segment of injured nerve (Lieberman,  1974; 
Ygge, 1989; Shietal., 2001).
Table 1.1: DRG neuron loss after nerve lesions in adult mammals
Study Animal
Nerve
damaged
Ganglia
examined
Survival time DRG cell loss
Risling et 
al., 1983 Cat Sciatic L7 35,  90  &190 
days
30% at 30 days, 10% 
at 190 days
Ygge, 1989 Rat Sciatic L4/5 120 days 27% proximal lesion, 
7% distal lesion
Swett et al., 
1995 Rat
Sciatic, 
common 
peroneal 
or sural
Lumbar 15-187 days
Essentially none 
except 19% after 
peroneal crush
Vestergaard 
et al., 1997 Rat L5 L5 4-45 days 35% by 45 days
Groves et 
al., 1997 Rat Sciatic L4/5 30-180 days
5.4% at 30 days, 17% 
at 90 days, 14% at 
180 days
Tandrup et 
al., 2000 Rat Sciatic L5 14-224 days
6% at 14 days,  14% 
at 56 days, 37% at 
224 days
Shi et al., 
2001 Mouse Sciatic L5 7-28 days
24% at 7 days, 54% 
at 28 days
45McKay Hart 
et al., 2002 Rat Sciatic L4/5 4-180 days 15% at 7 days, 35% 
at 60-180 days
Groves et 
al., 2003 Rat Sciatic L4/5 30-90 days 7.2% at 10 days, 
2.5% at 90 days
Peripheral axotomy results in greater and more rapid neuronal loss in neonatal DRG 
than in the adult, possibly due to the higher dependence of neonatal neurons on target- 
derived trophic factors (Aldskogius and Risling,  1981; Risling et al.,  1983; Bondok and 
Sansone, 1984; Schmalbruch,  1987a). In the axotomised adult DRG, different animal 
models, different injury types and locations and times and counting techniques accounted 
for the wide range of 7-50% of neuronal loss (Groves et al., 1997; Tandrup et al., 2000; 
McKay Hart et al., 2002). Transection with ligation of adult rat spinal nerve produced 
around 35% L5 DRG neuronal loss by 45 days (Vestergaard et al., 1997).
Whether there is a preferential type of primary afferent neurons lost after peripheral 
axotomy is still controversial. Some studies demonstrated a selective loss of small diameter 
neurons (Ranson, 1909; Cavanaugh, 1951; Rich et al.,  1989; Vestergaard et al.,  1997); 
however others found loss of larger neurons (Bondok and Sansone,  1984), or no selective 
effects (Ygge and Aldskogius,  1984; Arvidsson et al.,  1986). Possible explanations include 
differences in the type and/or the lesion, age of the animals when the procedure was 
performed, the survival time before the neuronal number was counted and the method used 
to estimate sizes.
1.3.2  Stereological method  for neuronal counting
Stereology was developed to avoid the biases inherent to serial reconstructions; in 
particular one stereological technique, the physical disector, was used in this study to 
estimate neuron number in each ganglion (Sterio,  1984; Gundersen et al.,  1988; Williams
46and Rakic,  1988). Stereological counting usually involves either the optical disector 
method, which counts particles in a three dimentional counting frame on thick tissue 
sections, or the physical disector method, which counts particles in one of two adjacent thin 
serial sections (3-4 pm in this study). Both make no assumptions about the size, shape or 
distribution of particles (such as neurons in this study) and avoid the bias derived from 
multiple or split nucleoli or nuclei. Compared to serial reconstruction technique, in which 
nuclei or nucleoli of neurons are counted in selected serial sections of ganglia and 
multiplied by the total number of serial sections with the application of a correction factor 
(Cavanaugh, 1951; Ygge et al., 1981; Himes and Tessler, 1989), the stereological method 
produces accurate reproducible estimations of neuron numbers in DRG (Coggeshall,  1992; 
Tandrup,  1993, 1995; Groves et al.,  1997; Groves et al.,  1999; Groves et al., 2003).
However, comparing absolute numbers of DRG neurons will require larger groups 
of animals due to high degree of variation between animals. Counting the neuron numbers 
in both L4 and L5 DRGs should also be used.
1.3.3  Neuronal apoptosis
The early perikaryal response to axotomy seen in nerve cells including DRG 
neurons is known as chromatolysis (Grafstein,  1983). This is characterised by the 
redistribution of Nissl substance from the central region of the perikaryon to the periphery, 
the displacement of nuclei to the periphery of the perikaryon, indentations of the nuclear 
membrane and alteration of neuronal shape. Chromatolysis is observed in affected neurons 
24-48 hours after axonal damage, a time that depends on the distance of the injury from the 
DRG, and persists for 2-3 months after permanent axotomy (Pannese,  1963; Lieberman,
471974). After transient axotomy (axonotmesis) the chromatolytic appearance disappears as 
axons regenerate and contact their target.
Chromatolysis is not a process leading invariably to death of the cell. It is 
associated with increased RNA and protein synthesis and is primarily a regenerative 
response (Kreutzberg, 1996). Apoptosis, also known as programmed cell death, was first 
described by Kerr et al. in 1972 as a form of cell death followed by the disposal of 
unwanted cells during embryogenesis, metamorphosis, normal cell turnover as well as in 
some pathological situations (Steller, 1995; Nicholson,  1996). Unlike necrosis, apoptosis is 
an active process and is important in maintaining the integrity and homeostasis of 
multicellular organisms. During necrosis, synthetic functions suddenly stop and disruption 
of the plasma membrane leads to the influx of water and swelling of cells and organelles, 
rapidly followed by loss of the cell contents and cell disintegration (Majno and Joris,  1995). 
In contrast, apoptosis involves a process of chromatin condensation, internucleosomal 
DNA cleavage, blebbing of cell membrane, destruction of the nuclear membrane, 
condensation of cytoplasm, and finally the formation of membrane-bound apoptotic bodies 
(Majno and Joris,  1995; Hacker, 2000). Without any apparent breach of the cell membrane, 
the final products are finally phagocytosed without inducing inflammatory reaction or 
damaging adjacent tissues (Hacker, 2000). Apoptosis-inducing factors include damage to 
DNA by UV or y-irradiation, oxidative damage, chemotherapeutic drugs, heat shock, 
withdrawal of growth factors and exposure to certain cytokines such as TNF-a and 
transforming growth factor (TGF)-p.
In the last few years, many of the molecules that participate in the execution of 
apoptosis have been identified. Various pro-apoptotic signals operate through two principal
48pathways which use caspase-8 and caspase-9 to mediate the signalling pathways (see 
Vaughan et al., 2002). Caspase-8 is activated by stimuli through the cell membrane death 
receptor followed by recruitment of the Fas associated death domain (FADD), and caspase- 
9 is activated by the release of cytochrome c from mitochondria triggered by other stimuli, 
including radiation and cytotoxic drugs. Subsequently, the key regulator, p53, may activate 
caspase-3, -6, or -7, which are synthesised within cells as catalytically inactive pro- 
caspases and cleaved to active proteases in response to an apoptotic signal, and are 
activated by both apoptotic pathways (Nicholson and Thomberry,  1997; Slee et al., 2001). 
In particular, caspase-3 alone appears the last caspase to be activated for completing the 
final stage of apoptosis. Both immediate caspase-mediated destruction and components 
further downstream may cleave the proteins involved in maintenance of cellular function 
and structural proteins and lead to cell destruction (Nicholson and Thornberry,  1997). 
During apoptosis, a few proteins have been found to be able to modulate the processing of 
signals (see Vaughan et al., 2002); these include the Bcl-2 family which are involved in the 
suppression of cytochrome c release, FLICE-like inhibitory protein (FLIP)’s binding to 
FADD, and Inhibitors of Apoptosis Proteins (IAP’s) suppressing caspase-9 and caspase-3 
directly.
With regard to the correlation between apoptosis and neurotrophins, it is known that 
NT-3 and NGF knockout mutants show higher expression of activated caspase-3 and 
caspase-9 (Farinas et al., 2002), which are also activated in embryonic DRG during normal 
development, indicating the involvement of these effectors in neurotrophin deprivation- 
induced apoptosis (Yuan and Yankner, 2000). Caspase-3 inhibition rescues retinal ganglion 
cell apoptosis following axotomy and reduces ischaemia-induced hippocampal cell loss
49(Chen et al., 1998; Kermer et al., 1998), but only slows the progress of neonatal 
motoneuron apoptosis following axotomy (Vanderluit et al., 2000). Immunostaining by 
antiserum against the active caspases in apoptotic pathway has been used to identify 
apoptotic cells in rats (Vanderluit et al., 2000).
Apoptotic neurons have been described in axotomised DRG (Ekstrom,  1995;
Groves et al.,  1997, 1999; Leclere et al.,  1998; McKay Hart et al., 2002), and as early as 24 
hours by McKay Hart et al. (2002), who used a staining technique named terminal 
deoxyribonucleotidyl transferase (TdT) uptake nick-end labelling (TUNEL) to label and 
visualise apoptotic cells (Gavrieli et al.,  1992). In DRG, the peak was seen at 2-3 weeks 
and continued for at least 6 months after axotomy (Groves et al.,  1997; McKay Hart et al.,
2002). The TUNEL technique uses enzymatically mediated polymerisation of labelled 
nucleotides onto the free 3’-OH DNA ends of DNA strand breaks, which results from DNA 
digestion by calcium-activated endonuclease, followed by the detection of incorporated 
nucleotides by a secondary antibody; therefore DNA fragmentation happening in apoptosis 
can be detected by using TUNEL stains (Charriaut-Marlangue and Ben-Ari,  1995; Sanders 
and Wride,  1996; Yuan and Yankner, 2000).  However, similar features have been shown 
to be non-specific for apoptosis as they can also be observed and stained in necrosis. In situ 
end-labelling technique (ISEL) is another technique used to detect single-stranded DNA 
existing in these two processes.
Although the methods introduced above are popular as tools to identify apoptotic 
cells, morphological criteria alone are well established and used to detect apoptosis in 
studies (Tong et al., 1996; Groves et al.,  1997); only rarely is there ambiguity in identifying 
apoptotic DRG neurons in well-perfused tissue. It has been shown that only asubpopulation of axotomised neurons dies after peripheral axotomy (Groves et al.,  1997; 
Tatton et al.,  1998; Tandrup et al., 2000; McKay Hart et al., 2002); however the factors 
which ultimately determine whether a specific subpopulation of neurons survives or dies 
after an injury are not understood.
In contrast to transection of peripheral axons, axotomy of dorsal roots, the centrally 
directed axons, of DRG neurons does not lead to an observable cell death in DRGs, and 
results in no chromalytic reaction in the affected sensory neurons (Lieberman, 1974;
Titmus and Faber,  1990).
In my study, I proposed to use caspase-3 immunoreactivity and morphological 
criteria to characterise neuronal apoptosis. Activation of caspase 3 appears to be a key 
event in the execution of apoptosis in the central nervous system and has been observed in 
neurons undergoing apoptosis following CNS infarct (Charriaut-Marlangue 2004); 
activation of caspase 3 in other conditions has not been reported.
1.3.4  Ganglion volume and neuronal size profiles
Axotomy produces a reduced volume of the ipsilateral L4 and L5 DRGs when 
compared to the contralateral side (Rich et al.,  1987). This decline in volume starts 1  week 
after axotomy and reaches a plateau by 2 months. The decrease in ganglion volume 
following peripheral axotomy reflects the neuronal loss and volume reduction of surviving 
neurons in injured ganglia. Previous studies have described the increase in rat L4 and L5 
DRG volume by approximately 27% from birth to its maximum at 4 months of age or older 
(Bergman and Ulfhake,  1998; McKay Hart et al., 2002), and there is a general increase of 
neuron size when the neuronal profiles in postnatal day (P) 100 are compared to those in PI
51rats (Farel, 2002). The degree of shrinkage of DRG neurons is to some degree related to the 
distance from the transection site to the DRG: Vestergaard et al. (1997) reported reduction 
of mean neuronal volume by 33% by 4 days after L5 spinal nerve transection, which 
persisted for at least 6 weeks, and both L and SD cells showed similar degree of shrinkage; 
Rich et al. (1987) reported a decrease of neuronal area by 19% at 3 weeks and  16% by 6 
weeks after sciatic nerve transection at the level of the tendon of the obturator; Bergman et 
al. (1999) described a 10% decrease of cross-sectional cell profile area one week after mid­
thigh sciatic transection. These authors used different methods to measure neuronal volume 
In my study, I compared cross-sectional cell profile in the injured ganglia to that in the 
contralateral L4+L5 DRGs in each animal, minimising the factor of possible neuronal sized 
change during tissue processing.
1.3.5  Reactions of  satellite cells
Satellite cells have apparently slightly flattened nuclei, flattened cell bodies and 
narrow, laminar processes, embracing DRG neurons (Bunge et al.,  1967). The satellite cells 
make their appearance in the DRG after neuroblasts (Pannese,  1974), and one of their 
supposed roles is to regulate ion concentration in the microenvironment of neurons 
(Pannese, 1981). Recently, Pannese et al. (2002) reported immunoreactivity for trkA and 
p75N TR in satellite cells, suggesting the regulation of satellite cells by NGF or other 
neurotrophins.
The satellite cells retain their mitotic capability as revealed by their change in 
number after sciatic nerve injury (Pannese,  1964; Fenzi et al., 2001). Studies on axotomised 
neurons showed hypertrophy and hyperplasia of satellite cells after axotomy (Humbertson
52et al., 1969), induction of satellite cell apoptosis both in neonates (Whiteside et al., 1998) 
and adults (Groves et al., 1997; McKay Hart et al., 2002), and the synthesis of neurotrophic 
factors, such as NGF and NT-3 (Zhou et al., 1999b). Under electron microscopy, Pannese 
et al. (2003) reported that the perineuronal satellite cells responded to axonal injury by 
forming new gap junctions between adjacent satellite cells, however no gap junctions were 
found between neurons and their surrounding satellite cells. Sensory neurons in injured 
ganglia may emit signals by mechanisms other than gap junctions to initiate the reaction of 
satellite cells after peripheral nerve injury (Aldskogius and Kozlova,  1998). However, the 
precise role of satellite cells in axotomised DRG is not clear.
1.3.6  Possible causes of axotomy-induced neuronal death
The exact mechanisms which mediate injury-induced changes in DRG neurons and 
the factors that ultimately determine whether a DRG neuron will survive or die after 
axotomy are poorly understood. One possible mechanism is the reduction in the normal 
retrograde transport of target-derived neurotrophic factors; this hypothesis is supported by 
the finding that blockade of normal axonal transport by vinblastine induces changes similar 
to transection with regard to neuropeptides, such as vasoactive intestinal peptide (VIP) and 
galanin (Knyihar-Csillik et al.,  1991; Kashiba et al., 1992). Other signals are initiated or 
processed at the injury site and lead to the neuronal death or adaptive responses in DRG 
(Hanz et al., 2003). In addition, the expression of bcl-2 family in DRG neurons was 
regulated after sciatic transection, revealing that the ratio of two members of this family as 
cell death repressors, bcl-2 and bcl-xL, to a cell death promotor Bax may be related to the 
susceptibility of DRG neurons to axotomy-induced cell death (Gillardon et al.,  1996).
531.3.7 Injury-induced neuropathic pain
Neuropathic pain is induced by injury or disease of the nervous system. The 
pathophysiology of neuropathic pain is complex and remains poorly understood (Wang et 
al., 2002a). Following peripheral nerve injury, sympathetic axons which normally innervate 
blood vessels in DRG sprout to form varicose baskets around large diameter neurons 
(Chung et al.,  1996; Zhou et al.,  1996; Michael et al.,  1997; Zhou et al.,  1999b). This 
process has been implicated in the development and maintenance of neuropathic pain after 
nerve injury (Chung et al.,  1996). The synthesis of NGF and NT-3 in reactive satellite cells 
and NGF and BDNF in activated Schwann cells may be involved in the induction of 
sprouting and neuropathic pain (Frostick et al.,  1998; Zhou et al.,  1999b). Delivery of 
exogenous NGF or BDNF directly into intact DRGs also triggers a persistent mechanical 
allodynia, but NT-3 does not (Zhou et al., 2000). Systemic injection of antisera to NGF, 
BDNF or NT-3 prevented sprouting and attenuated hyperalgesia and allodynia, confirming 
that endogenous NGF, BDNF and NT-3 induce sympathetic sprouting and are likely to be 
involved in the formation of neuropathic pain after peripheral nerve injury (Deng et al., 
2000; Zhou et al., 2000).
Other events happening in spinal cord after axotomy are also linked to chronic 
neuropathic pain. In the normal animal, low threshold mechanoreceptors terminate in 
laminae III and IV and convey nociceptive inputs whereas unmyelinated C fibres, most of 
which are nocireceptors, terminate predominantly in lamina I and II in the dorsal horn of 
spinal cord. After peripheral axotomy, the central terminals of axotomised myelinated 
afferents, including A(3 fibres, were reported to sprout into lamina II with the consequence
54of hyperalgesia (Woolf et al.,  1992; Woolf et al.,  1995; Bennett et al.,  1996a; Doubell et al.,
1997); these studies mainly used retrograde and transganglionic neuronal tracers to label A- 
fibres. However, recent studies demonstrated that the sprouting of A-fibres after axotomy is 
very limited (Bao et al., 2002; Hughes et al., 2003); a phenotypic change in small DRG 
neurons with an up-regulation of the binding site for tracers resulted in the 
misinterpretation of C-fibres to be A-fibres in previous studies. Whether the limited 
formation of aberrant sprouting in spinal cord could lead to neuropathic pain is unclear. In 
addition, the enhanced anterograde transport of BDNF to spinal cord following sciatic 
nerve injury (Michael et al., 1999) also contributes to the increased synaptic transmission 
and sensitises the pain pathway (Mannion et al., 1999; Thompson et al.,  1999).
1.4  Changes of neurotrophin and neurotrophin receptor expression
following axotomy
1.4.1  Axotomy-regulated neurotrophin expression
Disconnection of the sensory neurons from their peripheral targets by nerve 
transection, results in a decrease or cessation of the retrograde transport of target-derived 
neurotrophic factors, neuronal atrophy, neuronal loss and altered expression of 
neuropeptides and cytoskeletal proteins (Hoffman et al., 1987; Wong and Oblinger, 1987). 
Although the effects of axotomy are well known, their molecular mechanisms have been 
investigated by a few groups and many events remain uncharacterised.
55To date, a few studies have examined the effect of peripheral axotomy upon 
messenger RNA (mRNA) and protein expression of neurotrophins and neurotrophin 
receptors in rat lumbar DRGs, using various semi-quantitative methods. These included in 
situ hybridisation, northern blotting, RNase protection assays and conventional RT-PCR, 
and the injury models used included spinal nerve transection, proximal and mid-thigh 
sciatic nerve transection and sciatic nerve crushing at various time points (Sebert and 
Shooter, 1993; Krekoski et al., 1996; Lee et al.,  1998; Bergman et al.,  1999; Michael et al., 
1999; Shen et al.,  1999a; Zhou et al.,  1999b; Karchewski et al., 2002). Because some of the 
neurotrophic factors are synthesised in both DRG and target organs of sensory neurons, 
quantitation at protein and mRNA levels will provide a more thorough picture of the 
adaptive reaction of DRGs to peripheral axotomy.
In unoperated DRGs, it has been reported that most neurons, but not their satellite 
cells, express NGF mRNA (Zhou et al., 1999b), and around 40% of the lumbar DRG 
neurons are NGF-immunoreactive, especially small- to medium-sized ones (Lee et al.,
1998). Peripheral axotomy, which produces an almost complete block of retrograde 
transport of NGF, produces an increase in NGF mRNA expression in the ipsilateral L4 and 
L5 DRGs from as early as 6 hours, to at least 3 weeks after the injury (Sebert and Shooter, 
1993). One study showed that the NGF protein level, detected by enzyme-linked 
immunosorbent assay (ELISA), within the DRG decreased by 6 hours after tight ligation of 
spinal nerve, due to the effect of the decrease of retrograde transport, but almost fully 
recovered to normal levels by 2 days, suggesting the synthesis of NGF in DRG increased 
after peripheral nerve injury (Lee et al.,  1998). The possible sources of newly synthesised 
NGF include satellite cells, which do not synthesise NGF in intact state, and sensory
56neurons (Lee et al., 1998). This possibility is supported by previous reports which 
demonstrated an increased NGF mRNA expression in the axotomised DRG (Sebert and 
Shooter,  1993; Shen et al.,  1997). NGF synthesis in many satellite cells occurs as early as 3 
days after spinal or sciatic nerve ligation and is also increased in DRG neurons (Lee et al., 
1998; Zhou et al., 1999b).
Sciatic nerve and spinal nerve transection leads to considerable increase in BDNF 
mRNA and protein in DRG throughout a period lasting from 12 hours to 4 weeks (Sebert 
and Shooter, 1993; Karchewski et al., 1999; Michael et al.,  1999; Shen et al.,  1999a). In 
uninjured DRG, BDNF is mainly synthesised in trkA-expressing small neurons exerting 
paracrine and autocrine functions (Michael et al.,  1999; Karchewski et al., 2002); however, 
sciatic axotomy results in a major increase of BDNF mRNA from 2% of all neurons to 50% 
in trkB-expressing neurons and from  18% to 56% in trkC-expressing neurons without a 
significant change in the number of trkA-expressing neurons by 2 days (Michael et al., 
1999). The increase in BDNF mRNA mainly occurs in the medium-to-large diameter DRG 
neurons (Cho et al.,  1997; Tonra et al., 1998; Michael et al.,  1999; Zhou et al.,  1999a). 
Changes in mRNA level are reflected in BDNF protein expression with an increase of 
BDNF immunoreactivity in most neurons at 2 days and a shift to expression in mainly large 
neurons by 2 weeks (Karchewski et al., 2002). Expression of BDNF mRNA or protein in 
satellite cells has never been detected in intact or injured states.
In unoperated DRGs, NT-3 mRNA and protein are mainly localised in large 
neurons (Zhou et al.,  1999b). After sciatic nerve transection at mid-thigh level, NT-3 
mRNA increases in DRG by 75% at 16 hours after the lesion, and these levels persist for atleast 2 weeks (Zhou et al., 1999b). The increase of mRNA and protein is mainly localised 
to some satellite cells.
With regard to contralateral DRGs, although a few neurons appeared to be 
surrounded by NGF or NT-3-expressing satellite cells after axotomy, NGF and NT-3 
mRNA did not change significantly in these ganglia after unilateral sciatic nerve lesion 
(Zhou et al.,  1999b).
In addition to the up-regulation in DRGs, sciatic nerve transection also increases 
NGF mRNA in fibroblasts and Schwann cells of both proximal and distal stumps of the 
damaged nerve (Heumann et al.,  1987; Lindholm et al., 1988). Schwann cells in the distal 
stump increased the synthesis of NGF, BDNF, NT-4 and p75N TR following sciatic nerve 
transection (Heumann et al.,  1987; Meyer et al.,  1992; Funakoshi et al.,  1993).
1.4.2  Axotomy-regulated neurotrophin receptor expression
For quantitative analysis, radioisotope-labelled oligonucleotide probes have been 
used in most studies to determine the changes in the labelling density for mRNA encoding 
neurotrophin receptors (Verge et al.,  1992; Krekoski et al., 1996; Shen et al.,  1999b). The 
percentage and number of trkA-expressing neurons were studied in ipsilateral DRGs after 
spinal nerve ligation; a decrease in trkA mRNA was detected by ribonuclease protection 
assay as early as 3 days after surgery, reaching a maximum 30% decrease, and recovered to 
control levels by 2 months after injury (Shen et al.,  1999b). Similar changes of trkA protein 
expression were observed after sciatic transection (Raivich et al.,  1991; Verge et al.,  1992; 
Krekoski et al.,  1996; Shen et al.,  1999b). TrkA protein is present in the satellite cells of
58normal DRGs (Pannese and Procacci, 2002), but whether its expression in satellite cells is 
regulated by axotomy is not clear.
There are contrasting findings on the expression of p75NTR: some studies observed a 
decrease in its expression (both mRNA and protein) after peripheral axotomy (Verge et al., 
1992; Krekoski et al.,  1996; Zhou et al.,  1996; Bergman et al., 1999), whereas Ernfors et al. 
(1993) reported an increase of p75N TR mRNA one week after sciatic nerve crush using 
Northern blotting. However, sciatic nerve injury up-regulates p75N TR expression in satellite 
cells surrounding large neurons, from  1  week to 2 months afterwards (Zhou et al.,  1996).
1.5  Gene expression pattern following axotomy: microarray studies
The adaptation of neurons to a certain stimulus or injury is first reflected at 
transcriptional and translational levels, and only subsequently structural and functional 
modifications. In addition to the studies focusing on individual genes, especially 
neurotrophins and their receptors, a few studies have been carried out using oligonucleotide 
or cDNA microarrays to investigate more regulated genes in the DRG after peripheral 
nerve injury (Fan et al., 2001; Costigan et al., 2002; Kubo et al., 2002; Xiao et al., 2002).
1.5.1  Introduction of microarray
Microarray is a new technology which can monitor the whole genome or thousands 
of selected genes on a single array and provide researchers with information on the 
complex interactions of a lot of genes simultaneously by examining their changes.
59An array is an orderly arrangement of oligonucleotides or cDNA complementary to 
known and unknown genes on solid surfaces, generally on glass but sometimes on nylon 
substrates and made by high-speed robotics. There are two major applications for the 
microarray technology: (1) Determination of expression level (abundance) of genes; and (2) 
Identification of sequence (gene / gene mutation). There are two formats of microarray 
technology: (1) cDNA microarray. cDNA (500-5,000 bases long) is immobilised to a solid 
surface such as glass and exposed to a set of targets either separately or in a mixture. (2) 
oligonucleotide microarray. 20~80-mer oligonucleotide probes are synthesised and 
followed by immobilisation to a chip. These arrays are exposed to labelled sample RNA or 
DNA, hybridised, and the identity/abundance of complementary sequences are determined 
(http://www.affymetrix.com)(Shoemaker and Linsley, 2002). In the current study,
Affymetrix Rat Neurobiology U34 array, which is an oligonucleotide array, was used to 
examine the mRNA expression of more than one thousand neurobiology-related genes.
1.5.2  Application of microarray to the study of  peripheral nerve injury
A DRG contains the cell bodies of primary sensory neurons, satellite cells, Schwann 
cells, mast cells, fibroblasts, perineurial and endothelial cells; therefore microarray data 
show the pooled expression of genes in all of these cells. Commercial arrays and specific 
‘Custom-made’ arrays, from which researchers can select the content of their arrays and the 
array size, have been used on various animal models of peripheral nerve injury to examine 
the gene expression changes over extended periods of time, ranging from 3 days to 4 weeks 
(Xiao et al., 2002), or focusing their observations only on one specific time point (Fan et al., 
2001; Costigan et al., 2002; Kubo et al., 2002). In some studies, array hybridisations were
60carried out in triplicate to reduce false positives and negatives, but, in some others, only 
one array per time point was performed. The alterations of gene expression in injured DRG 
are possibly triggered by a loss or decrease of trophic support from target organs or by 
other signals initiated or secreted at the injury site (as previously discussed). The 
differentially expressed genes appear to reflect the adaptive, maladaptive or compensatory 
responses, such as the capacity to survive the injury and regeneration of the injured axon 
after nerve transection, by structural and functional modifications of DRG cells (Xiao et al.,
2002). Differences in mRNA levels, compared with controls, may result from changes in 
either the transcription rate or the half-life of the transcripts.
Comparison of the profiles of regulated genes between different studies, using 
different platforms to carry out array hybridisations, are complicated by the different 
criteria used to define the regulated genes, the different genes included in commercial and 
customised arrays, the various sciatic nerve injury models used and different time points 
chosen.
Recently Costigan M et al. (2002) published a study using 8.8K oligonucleotide 
arrays in triplicate to analyse genes regulated in the DRG three days following mid-thigh 
sciatic nerve transection. Of these, 52-54% of the genes included were detected in arrays 
and 240 (5.1%, including 2.8% up-regulated and 2.3% down-regulated) genes were 
regulated by axotomy, defined by the criteria >1.5-fold change and with a p value of <0.05, 
using unpaired, two-tail t-test (Costigan et al., 2002). 8.5K cDNA Incyte mouse GEM 
arrays were used in a study investigating the gene expression pattern in DRG 7 days after 
mid-thigh transection of sciatic nerve (Bonilla et al., 2002). Twelve genes were up- 
regulated by more than 2-fold and 4 genes down-regulated. Xiao et al. (2002) used 7.5K
61cDNA arrays to analyse genes regulated in DRG 2, 7, 14 and 28 days following sciatic 
nerve transection at mid-thigh level with one array at each time point and observed 122 
genes and 51 expressed sequence tags (ESTs) regulated at least at one time point after 
axotomy (Xiao et al., 2002). The genes up-regulated or down-regulated in injured DRG 
detected by microarrays were then classified into functional categories, including signal 
transduction, cytoskeleton, ion channel, cell surface receptors, growth factors, cytokines, 
neurotransmission and apoptosis, and analysed with the help of data mining tools (Kubo et 
al., 2002; Xiao et al., 2002).
However, microarrary hybridisation investigating the effects of exogenous 
neurotrophins (e.g. NT-3) on injured DRG at any time point after sciatic nerve transection 
has never been done. The time point of 2 weeks was chosen in this study to explore the 
molecular mechanisms which may be involved in my morphometric findings.
1.6  Effects of neurotrophins on sensory neurons following axotomy
After sciatic nerve injury, surviving DRG neurons undergo structural and 
biochemical changes including alterations in morphology and in expression of enzymes, 
peptides, growth-associated molecules, cytoskeletal proteins and receptors; many of these 
changes reverse after successful regeneration (Groves et al.,  1996; Costigan et al., 2002; 
Xiao et al., 2002). Administration of exogenous trophic factors to the injured nerve may 
replace a missing component derived from the target organ.
1.6.1  Delivery of neurotrophic factors
62For these neurotrophins to be of widespread use clinically, it is important that they 
can be applied via a less traumatic route such as via the systemic circulation rather than 
intrathecally or intraneurally as used by a number of groups so far.  Application of 
neurotrophins to the proximal stump of transected nerve impedes the regeneration of nerve. 
Neurotrophins are proteins and cannot get access to the central nervous system through 
blood-brain barrier (BBB)(Poduslo and Curran,  1996; Pan et al.,  1998). On the other hand, 
peripheral sensory neurons have no barrier in DRG to prevent systemic proteins from 
coming into contact and are less protected and are better candidates for neurotrophin 
therapy (Jacobs et al.,  1976; Olsson, 1968). Intravenously (IV) administered NGF, and 
particularly NT-3 and BDNF, have been shown to accumulate in the endoneurial 
compartment, indicating that they are capable of reaching peripheral axons via an active 
transport mechanism (Poduslo and Curran,  1996). Furthermore, the capillaries of rat DRGs 
are fenestrated and will allow the passage of proteins into the extracellular space: 
horseradish peroxidase (Molecular weight (MW): 44,000) comes into contact with the 
perikaryal membranes of DRG neurons within 5 minutes of IV administration into the 
femoral vein (Jacobs et al.,  1976). NGF administered subcutaneously by micro-osmotic 
pump reaches maximal serum concentrations 6 hours later, declining to a steady state level 
after 3 days (Tria et al., 1994); NT-3 (MW 15,000) has a higher permeability coefficient- 
surface area product than NGF at the blood-nerve barrier (Poduslo and Curran, 1996). 
These data indicate thatNT-3 in the systemic circulation would come into contact with 
both the axonal and perikaryal membranes of DRG neurons, where trk receptors are 
expressed, very soon after pump implantation and start-up. Other chronic delivery systems 
include intrathecal delivery, subcutaneous or intraperitoneal injection, and targeted
63administration to the nerve stump using bioresorbable materials, including fibrin glue, 
fibronectin mats and collagen. Fibrin glue is prepared from a mix of fibrinogen concentrate, 
aprotinin solution, thrombin and calcium chloride solution; the polymer network can slowly 
release the neurotrophic factor bound inside as the network is gradually lysed (Yin et al.,
1998). However, direct application of trophic factors may be problematic when a long-term 
infusion is required. In future, gene therapy, transduced in adenovirus, or transfer of 
specific cells which produce the desired trophic factors may be applicable to peripheral 
nerve injury (Emerich et al.,  1997; Hoffer and Olson,  1997).
1.6.2  Effects of  NGF administration
The protective effect of exogenous NGF on axotomy-induced neuronal loss was 
demonstrated via intrathecal infusion (Ljungberg et al.,  1999) and via proximal nerve 
stump (Otto et al., 1987; Rich et al., 1989) after either spinal nerve or sciatic nerve 
transection. In addition, after intrathecal, systemic and in vitro NGF treatment, the NGF- 
responsive neurons in unoperated lumbar DRGs up-regulate the expression of p75N TR and 
trkA receptor (Lindsay et al.,  1990; Miller et al.,  1991; Verge et al.,  1992). The decrease of 
trkA and p75N TR mRNA DRG in both DRG and deafferented dorsal horn cells after 
peripheral nerve transection can be at least partly reversed by exogenous NGF (Fitzgerald 
et al., 1985; Verge et al., 1992). These observations suggest a positive feedback mechanism 
which may be important in the survival and differentiation of NGF-responsive neurons 
during development, and their maintenance and regeneration in the adult.
Furthermore, NGF can regulate levels of other neurotrophins; following systemic 
and intrathecal NGF injection, BDNF levels were increased in unoperated DRG by 24
64hours, especially in trkA-expressing neurons (Apfel et al., 1996; Michael et al.,  1997). 
Systemic NGF administration lasting for 3 days to 2 weeks after unilateral sciatic nerve 
transection results in up-regulation of BDNF mRNA in both the number and intensity in 
both neurons in injured and uninjured DRGs (Verge et al., 1996; Obata et al., 2003).
Either systemic, intrathecal, or local NGF administration has been reported to 
activate the existing signalling pathways in some DRG neurons and satellite cells, 
increasing the levels of phosphorylated-extracellular signal-regulated protein kinase-1/2 (p- 
Erk-1/2) in trkA-expressing small-to-medium neurons (Averill et al., 2001; Obata et al.,
2003); the p-Erk-1/2 immunoreactivity was induced in medium-to-large neurons after 
peripheral nerve injury (Obata et al., 2003). In compartmented cultures of rat E14 DRG 
neurons, Watson et al. (2001) found that NGF and BDNF stimulated axon terminals and 
then activated Erk-5 pathway for retrograde signalling; at the same time, local Erk-1/2 
signalling cascades were also activated, but restricted within the distal axon. In contrast, 
neurotrophin stimulation of cell bodies activates both Erk-1/2 and Erk-5 cascades (Watson 
et al., 2001). These may explain the discrepancies in studies using different routes of 
neurotrophin administration.
In addition to its effects on neurotrophins and their receptors, NGF supplied 
intrathecally or through the proximal stump of the nerve partly prevented or reversed the 
injury-induced degenerative atrophy, and the decreased expression of medium 
neurofilament subunit (NF-M), peptides a- and P-CGRP and substance P (Csillik et al., 
1985; Fitzgerald et al., 1985; Rich et al., 1987; Verge et al.,  1990; Inaishi et al.,  1992; 
Verge et al., 1995). NGF administration also counteracts the injury-induced increases in 
immediate early gene protein cJUN (Gold et al.,  1993), peptides galanin, neuropeptide Y
65(NPY), VIP and cholecystokinin (CCK)(Verge et al., 1995). Daily injection of NGF 
antiserum to normal adult rats results in a decreased axonal calibre and neurofilament 
expression in the proximal axon of DRG neurons, implying the importance of retrogradely 
transported NGF in maintaining the axonal calibre, at least in certain subsets of neurons 
(Gold et al.,  1991). Functionally, NGF application to the transected proximal nerve stump 
counteracts the decrease in primary afferent depolarization after sciatic nerve axotomy 
(Fitzgerald et al.,  1985).
Importantly, subcutaneous injections of NGF caused mechanical and heat 
hyperalgesia and an increase in nociceptive fibre sprouting (Lewin and Mendell,  1993), 
which may be a problem in the event of therapeutic use of NGF. Phase I, II and III clinical 
trials of recombinant human NGF (rhNGF) for treating diabetic peripheral neuropathy have 
revealed significant beneficial effects after 6 months of treatment with injection site 
hyperalgesia the most common adverse event (Petty et al.,  1994; Apfel et al.,  1998).
1.6.3 Effects of  BDNF administration
Studies of the effects of BDNF on DRG after peripheral nerve injury are limited. 
Intrathecal infusion of BDNF has no rescue effect on neuronal loss of T13 DRG after 
spinal nerve transection (Ljungberg et al.,  1999); however, systemic BDNF administration 
improves the diameter and myelin thickness of regenerating axons after sciatic nerve 
transection and repair and increases functional recovery by 80 days (Lewin et al., 1997).
1.6.4 Effects of  NT-3 administration
66Exogenous NT-3 has been shown to have beneficial effects on morphological 
changes, gene expression alterations, electrophysiological deficit and functional recovery 
after peripheral nerve injury (Verge et al.,  1996), although its mechanisms of action are not 
clear. NT-3 administration intrathecally or at the proximal stump effectively prevented 
lumbar (Groves et al.,  1999) and thoracic (Ljungberg et al.,  1999) DRG neuron loss after 
peripheral nerve transection. Intrathecal administration of NT-3 also promotes axonal 
regeneration across the dorsal root entry zone (DREZ) which is a CNS-PNS interface in 
spinal cord, and recovery of proprioceptive function after dorsal rhizotomy (Ramer et al., 
2002). Intrathecal NT-3 administration for one week was shown to partly counteract the 
decreased p75NTR expression in injured DRG after 2 week axotomy (Verge et al.,  1996). 
NT-3 administration, either to the proximal nerve stump or systemically, can partly prevent 
the decrease of conduction velocities and excitatory postsynaptic potentials (EPSPs) after 
axotomy or in streptozocin (STZ)-induced diabetic rats (Munson et al.,  1997; Mendell et al.,
1999). Subcutaneous administration of NT-3 also reduced functional and 
electrophysiological deficits of large-fibre sensory neuropathy induced by vitamin E *6 
(Pyridoxine)(Helgren et al.,  1997). Delivered by grafting impregnated fibronectin in the 
axotomised sciatic nerve, NT-3 does not effect the expression of CGRP, SP or VIP, but 
attenuates the up-regulation of NP-Y at 30 days after axotomy (Sterne et al.,  1998). While 
NT-3 prevents neuron loss (Ljungberg et al.,  1999), it did not prevent apoptosis of DRG 
neurons in vitro (Edstrom et al., 1996). Whether the neuron number, neuronal apoptosis, 
expression of neurotrophins, neurotrophin receptors and neurofilaments, and the gene 
expression profile in axotomised DRG are regulated by systemic NT-3 administration in 
vivo is not clear.
671.6.5  Other neurotrophins/cytokines
Cytokines are a group of polypeptide mediators, and include interleukins, 
chemokines, tumour necrosis factors, interferons, colony stimulating factors, growth factors, 
neuropoietins and neurotrophins. Glial-derived neurotrophic factor (GDNF) (Lin et al., 
1993), ciliary neurotrophic factor (CNTF) (Sendtner et al.,  1994), basic fibroblast growth 
factor (bFGF)(Eckenstein,  1994) and leukemia inhibitory factor (LIF)(Murphy et al.,  1993) 
support the survival of particular sensory neurons in culture. In vitro studies using DRG 
explants showed that GDNF stimulates axonal outgrowth of IB4-labelled small diameter 
neurons which do not express trkA or other neurotrophin receptors (Leclere et al.,  1998; 
Bennett et al.,  1998). GDNF also reverses the decrease in IB4 labelling in DRG neurons, 
improves the conduction velocity of these small diameter sensory neurons after axotomy 
(Bennett et al.,  1998), and also reduces apoptosis in explants (Leclere et al.,  1998).
1.7  Neurogenesis in nervous system
1.7.1  Neurogenesis in adult central nervous system
There is thought to be very limited neuronal generation/regeneration in post-natal 
CNS. Exceptions to this generalisation are two areas of the post-natal brain in mammals 
which are known to generate new neurons: the dentate gyrus of the hippocampal formation, 
and the subventricular zone (SVZ) which has a projection through the rostral migratory 
stream to the olfactory bulb (Eriksson et al.,  1998; Ciaroni et al.,  1999; Doetsch et al.,
1999). Proliferating SVZ cells are located along the lateral edge of the lateral ventricle,
68mainly along the frontal horn. Olfactory receptor neurons are ageing and dying and being 
replaced continuously by new neurons generated from a pool of neuronal progenitor cells. 
Neurogenesis in these regions mainly depends on proliferation of stem cells or 
undifferentiated precursor cells (Cameron et al., 1993; Ciaroni et al.,  1999), which can be 
identified by 3H-thymidine and BrdU incorporation.
Neural stem cells (NSCs) are defined as self-renewing multipotent cells that have 
the potential for bidirectional glial/neuronal differentiation into neurons, astrocytes and 
oligodendrocytes in the developing CNS (Reynolds and Weiss, 1992). NSCs have been 
shown to exist throughout life in the adult brain, particularly the subventricular zone and 
the dentate gyrus of the hippocampus (Reynolds and Weiss,  1992; Richards et al.,  1992). 
Stem cells can also be isolated from other regions of brain and spinal cord (see Gage et al, 
1995; Gage, 2002; Shihabuddin et al., 2000). In addition, marrow stromal cells (MSCs) can 
differentiate into neurons and astrocytes after exposure to a brain environment in vivo, or to 
epidermal growth factor (EGF) and BDNF in vitro (Eglitis and Mezey,  1997; Brazelton et 
al., 2000; Woodbury et al., 2000). Transplantation studies in rodents have showed that 
NSCs from embryonic hippocampus could bring a degree of recovery of cognitive and 
neuromotor function after brain insults, but the structural basis for this repair is not clear 
yet (Philips et al., 2001; Veizovic et al., 2001).
In the rodent brain, neurogenesis, assessed using BrdU incorporation, starts to 
increase at 7 days and peaks at 11 days after brain ischaemia (Sharp et al., 2002), which 
may explain the partial recovery of function following global brain ischaemia. Many 
factors are able to regulate neural stem cells in vitro, including bFGF, epidermal growth 
factor (EGF), transforming growth factor (TGF), insulin-like growth factor-1   (IGF-1),
69glutamate, y-aminobutyric acid (GABA), opioid peptides, platelet-derived growth factor 
(PDGF), CNTF and neurotrophins (Kuhn et al.,  1997; Cameron et al.,  1998; Namaka et al., 
2001).
Nestin, a member of intermediate filament protein family, is expressed in common 
progenitors or neural stem cells which can give rise to both neurons and non-neuronal cells 
(Messam et al., 2000). In mice, it is expressed early from embryonic day E7.5 in many 
proliferating CNS regions, followed by expression in the rostral and caudal neuronal tube at 
E10.5, cerebellum at E15.5, and ventricular and subventricular areas of the developing 
telencephalon at postnatal day P0 (Dahlstrand et al., 1995). Nestin expression declines 
rapidly during the cells transition from proliferating to postmitotic state, and this is 
accompanied by the onset of expression of glial fibrillary acidic protein (GFAP) in 
astrocytes and neurofilaments in neurons (Dahlstrand et al.,  1995). In rat brain, nestin 
expression diminishes by P6 in the spinal cord and by P21  in the cerebellum (Hockfield 
and McKay,  1985). Nestin is also expressed in endothelial cells and ependymal cells in the 
subventricular zone in CNS and in Schwann cells in PNS (Friedman et al.,  1990; Tohyama 
et al., 1992; Duggal et al.,  1997). Nestin has been detected in some pathological conditions 
including CNS tumours, where its amount has been correlated with the severity of the 
tumour (Dahlstrand et al., 1992), and excitotoxic and traumatic brain injury. After focal 
brain ischemia and spinal cord injury, nestin expression is present in some cortical neurons 
and reactive astrocytes (Clarke et al., 1994; Frisen et al.,  1995; Duggal et al.,  1997). The re­
expression of this early fetal gene and co-expression of a few markers for early embryonic 
development and neuronal differentiation, such as vimentin, embryonic neural cell 
adhesion molecule (E-NCAM), neuron-specific enolase (NSE) and microtubule-associated
70protein 2 (MAP-2)(Vinores et al.,  1984; Geisert et al.,  1990; Le Gal La Salle et al.,  1992), 
in response to cellular stress in the CNS may represent a reversion to an more immature, 
embryonic cell state and a potential to repair damaged neuronal processes and synaptic 
plasticity (Duggal et al., 1997), or it may indicate the recent formation of those neurons 
from nestin-IR precursors (Woodbury et al., 2000).
1.7.2  Neurogenesis in adult peripheral nervous system
During development, DRG neurons are derived from precursors in the neural crest 
cells and neurogenesis was proposed to end perinatally in the PNS (Farinas et al.,  1996; 
Greenwood et al.,  1999). Recent work has suggested that neuronal differentiation continues 
postnatally (Farel, 2002). In rat DRG, the first evidence for the existence of possible post­
natal neurogenesis or continuing neurogenesis was based on the slow accretion of neuron 
numbers occurring in adulthood (Devor and Govrin-Lippmann,  1985). In that study, a 
profile-based neuron Counting method was applied to count neurons in L4/L5 DRGs, but 
the researchers did not try to observe dying neurons. Using profile counts or stereological 
counting methods to support the age-related increase in DRG neurons, postnatal 
neurogenesis in rat DRG has also been observed by several authors (Cecchini et al.,  1995; 
Popken and Farel,  1997; Farel, 2002, 2003); however, whether neurogenesis occurs in 
DRGs during adult life is still unclear. In contrast, others reported that neuron number 
remains unchanged after birth (Pover et al., 1994; Mohammed and Santer, 2001). Profile- 
based neuron counts are potentially biased by changes in neuron size, such as occurs in 
male rats with age. Stereological counting techniques make less assumptions about size and 
shape and so are less likely to be biased by any such changes (see Coggeshall,  1992).Thelack of observation of dying neurons also makes any conclusions about neuronal death very 
suspect. In vitro, neurogenesis was seen in DRG cell culture from postnatal (day 1-2) mice 
in the presence of bFGF, epidermal growth factor, NGF, BDNF, NT-3 and GDNF (Namaka 
et al., 2001). Some neuron-like cells in these newly generated spherical cell aggregates 
appear to incorporate thymidine analogue BrdU which detects DNA synthesis, and these 
cells are labelled by neuron-specific markers neurofilament-160 and microtubule- 
associated protein-2 (MAP-2), and extended axon-like processes and presented electrical 
properties characteristic of neurons. Using another experimental model, in which 
deficiency of vitamin E enhances neurogenesis in a specific period of time, some satellite 
cells and round, spindle or bell-shaped cells were labelled by BrdU (Ciaroni et al., 2000). 
Double stained by BrdU and NF-200 antibody, some of these cells were suggested to be 
transitional neuroblasts which exist in developing DRGs. Whether nerve transection leads 
to neurogenesis in PNS and which are the factors regulating any neurogenesis in PNS are 
not well studied.
In this thesis, the hypotheses are:
(1) Axotomy may cause certain cells to differentiate into DRG neurons and NT-3 
may stimulate this process.
(2) Axotomy and systemic NT-3 administration may produce molecular changes in 
DRG that may assist regeneration.
72CHAPTER 2: MATERIALS AND METHODS
732.1 Animals
A total of 150 adult male Sprague-Dawley rats weighing between 275 —  325 g were 
used. Animals were housed singly with food and water available ad libitum, and they were 
kept in a colony room maintained at 22°C and with a 12-h alternating light-dark cycle. 
Experiments conformed to Home Office regulations.2.0.1  Surgical procedures: anaesthesia, 
analgesia and post-operative care.
Animals were anaesthetised with halothane via a Boyle’s inhalational apparatus. An 
intramuscular injection of Temgesic (buprenorphine hydrochloride: Reckitt and Colman), 
10 pg/kg, was injected intramuscularly for post-operative analgesia.
All animals were monitored daily for signs of autotomy after procedures. Two rats 
were found to have more than two toes missing and were humanely destroyed.
Table 2.1: Numbers of animals used and the surgical procedures carried out
Procedure
Number of 
animals
Right sciatic nerve transection 13
Right sciatic nerve transection + vehicle administration 48
Right sciatic nerve transection + NT-3 administration 52
Unoperated 45
Total 158
2.1.1  Laboratory reagents
General lab chemicals were from Sigma and of analytical grade. Unless stated 
otherwise, solutions and buffers were prepared using de-ionised water. Autoclaving 
procedures were carried out at 121 °C,  15 lbs/square inch for 30 minutes.
742.1.2  Surgical procedures: anaesthesia, analgesia and post-operative care
Under halothane anaesthesia, an 1  cm incision was made on the skin at mid-thigh 
level and the right sciatic nerve was exposed after carefully blunt dissecting the muscles 
surrounding it. The nerve was tightly ligated at mid-thigh level by sterile silk suture 
material, and transected at 2 mm distal to the tie. A 5mm length of the distal stump was 
removed to prevent any regeneration, the muscle was sutured in layers. After application of 
antibiotic powder (Cicatrin), the skin incision was closed by surgical stapler. Another 
incision was then made in the skin of the dorsum of the rat, where it cannot be reached by 
claws or mouth, and a subcutaneous pocket was created by separating the dermis from the 
underlying muscle layer. An “Alzet” micro-osmotic pump (Alza Corporation, USA) 
containing a solution of human recombinant NT-3 in vehicle (Regeneron Pharmaceuticals 
Inc.) or vehicle (4.5% mannitol, 0.5% sucrose and lOmM histidine, pH 5.0 in sterile saline) 
in the operated control group animal was inserted into the pocket and the incision sutured. 
Treatments lasted for 1  week (pump model 2001,  lOOpl  12.5mg/ml NT-3), 2 weeks (model 
2002, 200pl 3.125 or 12.5mg/ml NT-3), or 4 weeks (model 2004, 200pl 6.25 or 25mg/ml 
NT-3). For the 1  day (24 hours) administration group, one subcutaneous injection of 
0.179mg/15pl NT-3 or 15pi vehicle was given immediately after the operation. Antiseptic 
“Sprilon” spray was then applied to the wound and the animals allowed to recover.
Seven groups of animals were used for the morphometric and neuron apoptosis 
study: (1) unoperated rats (n=7); (2) 2 weeks after axotomy with vehicle pump infusion 
(n=4); (3) 2 weeks after axotomy with NT-3 (0.625mg) pump infusion (n=5, 0.045mg/day); 
(4) 4 weeks after axotomy without any treatment (n=5); (5)4 weeks after axotomy with
75vehicle pump infusion (n-5); (6) 4 weeks after axotomy with NT-3 (1.25mg) pump 
infusion (n=5, 0.045mg/day); (7) 4 weeks after axotomy with NT-3 (5mg) pump infusion 
(n=4, 0.179mg/day).
Nine groups of animals were used for the real-time quantitative PCR investigation: 
(1) unoperated rats (n=5); (2) 1  day after axotomy with subcutaneous 15pl vehicle injection 
(n=5); (3) lday after axotomy with subcutaneous 0.179mg/15pl NT-3 injection (n=5); (4) 1  
week after axotomy with vehicle pump infusion (n=5); (5) 1  week after axotomy with NT-3 
(1.25mg) pump infusion (n=5, 0.179mg/day); (6) 2 weeks after axotomy with vehicle pump 
infusion (n=5); (7) 2 weeks after axotomy with NT-3 (2.5mg) pump infusion (n=5, 
0.179mg/day); (8) 4 weeks after axotomy with vehicle pump infusion (n=5); (9) 4 weeks 
after axotomy with NT-3 (5mg) pump infusion (n=5, 0.179mg/day).
Three groups of animals were used for microarray analysis: (1) unoperated rats 
(n=12); (2) 2 weeks after axotomy with vehicle pump infusion (n=12); (3) 2 weeks after 
axotomy with NT-3 (2.5mg/2 weeks = 0.179mg/day) pump infusion (n= 12)
2.1.3  Preparation of micro-osmotic pump with NT-3 and vehicle solution.
Alzet micro-osmotic pumps (Alza co., Palo Alto, CA), model 2001  (100 pi, for 1  
week administration), 2002 (200 pi, for 2 weeks) and 2004 (200 pi, for 4 weeks), were 
used in the study for delivering NT-3 and vehicle into the subcutaneous space, and proper 
sterile technique was used during the preparation of solution and filling of the pumps. The 
subcutaneous micro-osmotic pumps we used to deliver NT-3 to the systemic circulation for 
up to 4 weeks after sciatic nerve transection avoid fluctuating serum NT-3 levels produced 
by repeated injections or weekly refilling of reservoirs. NT-3 (18.8mg/vial) was kindly
76provided by Regeneron Pharmaceuticals, Inc., aliquotted and stored at -70° C. Five 
dilutions of NT-3 were prepared for morphometric and molecular studies using sterile 
normal saline: 0.18 mg/15pl (1 day, molecular study),  1.25 mg/100 pi (1 week, molecular 
study), 0.625 mg/200 pi (2 week, morphometric study), 2.5mg/200pl (2 week, molecular 
study),  1.25 mg/200 pi (4 week, morphometric study) and 5 mg/200 pi (4 week 
morphometric and molecular studies).
2.2  Axotomy-induced apoptosis in adult rat dorsal root ganglia
2.2.1  Tissue preparation
Two and four weeks after the procedure, the rats for morphometric study were 
deeply anaesthetised with intraperitoneal pentobarbitone (60mg/kg) injection and perfused 
transcardially with 600ml of 4% depolymerised paraformaldehyde in 0.1 M phosphate 
buffer, pH 7.4 over a period of 15 minutes at room temperature. The solutions were 
pumped into the aorta at a pressure of approximately 13 lb/inch2 by means of a catheter 
connected to a peristaltic pump. The left and right L4 and L5 DRGs, which appeared as 
yellow swellings, were removed with 2 mm of roots and nerve either side and allowed to 
fix in the same fixative for 24 hours. The DRGs were then held between two biopsy 
sponges, put in “Tissue-tec” cassettes and processed overnight by a Shandon Citadel 
automated tissue processor as follows:
(1) Formol alcohol:  lhr.  15 mins; (2) 70% alcohol:  1  hr; (3) 90% alcohol:  1  hr; (4) 
Absolute alcohol  1:  1  hr; (5) Absolute alcohol 2:  lhr 30 mins; (6) Absolute alcohol 3:  lhr.30 mins; (7) Chloroform 1:  1  hr. 30 mins; (8) Chloroform 2: 2hrs; (9) Molten paraffin wax 
1:  1  hr; (10) Molten paraffin wax 2:  1  hr; (11) Molten paraffin wax 3:  1  hr. 30 mins.
Serial 3 pm sections of each ganglion were cut longitudinally and mounted onto 
glass slides in strips of 5. All sections were retained.
2.2.2 Apoptotic neuron counting
Every other slides prepared from perfused animals were deparaffinized, rehydrated 
and stained with acidified 0.01% cresyl fast violet at 60°C for 20 minutes before being 
dehydrated, cleared and mounted. Each section was then examined at 250 x magnification 
for the presence of apoptotic neurons using morphological criteria, including condensed 
nuclear chromatin, irregular nuclear and cellular shape and darkly staining cytoplasm. The 
incidence of apoptotic neurons was expressed as a fraction of half of the estimated total 
number of neurons in the ipsilateral L4 and L5 DRGs (pooled). Structures  15-30pm in 
diameter that were empty except for the remains of some condensed DNA, and which were 
surrounded by satellite cells corresponded to the “ghost cells” reported from cell culture 
studies of sympathetic neurons undergoing apoptosis (Edwards and Tolkovsky,  1994). 
These were not counted as neuronal, apoptotic or otherwise.
2.2.3 Neuronal counting
To examine if there was neuronal loss two and four weeks after axotomy and 
systemic NT-3 administration, neuronal counting was carried out on the same stained 3 pm 
cresyl fast violet sections which we used to identify apoptotic neurons. A physical disector 
method of stereology was used (Sterio, 1984; Coggeshall, 1992; Groves et al.,  1999). Ten
78pairs of sections, regularly spaced through DRG, were examined in each ganglion, 
therefore the total number of sections containing neuronal cell bodies were divided by 10 
(= x) to find the number of sections in an interval between levels. The starting pair was 
chosen by selecting a number randomly between 1  and x. The first section in each pair of 
sections is called the “reference section”: the next section is called the “look-up” section. 
Section pairs were examined at a magnification of250x on a Zeiss microscope with 
planapochromat objectives, connected to a Leica Quantimet 500 image analyser, which 
consists of a JVC 3CCD video camera connected to an IBM-PC Pentium with associated 
video processing hardware and Leica image analysis software. The magnification obtained 
with the image on the monitor is around xlOOO with the x25 objective. The image analyser 
and video camera were used to store the image of the field of reference section being 
examined and we could examine the contiguous look-up section to count the particles at the 
same time. Only the nuclei which existed in the reference section but not in the look-up 
section (called “tops”) were counted (Figure 2.1). More than  100 “tops” should be counted 
for an accurate estimation of nuclear density, and it has been concluded that more than 200 
“tops” counted will not lead to any greater accuracy (Sterio,  1984; Gundersen et al.,  1988). 
The areas of partial disectors were measured using the image analyser. The mean section 
thickness of the reference sections was measured using a Heidenhain MT12 microcator 
attached to the stage of a microscope in conjunction with a x63 oil immersion objective 
with a numerical aperture of 1.4, giving a depth of field of around 0.5pm. The thickness of 
a section was determined by establishing the top and bottom of the section, and the 
thickness could be read from the microcator. The mean ganglion area of the reference 
section sampled was calculated and multiplied by the average thickness of the sections and
79the total number of sections to obtain the volume of the ganglion (Vref). By dividing the 
number of tops counted for each ganglion by the product of the mean reference section 
thickness and the total areas of the disectors, the numerical density of neuronal nuclei can 
be calculated. The total number of neurons was then estimated by multiplying the ganglion 
volume (Vref) by the numerical density. If enough tops are sampled in an unbiased way, the 
numerical density will reflect the density of neurons in the ganglion examined.
Numerical density = EQ~ -s-  I V d jS ecto rs
(Q~ = number of tops in each disector; Victors = volume of each disector; £: the sum of a 
set of values)
The volume of the ganglion was estimated using the Cavalieri principle (Gundersen et al., 
1988)
Volume of ganglion (Vref) = (mean reference section area) x (mean section thickness) x 
(number of sections)
The degree of neuronal loss for each animal was calculated as the ratio of the 
number of neurons in the ipsi lateral (right) to that in the contralateral (left) L4 and L5 
DRGs. A value of 1   for this ratio would indicate equal numbers of neurons in the ipsi- and 
contralateral ganglia, and a value lower than 1   indicates fewer neurons in the injured DRGs 
than in the contralateral ganglia, as no degenerating neurons were seen in any serially- 
sectioned contralateral or control DRGs.
80Figure 2.1: Examples of a reference section (A) and an adjacent “look-up” section (B). The 
arrowhead indicates a neuronal nucleus that appears in the reference section but not in the 
look-up section, and is therefore counted. Scale bar=10 pm.
2.2.4  Measurement of neuron diameters.
The diameters of sensory neurons in L4 and L5 DRGs were measured using a Leica 
Quantimet 500 image analyzer and JVC 3-CCD colour video camera attached to a Zeiss 
microscope. Three sections were taken from each ganglion and neuronal areas were 
measured if the nucleus was bound by a defined nuclear membrane and contained at least 
one nucleolus. A total of more than 600 neurons were examined in each side and three 
animals were studied in group (i)-(iii) and (v)-(vii) for morphometric study. The actual 
diameters of these neurons were converted from their calculated area and plotted in 
histogram form. Cell size in sections of paraffin-embedded ganglia are reported to be 
reduced compared with those in frozen sections (McCarthy and Lawson,  1990), but the 
pattern of neuronal size distribution are unaffected (Lawson and Harper,  1985). For 
minimising the influences resulted from tissue preparation, including transcardial perfusion 
with 4% depolymerized paraformaldehyde and processing in a Shandon Citadel automated
8 1tissue processor, the graph of results was shown by comparisons between both side L4+L5 
DRGs in each animal.
In this study, the pattern of cell diameter distribution was taken into consideration 
instead of actual size; the latter is only useful if all the ganglia were from animals of the 
same age and processed at the same time, and should be assessed using stereological 
criteria.
2.3  Immunohistochemical study of activated caspase-3, nestin, g-111
tubulin. trkA, trkC and CGRP
2.3.1  Immunohistochemistry for activated caspase-3 and nestin
Half of the remaining serial 3 pm sections from the study of apoptotic neuron 
counting (section 2.2.2) were immunostained for activated caspase-3, a proteolytic enzyme 
that is activated during apoptosis. Three 3pm sections from 3 non-adjacent levels, equally 
spaced through DRG, in unoperated (n=4), 4 week axotomy + systemic vehicle 
administration (n=4), 4 week axotomy + systemic NT-3 (5mg) administration (n=4), and 8 
week axotomy + systemic vehicle administration (n=4) rats were used for nestin 
immunohistochemistry. Remaining sections were used for double-labelling experiments.
Sections were deparaffmized in xylene and rehydrated in graded alcohols before 
being immersed in 600ml of 0.1 M citrate buffer pH 6.0 and microwaved at full power for 
20 minutes in a 650 watt microwave oven. The slides were then washed in 3 changes of 
phosphate-buffered saline pH 7.4 (PBS) and blocked in 10% non-immune swine serum for
8230 minutes. This was tipped off before the sections were incubated overnight at room 
temperature in either rabbit polyclonal anti-activated caspase-3 antibody (R&D Systems 
Europe Ltd) diluted 1:1000 in PBS containing 0.1% triton-X (PBS-TX) or mouse 
monoclonal anti-nestin antibody (1:1000; RAT-401: DSHB). Sections of El 4 rat embryos 
were used as positive controls.
After washing in PBS for 3 times (5 minutes each wash), the sections were 
incubated for 1  hour at room temperature in either biotinylated swine anti-rabit secondary 
antibody (1:500 in PBS-TX; Dako) or biotinylated goat anti-mouse secondary antibody 
(1:200 in PBS-TX; Dako). All sections were then rinsed 3 times in PBS and further 
incubated for 1  hour at room temperature in peroxidase-conjugated strptavidin (1:300 in 
PBS-TX: Sigma). All sections were then immersed in 0.05% diaminobenzidine (DAB) in 
PBS containing 0.04% nickel chloride (NiCh) to intensify the chromogen reaction and 
0.01% hydrogen peroxide (H2O2) for 10 minutes to visualise antibody binding. The 
sections were then washed in PBS twice, rinsed in distilled water, dehydrated through 
graded alcohols and mounted.
Immunoreactive cells and neurons appear blue/black. The diameters of nestin- 
immunoreactive neurons were measured using the methods described in section 2.2.4. The 
incidence of nestin-immunoreactive DRG neurons was estimated by counting the number 
of nestin-immunoreactive and non-nestin-immunoreactive neurons at 3 widely spaced 
levels from each ganglion; all profiles with nuclei were counted. Nestin-immunoreactive 
and non-nestin-immunoreactive neurons had to be at least 15pm in diameter, and to have 
the morphology of neurons (round or polygonal shape, large nuclei with nucleoli and little 
chromatin) to be counted.
832.3.2  Double immunofluorescence for nestin and fi-III tubulin, trkA, trkC or CGRP
Double-labelling immunofluorescence was used to investigate the co-expression of 
nestin (mouse monoclonal antibody) with the neuronal antigen (3-III tubulin (1:1000, mouse 
monoclonal; Sigma), trkA (1:500, rabbit polyclonal; Santa Cruz), trkC (1:100, rabbit 
polyclonal; Santa Cruz), or CGRP (1:1000, rabbit polyclonal; kindly provided by P. Facer, 
Imperial College London).
For polyclonal antibodies, the sections were deparaffinized, rehydrated, 
immunostained for nestin in the same way as described in 2.3.1 except the fluoroscein- 
conjugated avidin was used instead of horseradish peroxidase-conjugated streptavidin. 
Polyclonal antibodies were diluted in PBS-TX and were incubated with the nestin primary 
antibody and visualised with Texas red-conjugated goat anti-rabbit secondary antibody 
(1:100; Sigma). After washing in PBS the sections were coverslipped in Citifluor (Agar) 
and viewed with a Zeiss Axioskop fluorescence microscope with filter sets for fluoroscein 
and Texas red.
For the monoclonal anti-P-III tubulin antibody, nestin was immunostained first, 
incubated with biotinylated secondary antibody and then fluoroscein-conjugated avidin.
The slides were then blocked in rabbit anti-mouse antibody (1:10 in PBS-TX) for 30 
minutes before incubation in the second primary antibody and subsequent detection with a 
Texas red-conjugated goat anti-mouse secondary antibody (1:100 in PBS-TX; Sigma).
After washing in PBS, these slides were coverslipped and viewed under fluorescence 
microscope as described in previous paragraph.
84Controls for double labelling included omission of primary or secondary antisera 
and reversal of the order of primary antibody staining.
2.4  mRNA expression: studied by real-time quantitative PCR
2.4.1  Total RNA extraction
At 1  day,  1  week, 2 weeks and 4 weeks after surgical procedure,  10 rats (5 vehicle- 
treated and 5 NT-3-treated), at each time point were terminally anaesthetised with an intra- 
peritoneal injection of pentobabitone (60 mg/kg). Five additional unoperated animals 
provided normal tissue. The right and left L4 and L5 DRGs were identified by dissection of 
their spinal nerves as far as they fuse to form the sciatic nerve, and were removed rapidly 
and kept separate in ice cold  150 pi RNAlater (Qiagen) to minimise RNA degradation. For 
minimising the interference of RNA contributed by cells other than DRG cells, the 
surrounding capsule tissue was stripped off by fine surgical forceps under operative 
microscope. The protocol of RNeasy Mini Kit from Qiagen was used to isolate total RNA. 
A 2 ml tube was used to prepare the lysis Buffer RLT (add 6 pi (3-Mercaptoethanol to 600 
pi Buffer RLT from RNeasy Mini Kit). These ganglia were then cut thoroughly in 
appropriate amount of Buffer RLT using sterile disposable scalpels, and the L4 and L5 
DRGs on the same side in each animal were pooled together and processed as follows: the 
cut-up DRGs were pipetted into a 2 ml tube with Buffer RLT in it, and homogenised by 
centrifuging in QIAshredder spin columns at 14,000 rpm (11,000 x g) for 2 minutes at RT. 
The used column was discarded, replaced by a cap, and the collection tube was centrifuged
85at the same speed for another 3 minutes. The supernatant was mixed to 600 pi 70% ethanol 
in a new 2 ml microcentrifuge tube, and aliquots of 700 pi were loaded and centrifuged at
10,000  rpm (8,000 x g) for 15 seconds in an RNeasy mini column to isolate total RNA. 350 
pi Buffer RW1 was added to the column and centrifuged at 10,000 rpm for 15 seconds to 
wash the RNA bound to the membrane. In order to prepare pure total RNA without DNA 
contamination, DNase Set (Qiagen) was used as described below.
10 pi DNase I solution (30 units) was gently mixed with 70 pi Buffer RDD and 
pipetted directly onto the RNeasy mini column for incubation for 20 mins at 20-30 °C.  350 
pi Buffer RW1 was applied into the RNeasy mini column and centrifuged at at 10,000 rpm 
for 1   minute to clear up the membrane-bound RNA. The RNeasy column was then 
transferred into a new 2 ml RNase-free collection tube. 500 pi of Buffer RPE was pippetted 
onto the RNeasy column, followed by centrifuging at 10,000 rpm for 15 seconds. The 
RNeasy column was transferred into a new 2ml RNase-free collection tube and was 
centrifuged at full speed for 1  min. RNeasy column was transferred to a 1.5ml RNase-free 
collection tube and eluted by 50 pi RNase-free water which was applied directly onto the 
RNeasy silica-gel membrane and stayed for 1   minute before being centrifuged at 10,000 
rpm for 1  minute. The extracted total RNA was proceeded to the next step for precipitation.
2.4.2  Precipitation of total RNA
A 1/10 volume of 2M Sodium acetate pH 4.0 was added to an RNA sample 
resulting from RNeasy mini kit extraction procedure. One volume of Isopropanol was 
added and vortexed briefly. The mixture was incubated overnight at -20 °C to precipitate 
the RNA. The RNA was pelleted by centrifuging at 12,500 rpm (10,000 x g) for 15 minutes
86at 4 °C. The supernatant was decanted and the pellet was washed with  180 pi of ice cold 
75% ethanol to remove the salt and centrifuged at 12,500 rpm (10,000 x g) for 15 minutes 
at 4 °C. The supernatant was drained and the tube was left drying in the air for 5 minutes. 
The RNA was resuspended in appropriate amount of RNA-free water to the concentration 
of 2 pg total RNA in 12.5 pi water.
2.4.3 Quantitation of total RNA in solution
Concentration and purity of total RNA were determined by measuring the ratio of 
the absorbance of RNA samples at 260nm and 280 nm respectively (ratios between 1.8 and
2.0  are acceptable). 2 pi of RNA sample was diluted into 78 pi of dP^O. RNA samples 
were measured in cuvettes in a GeneQuant II spectrophotometer (Pharmacia Biotech).
2.4.4 Reverse transcription
Ominiscript RT Kit (Qiagen), which is suitable for 50 ng -2 pg total RNA, was 
used for the reverse transcription reaction for cDNA (complementary or copy DNA) library 
synthesis. All the reagents were thawed on ice and the following procedures were also 
carried out on ice. Oligo-dT primer was used to anneal to the 3’ polyadenyl “tail” of the 
mRNA. A 20 pi master mix was prepared by adding 12.5 pi template total RNA, 2 pi  10 x 
Buffer RT, 2 pi dNTP (5 mM), 2 pi oligo-dT primer (10 pM), 0.5 pi RNase inhibitor and 1  
pi Omniscript reverse transcriptase (company Roche,  10 units/pi) into thin-walled PCR 
tubes and mixed thoroughly. The reaction was carried out in a in a GeneAmp PCR system9700 (Applied Biosystems). The 3-step programme included incubation at 37 °C for one 
hour, reverse transcriptase inactivation at 93 °C for 5 mins and rapid cooling to 4 °C.
2.4.5 Primer design and preparation
PCR primers for NGF, BDNF, NT-3, trkA, trkB (catalytic isoform), trkC (catalytic 
isoform), p75NTR, nestin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which 
is used as a housekeeping gene, were designed from published sequences (Table 2.2) and 
synthesised by MWG Biotech AG (Germany) and Sigma (St. Louis, USA). Primers need to 
be 18-30 nucleotides long; both primers should have similar G + C content in order to have 
similar annealing temperature, and they were carefully checked by Blast (National Centre 
for Biotechnology Information, website: http://www.ncbi.nlm.gov/Blast/) to confirm the 
specificity of these primers and by a software “Generunner (version 3.05, freely 
downloaded from http://www.generunner.com) to minimise the formation of secondary 
structures or primary duplexes. The dried primer was prepared to a concentration of 100 
pmol/pl (100 mM) by adding appropriate amount of distilled water shown on the product 
sheet from the suppliers. A 5 mM primer solution was then made by mixing 10 pi the 
lOOmM primer solution into  190 pi distilled water, and aliquots were made and kept at -20 
°C.
2.4.6 Polymerase chain reaction (PCR)
PCR is a method of DNA synthesis resulting in the amplification of a fragment of interest 
from single-stranded DNA template or cDNA libraries. Reactions were carried out in thin- 
walled PCR tubes in a GeneAmp PCR system 9700 (Applied Biosystems). HotStarTaq
88Master Mix Kit (Qiagen) was used and its instruction followed. Preparing a 30 pi reaction 
mix, 0.6 pi cDNA, 3 pi 5’ primer (0.5 pM), 3 pi 3’ primer (0.5 pM), 8.4 pi distilled water 
and 15 pi HotStar Master Mix were added. In all experiments, samples containing no 
template were included to serve as negative controls. The programme included pre­
incubation step at 95°C for 15 min to activate the DNA polymerase, denaturation at 95 °C 
for 45 seconds, annealing at 55 °C, 58 °C, or 61  °C for 1   min, and extension at 72 °C for 1  
min. After 40 cycles, a 10 mins final extension at 72 °C was carried out, followed by 
cooling to 4 °C.
89Table 2.2: Oligonucleotide sequences used in the real-time quantitative PCR reactions
Forward primer Reverse primer
GenBank
accession
number
NGF
ACAGGCAGAACCGTAC
ACAG
(337-356)
ATCCAGAGTGTCCGAAG
AGG
(595-576)
M36589
BDNF
CCGC  AAAC  AT  GTCT  AT
GAGG
(2485-2504)
GATTFFFTAGTTCGGCAT
TG
(2767-2748)
D10938 
(Yun et al., 
2002)
NT-3 AGAAGCCAGGCCAGTC 
AAAA (681-700)
TCCCGAGAGCCCAATCA 
CAA (1092-1073)
M33968 (Zha 
et al., 2001)
TrkA
ATGGAGAACCCACAGT 
ACTTC (1541-1561)
CGTGCAGACTCCAAAGA 
AGC (1791-1810)
M85214
TrkB
(catalytic)
AAAGGCCCAGCTTCCG
TCAT
(2054-2073)
GGGGGTTTTCAATGACA
GGG
(2183-2202)
M55291 
(Moshnyakov 
et al., 1996)
TrkC
(catalytic)
GGGAAGCAACCATGGT 
TC
(2308-2325)
AAACGCTTGGCCACCAG
T
(2535-2552)
L03813 
(Moshnyakov 
et al.,  1996)
P75N TR
TGCAGTGTGCAGATGT
GCCT
(428-447)
GGGATCTCTTCGCATTCA
GC
(672-691)
X05137
GAPDH
CCCATCACCATCTTCCA 
GGAGC (241-262)
CCAGTGAGCTTCCCGTTC 
AGC (713-693)
NM_017008-1
2.4.7  Preparation of  standard samples: agarose gel electrophoresis of  DNA
To check for the presence of a PCR product of the expected size and quantity as the 
result of optimisation of primers, PCR products were separated on agarose gels. A 2 % 
(w/v) agarose gel was made by dissolving 2.4 g agarose and 5 pi Ethidium bromide, which 
permits direct visualisation of DNA products with ultraviolet (UV) light, were dissolved 
into 120ml of 1   x TBE (lOOmM Tris, 83 mM Boric acid, 1  mM EDTA) in a microwave
90(600 w) for 10 minutes. The boiled transparent solution was left to cool before it was 
poured into a tape-sealed rectangular mould. A comb is positioned onto the sockets at the 
top of the mould for forming the wells. After the gel was solidified at RT, the comb and the 
tape seals were removed. The gel was placed into an electrophoresis tank filled with  1   x 
TBE to cover the surface of the gel and electrodes.  10 pi of each DNA sample was mixed 
with 2 pi of 6 x loading buffer (0.25 % bromophenol blue, 0.5 % xylene cyanol FF, 3 % 
glycerol in water) and loaded into the wells.  100 bp size standard markers were also mixed 
with 1:5 loading buffer and loaded into separate wells for determining the fragment sizes of 
the PCR products. Agarose gels were run at 110 V for 60- 90 minutes or until the dye front 
nearly run through the gel. The gel was then placed into a UV box and the relative size of 
the PCR products was visualised by EagleSight software version 3.2 (Stratagene). The 
densities of the PCR products from the same primers but with different annealing 
temperatures were compared to decide the best reaction condition.
2.4.8  Preparation of  standard samples: isolation and extraction of  DNA fragments from 
agarose gel
The whole gel was put into a UV box and the desired fragment was excised with a 
sharp sterile scalpel blade according to the visible fragment. The small block of gel 
including the fragment of interest was put into a 2 ml autoclaved tube and the instruction of 
QIAquick Gel Extraction Kit (Qiagen) was followed. The excised piece of gel was weighed 
for using appropriate amount of reagents during the extraction. Three volume (600pl) 
Buffer QG was added into the 2 ml tube and incubated at 50 °C for at least 10 mins until 
the gel was totally dissolved. One volume (200pl) of isopropanol was added, mixed well
91and pipetted into a QIAquick Spin column. The mix was centrifuged for 1  min at 14,000 g 
and the flow-through was discarded. Another 500 pi buffer QG was added and centrifuged 
for 1  min at 14,000 g to dissolve any residual gel. 750 pi Buffer PE was pipetted into the 
column and centrifuge for 1   min at  14,000 g for washing the membrane-bound PCR 
product. After discarding the flow-through, another 1   min centrifugation was carried out to 
dry the membrane inside the QIAquick column. The column was placed to a new 1.5 ml 
tube and put in a 37 °C incubator for 5 mins with cap open. For elution of PCR fragments, 
30 pi Buffer EB was carefully pipetted directly to the membrane, and centrifuged for 1  min 
at 14,000 g. The purified PCR product was stored at -20 °C for standard sample 
preparation.
2.4.9  Preparation of standard samples: agarose gel electrophoresis of  PCR templates
Another 2 % (w/v) agarose gel with  14 wells in it was made as described before.  15 
pi of each standard DNA sample was mixed with 3 pi of 6 x loading buffer (0.25 % 
bromophenol blue, 0.5 % xylene cyanol FF, 3 % glycerol in water) and carefully loaded 
into the wells.  1   pi (0.5 ng) of pBR322 DNA/BsuRI (Fermentas Inc. Hanover, MD, USA) 
marker was mixed with 1  pi 6 x loading dye and 4 pi distilled water, and loaded into two 
separate wells for determining the fragment sizes of the PCR products. Agarose gels were 
run at 110 V for 90 -  120 minutes or until the dye front nearly run through the gel when the 
one or two bands with the closest size to each PCR product could be clearly separated from 
other bands. The gel was then placed into a UV box and the relative size the PCR products 
was visualised by the EagleEye software in the computer. The function of “Integrated 
density analysis”, which was defined as the sum of the pixel values in a selected area, was
92used to determine the copy number of the standard sample by comparing to the marker with 
known amount of DNA. Standards were made by ten-fold serial dilutions of each recovered 
PCR products in tRNA (101  -106 copies/2pl except GAPDH 102-107 copies/2pl).
The calculation formula was shown as below:
For example (Figure 2.2):
15 pi of PCR products of trkA was loaded with 3 pi loading dye, and electrophoresis was 
performed with  1   pi (0.5 ng) of pBR322 DNA/BsuRI (company) marker in separate wells. 
Integrated density:
TrkA (270bp):  13896
Marker (267bp, 30.5ng in  1   pi): 4352 (left lane), 4330 (right lane)
TrkA: 30.5x(13896*(4352+4330)/2)=97.63ng (in 15pl) »  13.02ng trkA PCR products in 
2 pi.
Molecular weight of TrkA (270bp)=approximately 270 bpx660 g/bp=178,200g/6.02xl023 
molecules
» 1  ng=3.38xl09 molecules
» 2  pl=13.02ng=4.40xl010 molecules
Serial dilutions of trkA were prepared for standards:
6 standards were used in the real-time quantitative PCR:  106 molecules/2 pi,
105 molecules/2 pi,  104 molecules/2 pi, 103 molecules/2 pi,  102 molecules/2 pi,  101  
molecules/2 pi.
93267
Marker Marker
TrkB BDNF
TrkA GAPDH
Figure 2.2: Agarose gel electrophoresis of PCR templates.
2.4.10  Gene expression: real-time quantitative PCR
Real-time PCR was performed using a LightCyclerTM rapid thermal cycler system 
(Roche Diagnostics, Lewes, UK), which is an advanced instrument that conducts rapid 
thermal cycling of the PCR. It has been proven to be a more sensitive and accurate method 
for quantification than in situ hybridisation, northern blotting, or conventional RT-PCR 
(Mackay et al., 2002). In brief, SYBR Green I dye, whose fluorescence is greatly enhanced 
by binding to the minor grooves of the dsDNA, is included in the PCR buffer. After 
annealing and elongation phase of the PCR, all of the products have become double­
stranded, and a maximum amount of dye is bound. The fluorescence is recorded at the end 
of each elongation phase, and increasing amounts of PCR product can be monitored from 
cycle to cycle. Extension or termination of runs is also permitted, depending on the 
conditions.
94Reactions were done in a  lOpl volume using 5pM primers, dNTPs, FastStart Taq 
DNA polymerase, DNA double-strand-specific SYBR Green I dye and reaction buffer 
provided in the LightCycler-FastStart DNA Master SYBR Green I mix. SYBR Green I dye 
preferentially binds to double-stranded DNA and emits a fluorescent signal proportional to 
the amount of PCR products. The programme included pre-incubation step at 95°C for 15 
min, denaturation at 95°C for 15 seconds, annealing at 55°C (GAPDH), 58°C (TrkA, TrkB, 
TrkC and BDNF) or 61°C (NGF, NT-3, and p75NTR) for 20 seconds, and extension at 72°C 
for a variable time depending on PCR product size (10-24 seconds). Fluorescent detection 
to see the real-time amounts of PCR products was carried out at the end of each cycle after 
a 5-second step 3-5°C below the Tm of product (Figure 2.3). Each dsDNA product has its 
own specific melting temperature (Tm), which is defined as the temperature at which 50% 
of the DNA becomes single stranded, and 50% remains double stranded. The most 
important factors determining the Tm are the length and the GC content of PCR product.
To confirm amplification specificity, the PCR products from each primer pairs were 
subjected to a melting curve analysis (Figure 2.4) after 40-cycle amplification and 
subsequent 2% agarose gel electrophoresis. After completion of PCR, the copy number of 
target genes was calculated by LightCycler software version 3.5.3, which quantifies the 
sample using extrapolation from the standard curves (Figure 2.5). To make the data 
comparable between animals, the copy numbers of a gene were normalised to a 
housekeeping gene, GAPDH, before further statistical analysis. The expression of the genes 
investigated was shown as “copies/10,000 GAPDH copies.” The expression in the axotomy 
+ vehicle group was compared with that of the unoperated group in order to detect how 
these genes were regulated by the injury to the peripheral nerve, and the axotomy +
95systemic NT-3 group was compared with axotomy + vehicle group to assess the net effects 
of systemic NT-3 administration in injured ganglia.
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Figure 2.3: Real-time quantitative PCR. The graph shows increase in fluorescence during 
amplification of trkA using SYBR Green I dye.
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Figure 2.4: Melting curve analysis of trkB PCR fragment.
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Figure 2.5: Real-time quantitative PCR (standard curves). Fluorescence History Graph 
displays the development of fluorescence signal intensity in six standard samples of trkA.
2.5  mRNA expression:  in situ hybridisation
2.5.1 Tissue preparations
14 animals, including 2 animals in each experimental group (1  day,  1   week. 2
weeks) and 2 unoperated controls were perfused transcardially with 4% paraformaldehyde 
in 0.1 M phosphate buffer pH 7.4 at RT for 15 mins under terminal pentobarbitone 
anaesthesia. The right L4 and L5 dorsal root ganglia were removed and allowed to fix in 
10% formalin saline for a further 24 hours before being processed into paraffin. Seven- 
micrometer thick sections were cut and mounted onto Superfrost slides (BDH) in strips of 4 
and dried overnight at 37°C.
2.5.2 Probe preparation
97Oligonucleotide probes, purified by HPLC, were synthesised by MWG Biotech AG 
(Germany) and Sigma (St. Louis, USA). The sequences were complementary to NGF, 
BDNF, NT-3, trkA, trkB, trkC and p75N TR (Table 2.3). The trkB and trkC probes were 
located in the tyrosine kinase domain to detect the catalytic isoforms of them. The 
oligonucleotides were labelled at the 3’-end with digoxigenin by using DIG 
Oligonucleotide 3’-tailing kit (Roche, Lewes, UK), which in average could incorporate 5 
DIG molecules in a tail length of 50 to the 3’-end of the probe. In a 20 pi reaction volume, 
100 pmol oligonucleotide in 9 pi distilled water, 4 pi of 5 x reaction buffer (1  M potassium 
cacodylate, 0.125 M Tris-HCl,  1.25 mg/ml bovine serum albumin, pH 6.6), 4 pi of 25 mM 
C0CI2 solution,  1   pi of 1   mM DIG-dUTP solution,  1   pi of 10 mM dATP solution and  1   pi 
of terminal transferase (in 0.2 M potassium cacodylate,  1   mM EDTA, 200 mM KC1, 0.2 
mg/ml bovine serum albumin) were placed together, well mixed and incubated for 15 
minutes in a 37 °C water bath, followed by adding 2 pi 0.2M EDTA (pH 8.0) on ice to stop 
the reaction.
The DIG-labelled probes were stored in -20°C.
2.5.3  Tissue permeablisation
Paraffin sections were dewaxed in xylene, hydrated in graded alcohol and distilled 
water. The slides were put level in a plastic container and  150 pi of 20 pg/mL proteinase K 
(Sigma, St Louis, USA) was applied onto the sections which were incubated in a water bath 
incubator for 10 minutes at 37°C. The slides were moved to a plastic rack, rinsed in tap 
water and PBS; before being immersed in 0.1 M citrate buffer, pH 6.0, and heated in a 
650W microwave oven for 15 minutes. After a brief wash in PBS, the sections were
98incubated in 100 jj.1  of 1000 units/mL deoxyribonuclease I (Invirogen) for 30 minutes at 
37°C.
Table 2.3: Oligonucleotide sequences used in in situ hybridisation.
Probe GenBank 
accession number
NGF
CTG CGG GCT CTG CGG AGG GCT GTG TCA 
AGG GAA TGC TGA AGT TTA GTC CA (447- 
398) M36589 
(Nosrat et al., 
1997) NGF
Control
TGG ACT AAA CTT CAG CAT TCC CTT GAC 
ACA GCC CTC CGC AGA GCC CGC AG (398- 
447)
BDNF
CTC CAG AGT CCC ATG GGT CCG CAC AGC 
TGG GTA GGC CAA G (2255-2216) M36589 
(Nosrat et al., 
1997) BDNF
Control
CTT GGC CTA CCC AGC TGT GCG GAC CCA 
TGG GAC TCT GGA G (2216-2255)
NT-3
TTT GTC ATC AAT CCC CCT GCA ACC GTT 
TTT GAC TGG CCT GGC T (726-684) M36589 
(Nosrat et al., 
1997) NT-3
Control
AGC CAG GCC AGT CAA AAA CGG TTG CAG 
GGG GAT TGA TGA CAA A (684-726)
TrkA
AGG GTT GAA CTC AAA AGG GTT GTC CAT 
AAA GGC AGC CAT GAT G (1231-1189) M85214 
(Meakin et al., 
1992) TrkA
control
CAT CAT GGC TGC CTT TAT GGA CAA CCC 
TTT TGA GTT CAA CCC T (1189-1231)
TrkB
CCA TTA TTC ATA TGA GTG GGG TTA TCC 
AGC TGG AGG CAG CCG TGG (1734-1690) M55291 
(Middlemas et 
al.,  1991) TrkB
Control
CCA CGG CTG CCT CCA GCT GGA TAA CCC 
CAC TCA TAT GAA TAA TGG (1690-1734)
TrkC
TCC AAA GGC TCC CTC ACC CAG TTC TCT 
CTT CAA CAC GAT GTC TCT (1701-1657) L03813 
(Merlio et al., 
1992) TrkC
control
AGA GAC ATC GTG TTG AAG AGA GAA CTG 
GGT GAG GGA GCC TTT GGA (1657-1701)
p75N TR
CAC AAG GCC CAC GAC CAC AGC AGC CAA 
GAT GGA GCA ATA GAC AGG (918-873) X05137 
(Radeke et al., 
1987) p is™
control
CCT GTC TAT TGC TCC ATC TTG GCT GCT 
GTG GTC GTG GGC CTT GTG (873-918)
992.5.4 Hybridisation
Hybridisation mix without probes was preheated to 37 °C. For prehybridisation, 
sections were covered with  lOOpJL hybridisation mix, containing 2 x SSC, 5% dextran 
sulfate, 10% formamide, 200pg/ml SSDA and 0.1 mg/ml poly [A] (Roche), for 30 minutes 
at 37°C. Poly [A] was used to block the non-specific hybridisation of the DIG-dUTP/dATP 
tail to related homologous sequences. Then, the prehybridisation mix was poured off and 
100 |il hybridisation mix containing 0.5pg/mL sense (used as a negative control) or 
antisense probe and prehybridisation solution was applied gently to the slides. The slides 
were carefully covered with Parafilm membrane which was trimmed to fit the size of the 
section, avoided of any air bubbles and put into a tape-sealed plastic container incubated in 
a water bath incubator for 16 h at 37°C.
Post-hybridisation washes were undertaken as follows: Rinse in  1   x SSC once for 2 
minutes at RT,  1   x SSC for 15 minutes at 55 °C, 0.5 x SSC for 15 minutes at 55 °C, and 
once in 0.5 x SSC for 10 minutes at RT. Non-specific binding sites were blocked in 10% 
milk for 15 minutes at RT, followed by an  1   : 200 alkaline phosphatase-coupled sheep anti- 
DIG IgG (Roche), which binds to the DIG label of the oligonucleotide probe, in 2% milk 
for 30 minutes at room temperature. The anti-DIG-AP antibody was then washed away by 
3 washes in TBST buffer (100 mM Tris-HCl,  150 mM NaCl, pH 7.5) for 5 minutes at RT.
There were a number of controls added to my experiment to verify that the probes 
used were in fact binding selectively to the target mRNA sequences and not to other 
components of the cell or other closely related mRNA sequences. The tissue was digested 
with RNases prior to hybridisation with the oligonucleotide probe. The absence of binding 
after RNase treatment indicates that binding was indeed to RNA within the tissue. The
100sense control probe gives a measure of non-specific probe binding only due to the chemical 
properties of the probe.
2.5.5  Detection
The colour reaction was developed by NBT/BCIP, after 5 minutes incubation in 1   x 
detection buffer (0.1 M Tris-HCl, 0.1M NaCl, pH 9.5) at RT. The alkaline phosphatase 
substrate consists of 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) and nitro blue 
tetrazolium chloride (NBT). In a 20 ml tube protected from light with foil, one tablet of 
NBT/BCIP (Roche) was dissolved in  10 ml distilled water with  100 pi levamisole 
(20mg/ml, Sigma). Approximately 300 pi of AP substrate was the placed per slide. After 
appropriate time of reaction (3-16 hours), sections were washed with water, dehydrated in 
graded alcohol and mounted in aqueous mounting medium and examined under a light 
microscope. Under microscopy, the type of cells (neurons, Schwann cells, or satellite 
cells...) expressing a certain mRNA was identified and recorded to assist the data analysis 
from real-time PCR study.
2.6 mRNA expression: studied by microarrav
2.6.1  Tissue preparation
24 experimental rats with NT-3 or vehicle subcutaneous pump were sacrificed at 2 
weeks after operation by deep anaesthesia with pentobarbitone (60mg/kg, i.p.);  12 
additional unoperated animals provided control DRGs. The right L4 and L5 dorsal root
101ganglia were removed rapidly and kept in RNAlater solution (Qiagen) on ice. These 
ganglia were cut thoroughly and total RNA was isolated using QIAshredder spin column, 
RNeasy Mini Kit and DNase Set (Qiagen) as described in 2.3.1. RNA was assessed 
quantitatively by spectrophotometry and precipitated, using sodium acetate, pH 4.0, and 
isopropanol at -20°C overnight, and then resuspended in appropriate amount of RNase-free 
water. Triplicate measurements were carried out on different DRG tissue. Each RNA 
sample used for hybridisation of each array was extracted from rat right L4 and L5 DRGs 
(8 ganglia were pooled from 4 animals).
RNA samples were analysed by denatured gel electrophoresis and RNA quality was 
assessed by capillary electrophoresis (Bioanalyzer 2100 Agilent, Palo Alto, CA, USA) to 
ensure the 28S:18S rRNA ratio was > 1.0 for each sample.
2.6.2  Quantification of total RNA
RNA 6000 Nano LabChip Kit (Agilent Technologies) and Agilent 2100 bioanalyzer 
were used, following the maker’s instructions. 400 pi RNA 6000 Nano gel matrix was 
placed into a spin column and centrifuged at 4000 rpm (1500 x g) in an Eppendorf 
microcentrifuge for 10 minutes. 2 pi RNA 6000 Nano dye concentrate was added to 130 pi 
of filtered gel matrix, vortexed (model MS2-S8) and then centrifuged at 14,000 rpm 
(13,000 x g) for 10 minutes at 4 °C. 9 pi of the gel-dye mixture was properly pipetted to 
each of the three wells marked with “G”, and the chip was primed using Chip Priming 
Station to plunge 1  ml air for 30 seconds over the wells applied with gel-dye mixture. 5 pi 
RNA 6000 Nano Marker was pipetted into all the wells except the three filled with gel-dye 
mix. RNA 6000 ladder (Ambion Inc., cat. No. 7152) and all RNA samples were incubated
102at 70 °C for 2 minutes to prevent secondary structures.  1   pi of the each RNA sample and 
the ladder was pipetted into sample wells and the ladder well. Then the chip was vortexed 
for 1  minute at the IKA Vortex Mixer (model MS2-S8/MS2-S9). The assay started to be 
analysed after inserting the chip into the Agilent 2100 Bioanalyzer. The results of samples 
were shown by electropherogram and the quality and concentration of RNA was 
determined.
2.6.3 First strand cDNA synthesis
In a thin-walled PCR tube,  15 pi total RNA was added with 2 pL oligo[(dT)24 T7 
promotor]65 primer (100pmol/pl)(5’-GGC CAG TGA ATT GTA ATA CGA CTC ACT 
ATA GGG AGG CGG-(T)24-3’) and 4 pi distilled water, denatured at 70°C for 10 min and 
quick-chilled on ice for 2 minutes. After adding 8 pL 5x first strand RT-buffer (50mM Tris, 
250mM KC1; pH 8.3), 4 pi 0.1 M DTT (0.1M), 4 pi dNTP (10 mM each), and  1   pi RNase 
inhibitor (25 U/pL) to the 21  pi RNA/primer mixture, first strand cDNA synthesis was 
performed at 42°C for one hour using 2 pi AMV Rerverse Transcriptase (25 U/pl). The 
reaction was terminated by placing on ice.
2.6.4 Second strand cDNA synthesis
Adding 72 pi DEPC-treated water, 30 pi 5x second strand buffer, 1.5 pi  lOmM 
dNTP mix (10 mM each), 6.5 pi second strand enzyme blend (E. coli DNA Polymerase I, E. 
coli DNA ligase and RNase H) to the 40pl first strand reaction to make a final volume of 
150 pL. Second strand cDNA synthesis was done at 16°C for 2 hours and followed by 20pi T4 DNA Polymerase (1  U/pL) at 16°C for another 5 minutes to fill in the ends of the 
double-stranded cDNA. The reaction was stopped by adding 17 pi EDTA (0.2 M, pH 8.0).
2.6.5 Cleanup of double-stranded cDNA
GeneChip Sample Cleanup Module (Qiagen) was used. 600 pi cDNA Wash Buffer 
(prepared by adding 24 ml  100% ethanol to 6 ml concentrate of cDNA Wash Buffer) was 
added to the final preparation of double-stranded cDNA synthesis and vortexed briefly. The 
pH value was adjusted by adding 3M sodium acetate if the colour of the mixture was not 
yellow. 500 pi of the mixture was loaded to the cDNA Cleanup Spin Column and 
centrifuged at 10,000 rpm (8,000 x g) for 1   minute at RT. The flow-through was discarded 
and the remaining 150 pi of mixture was loaded and spun. The Cleanup spin column was 
transferred to a 2 ml autoclaved tube, and another 750 pi cDNA Wash Buffer was added 
and centrifuged at 10,000 rpm (8,000 x g) for 1  minute at RT. 5 minutes of centrifugation 
was carried out with the cap of the spin column opened to ensure complete drying of the 
membrane. The spin column was transferred into a 1.5 ml collection tube, and  14 pi of 
cDNA Elution Buffer was applied directly onto the membrane. After incubation at RT for 1  
minute, cDNA was eluted by centrifuging the column at 12,500 rpm (10,000 x g).
2.6.6 Synthesis of biotin-labelled cRNA
Double-stranded cDNA was transcribed in vitro into the copy RNA (cRNA) 
labelled with biotin-UTP and biotin-CTP using Enzo BioArray HighYield RNA Transcript 
Labeling Kit (Affymetrix). An IVT cRNA labelling mix was prepared (12 pi double­
stranded cDNA.  10 pi distilled water, 4 pi  10 x HY Reaction Buffer, 4 pi  10x Biotin-
104labelled Ribonucleotides, 4pl  10 x DTT, 4 jj.1  10 x RNase Inhibitor Mix and 2 jj.1 20 x T7 
RNA polymerase) at RT, and incubated for 5 hours in a 37 °C water bath with mixing 
gently every 45 minutes. The biotin-labelled cRNA was proceeded to cleanup procedure.
2.6.7 Cleanup of  Biotin-labelled cRNA
60 pi of RNase-free water was added to the 40 pi in vitro transcription reaction and 
mixed briefly. 350 pi IVT cRNA Binding Buffer was pipetted to the tube and well mixed, 
followed by adding 250 pi  100% ethanol and pipetting to mix. The total 700 pi of the mix 
was then applied to the IVT cRNA Cleanup Spin Column and centrifuged at 10,000 rpm 
(8,000 x g) for 15 seconds at RT. The column was transferred to a new 2 ml tube and 
washed by 500 pi IVT cRNA Wash Buffer at  10,000 rpm (8,000 x g) for 15 seconds at RT 
and 500 pi 80% (v/v) ethanol at 10,000 rpm (8,000 x g) for 15 seconds. The spin column 
was centrifuged for another 5 minutes at 13,200 rpm (10,000 x g) to dry the membrane. 
The spin column was transferred to a new 1.5 ml collection tube and 21  pi RNase-free 
water was applied directly onto the membrane and biotin-labelled cRNA was eluted after 
centrifuging for 1  minute at 13200 rpm.
2.6.8 Quantification of  Biotin-labelled cRNA
RNA 6000 ladder (Ambion Inc., cat. No. 7152) and all biotin-labelled cRNA 
samples were incubated at 70°C for 2 minutes to prevent secondary structures.  1   pi of a 
1:10 dilution of each cRNA sample and the ladder was pipetted into sample and ladder 
wells of RNA 6000 Nano LabChip Kit. The assay was analysed using the Agilent 2100 
Bioanalyzer as described before. The concentration of RNA was determined.
1052.6.9 Fragmentation of Biotin-labelled cRNA
2 jliI of 5  x Fragmentation Buffer was added in the 8  |u.l biotin-labelled cRNA and 
incubated at 94 °C for 35 minutes for breaking cRNA to 35-200 base fragments by metal- 
induced hydrolysis. The reaction was stopped by putting on ice.
2.6.10 Target hybridisation
Hybridisation buffer (12 x MES:  100 mM MES [70.4 g MES-free acid 
monohydrate,  193.3g MES sodium salt in 1000ml water], pH 6.5-6.7,  1  M NaCl, 0.01% 
Tween 20, 20 mM EDTA, 0.5 mg/ml acetylated bovine serum albumin (BSA), 0.1  mg/ml 
herring sperm DNA, 50pM control oligonucleotide B2, and eukaryotic hybridisation 
controls [1.5 pM bioB, 5 pM bioC, 25 pM bioD and  lOOpM ere]) was added to 34 pi 
fragmented cRNA of each sample, resulting the final volume of 100 pi. Pre-hybridisation 
of the arrays was performed with 1   x Hybridisation Buffer at 45 °C for 10 minutes with 
rotation in Hybridisation Oven 640 (Affymetrix), and the hybridisation cocktail was heated 
for denaturation at 99 °C for 5 minutes, followed by equilibration at 45 °C for 5 minutes. 
Samples were then hybridised to Rat Neurobiology U-34 microarrays (Affymetrix) at 45°C 
for 16 hours using Hybridisation Oven 640.
2.6.11 Washing and staining
Microarrays were washed with non-stringent Wash Buffer A (6 x SSPE [20 x SSPE 
3M NaCl, 0.2M NaH2P0 4 , 0.02M EDTA], 0.01% Tween 20) at 25 °C for 10 cycles of 2 
mixes/cycle and then stringent Wash Buffer B (lOOmM MES, 0.1M [Na+], 0.01% Tween20) at 50 °C for 4 cycles of 15 mixes/cycle using the Fluidics Station 400. The arrays were 
incubated with SAPE solution (100 mM MES, 1M [Na+], 0.05% Tween 20, 50 mg/ml 
acetylated BSA, 1  mg/ml streptavidin phycoerythrin (SAPE) and distilled water) at 25 °C 
for 10 minutes, followed by 10 cycles of 4 mixes/cycle wash with Wash Buffer A. The 
probe arrays were then sequentially incubated with Antibody Solution Mix (100 mM MES, 
1M [Na+], 0.05% Tween 20, 2 mg/ml acetylated BSA, 0.1 mg/ml normal goat IgG, 3 pg/ml 
biotinylated antibody and distilled water) at 25 °C for 10 minutes, and SAPE solution at 25 
°C for 10 minutes. Final wash was performed with Wash Buffer A at 30 °C for 15 cycles of 
4 mixes/cycle.
2.6.12  Scanning
The Agilent HP G2500A GeneArray Scanner, controlled by Affymetrix Microarray 
Suite, was used to scan the probe arrays (Figure 2.6). Multiple distinct oligonucleotide 
probes on each chip represent every gene, and the intensity and colour of each spot encode 
information on a specific gene from the tested sample. Relatively low background and high 
and uniform signals in this image provide a basis for comparison of the microarrays.  The 
intensity of signal for genes was adjusted to 100 so that the mean intensities for each array 
were equal.
107Figure 2.6: Scanned images of a neurobiology U-34 microarray.
2.6.13 Data analysis
The data were collected and globally scaled to a target intensity of 100 using 
Affymetrix Microarray Suite 5.0. Pairwise comparisons were generated using Microarray 
Suite and analysed using Affymetrix MicroDB and DataMiningTool 3.0. The other data 
analysis was performed using Genespring 5.1  (Silicon Genetics).
2.6.14 Confirmation by real-time quantitative PCR
PCR primers for neurofilament-light chain (NF-L), neuropeptide Y (NP-Y), 5HT3 
receptor (5HT-3R), p75NTR, heat shock protein (HSP) 70, peripheral-type benzodiazepine 
receptor, glutamate receptor subnit 5-2, and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), which is used as a housekeeping gene, were designed from published sequences 
(Table 2.4). Conventional PCR reactions were performed in a 30pl solution using 
HotStarTaq Master Mix Kit (Qiagen) to optimise the condition. In all experiments, samples 
containing no template were included to serve as negative controls.
108Table 2.4: Oligonucleotide sequences used in the real-time quantitative PCR reactions for 
microarray confirmation.
Forward primer Reverse primer GenBank 
accession number
NF-L
ATGCTCAGATCTC 
CG TGGAGATG 
(790-812)
GCTTCGCAGCTCA
TTCTCCAGTT
(1154-1132)
AF031880 
(Chidlow and 
Osborne, 2003)
NP-Y
TCCAGCCCTGAGA 
CACTGATT (273- 
293)
CACCACATGGAA 
GGGTCTTCA (364- 
344)
M15880 
(Song et al., 
2001)
5HT-3R
ACG CTC CTT CTG 
GGA TAC TCA GT 
(850-872)
TGCACACTACAAA
GTAGACACCAATG
(952-927)
D49395 
(Wang et al., 
2002a)
p 7 5 n t r
TGCAGTGTGCAGAT
GTGCCT
(428-447)
GGGATCTCTTCGCA 
TTCAGC 
(672-691)
X05137
HSP70
CAAGAATGCGCTC 
GAGTCCTA (1791- 
1811)
GGAGATGACCTCC 
TGGCACTT (1914- 
1894)
LI 6764 
(Song et al., 
2001)
Peripheral-type
benzodiazepine
receptor
TGGTATGCTAGCT
TGCAGAAACC
(131-153)
CGAATACAGTGTG 
CCCCAGAT (208- 
188)
J05122 
(Wang et al., 
2002a)
Glutamate
Receptor
subunit5-2
CGGCATGAATTAA
GAAGCTTGAA
(163-185)
CCTCCGATCCTGA 
GCACTTG (309-290)
M83561 
(Wang et al., 
2002a)
GAPDH
CCCATCACCATCTT 
CCAGGAGC (241- 
262)
CCAGTGAGCTTCCC 
GTTCAGC (713-693) NM_017008-1
1092.7 Statistics
The individual values for neuron number, neuronal loss (right to left ratios) and 
apoptosis for the animals in the two treatment groups, and the operated and unoperated 
control groups, as well as the relative gene expression data between the different treatment 
groups and the unoperated control group were analysed using one-way ANOVA to check 
whether the groups of rats came from a population with the same mean followed by 
Tukey’s post hoc tests at 95% confidence limits to identify the existence of significant 
difference between any two groups. All data are given as mean ± SEM. The difference 
between the absolute neuronal numbers of right and left L4&L5 DRGs in each group was 
analysed using paired-t test. These were performed using SPSS  11.5 for Windows on an 
IBM-PC.
noCHAPTER 3: RESIIT.TS
1113.1 Effect of NT-3 on axotomy-induced neuron loss in adult rat dorsal
root ganglia
Animals receiving NT-3 appeared to tolerate it well and increased in weight to an 
identical degree over 4 weeks when compared to those receiving vehicle. Using ANOVA 
analysis, there was no difference in weight of rats (p>0.05, Table 3.1). In addition, there 
was no noticeable difference in behaviour such as keeping the affected limb raised or in the 
incidence of autotomy between NT-3 and vehicle-treated animals. Macroscopic 
examination of heart, lungs, kidney, liver and gastrointestinal tract did not reveal any 
abnormalities in any group.
3.1.1  Morphology
In the ipsilateral ganglia of all operated groups, the number of non-neuronal cells 
increased and numerous chromatolytic neurons with eccentric nuclei, marginal Nissl 
staining and a slightly shrunken appearance were observed (Figure 3.1), when compared to 
unoperated rat ganglia. At 4 weeks after sciatic nerve transection the histological 
appearance of the ipsilateral ganglia from both NT-3-treated groups was not substantially 
different from that of the vehicle-treated or transection/no treatment groups, with many 
neurons having eccentric nuclei, marginal Nissl staining and a slightly shrunken appearance 
typical of chromatolysis produced by axotomy.
112Figure 3.1: Chromatolytic neurons (arrowheads) 4 weeks after axotomy with vehicle 
administration, stained with cresyl fast violet. Some vacuolated neurons are visible 
(arrows). Scale bar =  1Opm
3.1.2  Neuronal number in axotomised DRG
The results of neuronal counting, using the stereological physical disector technique 
on 3 pm sections of the L4 and L5 DRGs from all 7 experimental groups of animals are 
summarised in Table 3.1. The thickness of each examined section was checked using a 
microcator as described in 2.2.3.
Analysed by one-way ANOVA, there was no significant difference in the mean 
total number of neurons in left L4 and L5 dorsal root ganglia (pooled) in any of the 
experimental groups (ANOVA: p>0.05). The ratio of neuron numbers between right (L4 & 
L5) and left (L4 & L5) in unoperated rats shows a consistently and significantly (paired t- 
test: p=0.016) greater number (about 7%) of neurons on the right side than on the left. An 
asymmetry in rat DRG neuron number has been reported (Ygge et al..  1981; Arvidsson et 
al.,  1986; Schmalbruch,  1987b).
The ratio of numbers of neurons in the ipsilateral L4 and L5 DRGs to those in the 
contralateral DRGs (Figure 3.2) show that there was no significant loss of neurons in the 
ipsilateral ganglia 2 weeks after mid-thigh sciatic nerve transection and ligation, in either
113NT-3-treated or vehicle-treated groups when compared to unoperated controls (ANOVA: 
p=0.069). In the 4 week axotomy without treatment and 4 week axotomy with vehicle 
administration groups, there was a statistically significant neuronal loss (Tukey’spost hoc 
test: p<0.05) of around  16% after peripheral axotomy.
Table 3.1: Mean neuron numbers and mean ratios of neuron numbers between ipsi- (right) 
and contralateral (left) L4 and L5 DRGs in each treatment group. The ratios of neuron 
numbers between the different treatment groups and the unoperated control group, and 
weight of rats (before tissue preparation) were analyzed using one-way ANOVA followed 
by Tukey’s post hoc tests (Appendix  1).
Group
(Weight of rats: mean 
±SD)
Mean number 
of neurons in 
left L4 & L5 (± 
SEM)
Mean  number 
of neurons in 
right L4 & L5 
(± SEM)
Mean R:L ratio 
in neuronal 
number (± 
SEM)
P value 
(Tukey’s 
post hoc, 
compared 
to
unoperated)
Unoperated rats, n=7 
(293.6 ±24.45)
25998 ± 904 27800± 1036 1.070 ±0.019
2 weeks sciatic 
transection with 
vehicle pump, 
n=4(313.75 ±29.38)
26826 ± 853 27128 ±1151 1.015 ±0.055 0.579
2 weeks sciatic 
transection with NT-3 
(0.625mg/2 weeks) 
pump, n=5 
(308.8 ±24.89)
29335 ± 1556 27290 ± 653 0.938 ±0.044 0.057
4 weeks axotomy, n=5 
(327.6 ±16.44)
28976± 1431 25995 ±912 0.898 ±0.030 0.013*
4 weeks sciatic 
transection with 
vehicle pump, n=5 
(324.2 ± 24.65)
25922 ±617 23608 ±1017 0.912 ±0.043 0.025*
4 weeks sciatic 
transection with NT-3 
(1.25mg/4 weeks) 
pump, n=5 
(334.0 ±26.22)
26387 ±731 26757 ± 504 1.019 ±0.045 0.817
1144 weeks sciatic 
transection with NT-3 
(5mg/4 weeks) pump, 27599± 1129 28693 ± 1317 1.042 ±0.038 0.979
n=4
(333.4 ±44.29)
* indicates p<0.05, compared with unoperated group.
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Figure 3.2: Mean ratios (± SEM) of neuron number between right and left L4 and L5 
DRGs for each treatment group. * indicates p < 0.05 compared with vehicle-treated group
3.1.3  Effect of  NT-3 on neuron number in axotomised DRG at two doses
In contrast to the significant neuronal loss occurring in the 4-week axotomy without 
treatment group and the 4-week axotomy with vehicle administration group, NT-3-treated 
groups at the dose of either  1.25mg/4 weeks or 5mg/4 weeks suffered no significant 
neuronal loss of ipsilateral neurons, relative to the contralateral. There was no significant 
difference between the rats treated with  1.25mg and 5mg NT-3 for 4 weeks after axotomy 
(p=0.996). These data show that systemic NT-3 administration preserves the R : L ratio in 
neuron number in L4 and L5 DRGs for up to 4 weeks following injury.4 weeks sciatic 
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(5mg/4 weeks) pump, 27599± 1129 28693 ±1317 1.042 ±0.038 0.979
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3.1.3  Effect of  NT-3 on neuron number in axotomised DRG at two doses
In contrast to the significant neuronal loss occurring in the 4-week axotomy without 
treatment group and the 4-week axotomy with vehicle administration group, NT-3-treated 
groups at the dose of either 1.25mg/4 weeks or 5mg/4 weeks suffered no significant 
neuronal loss of ipsilateral neurons, relative to the contralateral. There was no significant 
difference between the rats treated with 1.25mg and 5mg NT-3 for 4 weeks after axotomy 
(p=0.996). These data show that systemic NT-3 administration preserves the R : L ratio in 
neuron number in L4 and L5 DRGs for up to 4 weeks following injury.
1153.2 Effect of NT-3 on axotomv-induced neuron apoptosis in adult rat
dorsal root ganglia
Neuronal apoptosis in DRG has been previously reported and described following 
sciatic nerve transection in adult rat and mouse (Ekstrom,  1995; Groves et al.,  1997;
McKay Hart et al., 2002), but whether systemic NT-3 administration can affect the 
morphological features of neurons or the incidence of neuronal apoptosis in axotomised 
DRG has never been studied. This section reports the number of profiles of apoptotic 
neurons assessed by morphological and immunohistochemical criteria 2 and 4 weeks after 
mid-thigh sciatic nerve transection with no treatment, systemic vehicle administration or 
systemic NT-3 administration at two different doses.
3.2.1  Morphology
Profiles of apoptotic neurons in DRG were identified by morphological criteria. The 
key criterion was the condensation of DNA into several spherical condensed bodies. 
Secondary criteria were indistinct and irregular nuclear membrane, and darkly staining 
cytoplasm with condensed Nissl substance and shrunken appearance. There were some 
variations in morphology, such as the number, size and distribution of condensed nuclear 
chromatin bodies (Figure 3.3). Structures  15-30 pm in diameter that were lacking any 
visible cellular contents except for the remains of some condensed DNA, and which were 
surrounded by satellite cells, corresponded to the “ghost cells” (Figure 3.4) reported from 
cell culture studies of sympathetic neurons undergoing apoptosis (Edwards and Tolkovsky, 
1994). Ghost cells were seen particularly at the 2 week time point. Due to the difficulty to 
identify the origin of these cells, they were not counted as either normal or apoptotic
116neurons in this study. Neurons undergoing apoptosis in the NT-3-treated animals did not 
differ in morphology from those in the vehicle-treated rats.
Neither apoptotic or degenerating neurons, nor any evidence of neuronophagia or 
neuronal activated caspase-3 immunoreactivity were seen in any of the serial sections of 
unoperated or contralateral DRGs from any group. These data indicate that there is no 
detectable neuronal apoptosis occurring in normal DRGs or contralateral DRGs in operated 
animals, which makes it reasonable to estimate neuronal loss by the ratio of neuron number 
between right (L4 & L5) and left (L4 & L5) DRGs.
3.2.2  Incidence o f neuron apoptosis
Each section was estimated at a magnification of x400 under light microscope for 
profiles of apoptotic neurons. The total number of profiles of apoptotic neurons in half of 
the sections of each ganglion were counted and this figure was multiplied by 2 to obtain an 
estimate of the total per ganglion.
Figure 3.3 (for legend see next page)Figure 3.3: Apoptotic DRG neurons 2 vfeeks 
after axotomy with vehicle administration, 
stained with cresyl fast violet (A, B) and 
anti-activated caspase-3 antibody (C). These 
neurons have a shrunken and condensed 
shape and the characteristic condensed 
chromatin (arrowhead). The grey-purple 
staining of activated caspase-3 was detected 
in both nucleus and cytoplasm.
Figure 3.4: A ‘ghost cell' (arrowhead) 4 
weeks after axotomy with vehicle 
administration, stained with cresyl fast violet. 
Scale bar =  10pm
The number of profiles of apoptotic neurons ranges from  10.6-19.4 in pooled L4 & 
L5 DRGs (Table 3.2). When the data were analysed by performing ANOVA, the number 
of profiles of neurons showing the morphological characteristics of apoptosis did not differ 
significantly between any of the experimental groups (p=0.59, Figure 3.5). All neurons 
identified as apoptotic by their morphology showed activated caspase-3 immunoreactivity 
in sections immunostained for it (Figure 3.3C). My results showed that there is no 
significant difference between the number of profiles of apoptotic neurons at 2 weeks in
118NT-3-treated and vehicle-treated groups, and that NT-3 treatment did not significantly 
delay the onset of neuron apoptosis, which normally starts during the first week after 
axotomy (Groves et al.,  1997; McKay Hart et al., 2002). NT-3 administration for 4 weeks 
at both doses also had no significant effect on profiles of apoptotic neurons, when 
compared to the vehicle-treated group or no treatment group.
Table 3.2: The number of profiles of apoptotic neurons in ipsilateral L4 and L5 DRGs in 
each treatment group (Mean ± SEM). The estimated number between the different 
treatment groups and the unoperated control group were analyzed using one-way ANOVA 
followed by Tukey’s post hoc tests (Appendix  1). (ANOVA: p=0.59)
Group
Number of profiles of apoptotic neurons in 
ipsilateral L4 & L5 (Mean ± SEM)
Unoperated rats (n=7) 0
2 weeks sciatic transection with vehicle 
pump (n=4)
15.5 + 3.0
2 weeks sciatic transection with NT-3 
(1.25mg/4 weeks) pump (n=5)
19.4 ± 4.8
4 weeks sciatic transection (n=5) 16.0 ±2.7
4 weeks sciatic transection with vehicle 
pump (n=5)
14.4 ±3.4
4 weeks sciatic transection with NT-3 
(1.25mg/4 weeks) pump (n=5)
10.6 ±3.2
4 weeks sciatic transection with NT-3 
(5mg/4 weeks) pump (n=4)
13.0 ± 3.1W ^>
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Figure 3.5: The number of profiles of apoptotic neurons in ipsilateral L4 and L5 DRGs in 
each treatment group (Mean ± SEM).
3.3 Cell size profile in axotomised dorsal root ganglion with and without 
NT-3 administration
3.3.1  Cell size profile in normal dorsal root ganglion
The cross-sectional area of sensory neurons in bilateral L4 and L5 DRGs was 
measured in three rats of each group studied; the neuronal diameter was calculated and the 
size frequency distribution histograms are shown in Figure 3.6. Adult rat sensory neurons 
vary enormously in size, with diameter ranges from  12pm to 65pm. Most of the cells 
appear to be round or oval. In unoperated animals, the size profile has a bimodal 
distribution, one peak at 26-30 pm and one at 42-46 pm, showing that there are at least two 
main subpopulations: one of smaller and one of larger neurons with some intermediate-size
120neurons (Figure 3.6A). The smallest neurons are 12-14 jam in diameter, and the biggest 
ones are more than 60 pm.
3.3.2 Cell size profile in axotomised DRG
Two weeks after right sciatic nerve transection and vehicle administration, the size- 
frequency histogram showed an obvious shift towards the left, indicative of a general 
decrease in cell size compared to the contralateral ganglia (Figure 3.6B). The bimodal 
distribution was grossly preserved, but the two peaks moved to 20-22 pm and 34-38 pm, 
respectively (Figure 3.6B).
Four weeks after axotomy (Figure 3.6C), the distribution of cell size appeared to be 
similar to that of two week axotomy group.
3.3.3 Effect of NT-3 on neuronal size distribution in axotomised DRG
Systemic NT-3 administration for 2 weeks and 4 weeks at the dose of 1.25mg/4 
weeks or 4 weeks at the dose of 5mg/4 weeks appeared to have no effect on the leftward 
shift of the size frequency distribution of neurons after peripheral axotomy (Figure 3.6D, E 
& F).
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Figure 3.6A: Size frequency histogram (±SD) illustrating the distribution of ipsilateral 
(right) and contralateral (left) L4 & L5 DRG neurons in unoperated rats (Appendix 3).
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Figure 3.6B: Size frequency histogram (±SD) illustrating the distribution of ipsilateral 
(right) and contralateral (left) L4 & L5 DRG neurons after 2 week axotomy + vehicle 
administration (Appendix 4).
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Figure 3.6C: Size frequency histogram (±SD) illustrating the distribution of ipsilateral 
(right) and contralateral (left) L4 & L5 DRG neurons after 4 week axotomy + vehicle 
administration (Appendix 5).
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Figure 3.6D: Size frequency histogram (±SD) illustrating the distribution of ipsilateral 
(right) and contralateral (left) L4 & L5 DRG neurons after 2 week axotomy + NT-3 
(1.25mg/4 weeks) administration (Appendix 6).
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Figure 3.6E: Size frequency (±SD) histogram illustrating the distribution of ipsilateral 
(right) and contralateral (left) L4 & L5 DRG neurons after 4 week axotomy + NT-3 
(1.25mg/4 weeks) administration (Appendix 7).
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Figure 3.6F: Size frequency histogram (±SD) illustrating the distribution of ipsilateral 
(right) and contralateral (left) L4 & L5 DRG neurons after 4 week axotomy + NT-3 (5mg/4 
weeks) administration (Appendix 8).
1243.4 Effect of NT-3 on nestin mRNA and immunoreactivity in adult rat
dorsal root ganglia
3.4.1  Axotomy-induced increase in nestin mRNA and immunoreactivity in adult rat DRG
I counted any neuron with light or strong nestin immunoreactivity distributed 
throughout its cytoplasm as positive. No neurons in normal or contralateral ganglia showed 
any nestin immunoreactivity at all, and the background staining was always minimal.
In normal L4 and L5 DRGs, nestin mRNA detected by PCR was expressed in 
normal rat DRG with low copy numbers and there was no difference between right and left 
DRGs (Figure 3.7). Some Schwann cells and satellite cells around large diameter neurons 
were nestin-immunoreactive (Figure 3.8), but there were no neurons showing nestin 
immunoreactivity in normal DRGs. At the time points I investigated, expression of mRNA 
for nestin in contralateral ganglia remained at the same levels after sciatic nerve transection.
In axotomised ganglia, nestin mRNA was markedly up-regulated at lday and 2 
weeks after operation (Figure 3.7). Although the mean expression at 4 weeks seemed even 
higher than at other times, this change was not significant, probably because of the 
relatively large variability from animal to animal in that group. Nestin immunoreactivity 
was observed in some cells with the size and morphology of small neurons after axotomy: 
1.60% in ipsilateral ganglia 4 weeks following injury and 3.64% at 8 weeks (Table 3.4).
The appearances of these nestin-immunoreactive cells varied from oval-shaped with 
peripherally-located nucleus (Figure 3.8) to round cells with a central nucleus. 
Immunoreactivity within these cells was concentrated around the nucleus and was usually
125absent in the periphery of the neuron; no axons were seen to contain nestin- 
immunoreactivity.
■ Axotomy + vehicle (right) □ Axotomy + vehicle (left) 
□ Axotomy+NT-3 (right)  □ Axotomy+NT-3 (left)
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Figure 3.7: The expression of mRNA for nestin in L4 & L5 DRG after sciatic nerve 
transection with systemic vehicle or NT-3 administration (Mean ± S.E.M.). * indicates 
p<0.05 versus unoperated control of the same side DRG. ** indicates p<0.05 versus 
vehicle administration of the same side DRG (Appendix 10). ANOVA with Tukey’s post 
hoc analysis.
Figure 3.8: Immunohistochemistry shows nestin-immunoreactive (IR) neuron size cells 
(arrow) and satellite cells (arrowheads) in L4 & L5 DRG after sciatic nerve transection and 
4 week systemic NT-3 administration (5mg). Scale bar = 10pm
1263.4.2  Effect of  NT-3 on mRNA expression and immunoreactivity for nestin
In axotomised DRG, the incidence of nestin-immunoreactive neurons was 
significantly up-regulated by NT-3 administration (5mg/4 weeks) 4 weeks following 
axotomy (Student’s t test: p<0.05)(Table 3.3). Nestin mRNA expression in NT-3-treated 
ganglia was statistically significantly increased at 1  week and 2 weeks after axotomy when 
compared to vehicle-treated ganglia and elevated at 4 weeks when compared to unoperated 
animal (Figure 3.6). The intensity and pattern of immunostaining was similar to those in 
the vehicle-treated rats. These discrepancies between immunohistochemical and molecular 
data show that the effects of NT-3 administration on nestin mRNA expression may be 
mainly contributed by the nestin-immunoreactive non-neuronal cells in these DRGs.
Table 3.3: Estimated % of the nestin-immunoreactive neurons and nestin mRNA 
expression in ipsilateral (right) and contralateral (left) L4 & L5 DRGs in unoperated, 4 
week sciatic nerve transection with vehicle or NT-3 administration and 8 week sciatic 
nerve transection with vehicle administration rats (Appendix 9).
Group
% of nestin- 
immunoreactive 
neurons in 
ipsilateral L4 & L5 
(Mean ± SEM)
% of nestin- 
immunoreactive 
neurons in 
contralateral L4 & 
L5
(Mean ± SEM)
mRNA expression 
for nestin in 
ipsilateral L4 & 
L5 (copies/10000 
copies of 
GAPDH; Mean ± 
SEM)
Unoperated rats (n=4) 0 0 0.28 ±0.01
4 week sciatic 
transection with vehicle 
pump (n=4)
1.60 ±0.46 0 3.20 ± 1.16
4 week sciatic 
transection with NT-3 
(5mg/4 weeks) pump 
(n=4)
3.73 ±1.28 0 6.66 ±2.14
8 week sciatic 
transection with vehicle 
pump (n=4)
3.64 ± 1.21 0 —
1273,4.3  Double immunofluorescence for nestin and fi-III tubulin, trkA, trkC or CGRP
All of the nestin-immunoreactive neuron size cells seen in axotomised ganglia 4 and 
8 weeks after axotomy with vehicle treatment and 4 weeks after axotomy with NT-3 
treatment are also immunoreactive for (3-III tubulin (Figure 3.9). Some of them express 
trkA (Figure 3.10), trkC (Figure 3.11) or CGRP (Figure 3.12). The characteristics and 
sizes of these cells were not different from those with only nestin immunoreactivity. 
Interestingly, nestin immunoreactivity is usually distributed in the center of neurons and is 
absent from the axon and the periphery of the perikaryon.
3.5  Effect of systemic NT-3 administration on mRNA expression of
neurotrophins after axotomy
3.5.1  mRNA expression of neurotrophins in normal DRG
In this study, the mRNAs for NGF, BDNF and NT-3 were detected in DRGs from 
unoperated animals using both real-time quantitative PCR and in situ hybridisation (Figure 
3.13,3.14A, 3.14D and 3.15A), as reported by others [using in situ hybridisation, RT-PCR 
and northern blot analysis] (Sebert and Shooter, 1993; Zhou et al.,  1999b). NGF mRNA 
was expressed in many small neurons (Figure 3.14A); BDNF mRNA was strongly 
expressed in some neurons of various sizes, especially small ones (Figure 3.14D); NT-3 
mRNA was very weakly expressed in small and medium-sized neurons (Figure 3.15A). 
Satellite cells around large neurons were not observed to have any signal of these 
neurotrophins. From the results of real-time PCR (Figure 3.13), the much higher copy
128Figure 3.9: Double immunofluorescence for nestin (green) and [3-11 1  tubulin (red) shows a 
nestin- and (3-III tubulin-IR cell (arrowhead) in L4 DRG after sciatic nerve transection and 
8 week systemic vehicle administration. The blue colour is a nuclear fluorescent stain, 
DAPI (4',6-Diamidino-2-phenylindole dihydrochloride).  Scale bar=  10pm
4
Figure 3.10: Double immunofluorescence for nestin (green) and trkA (red) shows a nestin- 
and trkA-IR cell (arrowhead) and a nestin-lR neuron (arrow) in L4 DRG after sciatic nerve 
transection and 8 week systemic vehicle administration. Scale bar = 10pmFigure 3.11: Double immunofluorescence for nestin (green) and trkC (red) shows a nestin- 
and trkC-IR cell (arrowhead) and a nestin-IR cell (arrow) in L4 DRG after sciatic nerve 
transection and 8 week systemic vehicle administration. Scale bar = lOfim
Figure 3.12: Double immunofluorescence for nestin (green) and CGRP (red) shows a 
nestin- and CGRP-IR cell (arrowhead) and a nestin-IR cell (arrow) in L4 DRG after sciatic 
nerve transection and 8 week systemic vehicle administration. Scale bar = lOfxmnumbers of BDNF (around  140 copies/10000 copies GAPDH) than those for NGF (3.5 
copies/10000 copies GAPDH) and NT-3 (12 copies/10000 copies GAPDH) implies that 
BDNF in uninjured DRG may play a more important role than the other two members of 
neurotrophin family. There was no significant difference (p>0.05) in levels of expression 
between the right and left DRGs in unoperated ganglia.
3.5.2 mRNA expression o f neurotrophins in axotomised DRG
One day after sciatic transection, levels of NGF in the ipsilateral DRG increased by 
4.7 fold and remained significantly higher than controls for at least one week (p<0.05; 
Figure 3.13A), largely in small-to-medium size neurons and some satellite cells as revealed 
by in situ hybridisation (Figure 3.14B).
BDNF expression increased by around 4 folds in small-to-large neurons at one day 
following axotomy and declined to control levels by one week (Figure 3.13B and 3.14E).
The expression of NT-3 mRNA had doubled at one day after axotomy (p<0.05; 
Figure 3.13C), mainly in small and some large neurons but also in satellite cells (Figure 
3.15B), but showed no significant elevation by one week.
The contralateral ganglia showed no change of mRNA expression of all these 
neurotrophins in any vehicle-treated groups, except for a significant elevation for BDNF at 
one day (p<0.005) that had subsided to control levels by 1  week (Figure 3.13B).
3.5.3 Effect o f  NT-3 on neurotrophin expression in axotomised DRG
Systemic administration of NT-3 significantly reduced the increase in NGF mRNA 
level seen in the ipsilateral ganglia  1   day after sciatic transection (p<0.05), but significantly
131increased it in medium-to-large neurons at 1   week compared with axotomised group 
(p<0.05; Figure 3.13A and 3.14C); by 4 weeks there was no significant difference in 
ipsilateral NGF mRNA levels between NT-3- and vehicle-treated groups. These data 
suggested that the exogenous NT-3 prolonged the elevation in NGF mRNA seen after 
axotomy for at least 2 weeks. The NGF mRNA in contralateral ganglia remained 
unaffected byNT-3 administration.
The expression of BDNF mRNA in the ipsilateral ganglia of NT-3-treated rats was 
significantly increased at all time points, expressed in most small neurons and more 
medium-to-large neurons, compared with those from vehicle-treated rats (Figure 3.13B 
and 3.14F). However, NT-3 administration prevented the elevation in BDNF mRNA seen 
at one day in the contralateral ganglia in vehicle-treated animals.
The profile of NT-3 mRNA expression was not significantly altered in ipsilateral or 
contralateral ganglia by NT-3 administration when compared to vehicle-treated rats, mainly 
in small neurons (Figure 3.13C and 3.15C).
Overall, these results suggest that the exogenous NT-3 has stimulated or maintained 
the expression of mRNAs for NGF and BDNF, at least temporarily.
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Figure 3.13: Neurotrophin expression. NGF (A), BDNF (B) and NT-3 (C) mRNA 
expression in L4 and L5 DRG after sciatic transection with systemic NT-3 or vehicle 
administration (Mean ± S.E.M.). * indicates p<0.05 versus unoperated control of same side 
DRG. ** indicates p<0.05 versus vehicle administration of the same side DRG; ANOVA 
with Tukey’s post hoc analysis (Appendix  11,12 and  13).
*
133Figure 3.14: In situ hybridisation for NGF mRNA in unoperated rat lumbar DRG (A), o 
week after axotomy with vehicle (B) and NT-3 (C) treatment in ipsilateral ganglia; BDN 
mRNA in unoperated DRG (D),  1   day after axotomy with vehicle (E) and NT-3 (F) treat  t
in ipsilateral ganglia. Scale bar =  10pm. Arrowheads indicate mRNA expression in satel 
cells.
134Figure 3.15: In situ hybridisation for NT-3 mRNA in unoperated rat lumbar DRG (A), 1  day 
after axotomy with vehicle (B) and NT-3 (C) treatment in ipsilateral ganglia; trkA mRNA in 
unoperated DRG (D), 2 weeks after axotomy with vehicle (E) and NT-3 (F) treatment in 
ipsilateral ganglia. Scale bar = 10pm. Arrowheads indicate mRNA expression in satellite 
cells.
135Figure 3.16: In situ hybridisation for trkB mRNA in unoperated rat lumbar DRG (A), 2 week 
after axotomy with vehicle (B) and NT-3 (C) treatment in ipsilateral ganglia; trkC mRNA in 
unoperated DRG (D), one day after axotomy with vehicle treatment (E) and 2 weeks after 
axotomy with NT-3 treatment (F) in ipsilateral ganglia. Scale bar = 10pm. Arrowheads 
indicate mRNA expression in satellite cells.
136Figure 3.17: In situ hybridisation for p75NTR mRNA in unoperated rat lumbar DRG (A), 1  
week after axotomy with vehicle in ipsilateral DRG (B) and 2 weeks after axotomy with NT-3 
treatment in contralateral DRG (C); negative control using sense probe for NT-3 mRNA (D), 
trkA mRNA (E) and trkC mRNA (F). Scale bar = 10pm.
1373.6  Effect of systemic NT-3 administration on mRNA expression of 
neurotrophin receptors after axotomy
3.6.1 Expression of neurotrophin receptors in normal DRG
The mRNAs of all neurotrophin receptors were detectable in normal DRG by real­
time quantitative PCR and in situ hybridisation. In terms of copy number and localisation, 
trkA showed the highest expression in small neurons (Figure 3.15D and 3.18A) and trkB 
showed the lowest copy numbers in various size neurons (Figure 3.16A and 3.18B); TrkC 
was expressed in medium-to-large neurons (Figure 3.16D and 3.18C), and all size neurons 
for p75NTR (Figure 3.17A and 3.18D). Occasionally satellite cells also showed trkA and 
trkC mRNA expression (Figure 3.15D and 3.16D).
3.6.2 Expression of neurotrophin receptors in axotomised DRG
Following sciatic transection, the level of mRNA for trkA in ipsilateral ganglia was 
reduced by -55% at two weeks (p<0.005; Figure 3.18A), after which it recovered to 
control levels. In situ hybridisation showed that trkA mRNA expression was still located in 
small neurons (Figure 3.15E). However, in contralateral ganglia the level of trkA mRNA 
was significantly elevated  1  day after sciatic nerve transection in neurons and satellite cells, 
compared with unoperated control levels. The error bar (SEM) shows the small variation of 
the expression of this gene between animals.
The level of trkB mRNA was significantly decreased by 2 weeks after transection, 
when its expression was 30% of unoperated control levels (p<0.05; Figure 3.16B and
1383.18B), returning to control levels by 4 weeks. The levels in contralateral ganglia did not 
alter significantly at any time point.
The levels of trkC mRNA were, in contrast to trkA and trkB, dramatically elevated 
in ipsilateral ganglia following sciatic transection, peaking at one day when the level was 
over six times that in unoperated ganglia (p<0.01; Figure 3.18C). In situ hybridisation 
showed that the increase was mainly in neurons of all sizes (Figure 3.16E), although some 
satellite cells also expressed trkC mRNA, particularly those associated with large neurons. 
The levels then decreased slowly but still remained significantly higher than normal until 4 
weeks after axotomy, by which time they had returned to normal levels. In the contralateral 
ganglia the trkC mRNA level was significantly increased at 1  day (p<0.005) and 4 weeks 
(p<0.05), in all sizes of neuron, but not in satellite cells.
The amount of mRNA encoding the low-affinity neurotrophin receptor p75N TR  in 
DRGs of both sides quickly decreased to a level below 10% of control values one day 
following sciatic nerve transection, and was only expressed in some small neurons (p<0.05; 
Figure 3.17B and 3.18D). The level remained depressed on both sides for at least one 
week and did not return to unoperated control levels until 2 weeks.
3.6.3 Effect of  NT-3 on neurotrophin receptor expression in axotomised DRG
NT-3 administration produced no effect on trkA and trkB mRNA expression in 
ipsilateral ganglia at one day and one week after injury compared to vehicle-treated rats 
(Figure 3.18). However, at 2 weeks both trkA and trkB mRNA expression was up- 
regulated by NT-3 administration in some neurons of all sizes, compared with vehicle- 
treated animals (p<0.005 and p<0.001  respectively; Figure 3.15F, 3.16C, 3.18A and
1393.18B), and at 4 weeks it was increased by 1.9- and 3.9-fold when compared with 
unoperated control levels (p<0.005). In contralateral DRGs from NT-3-treated animals the 
increase in trkA mRNA expression was prevented at 1 day after axotomy. Conversely, the 
expression of trkB mRNA in contralateral DRGs was significantly increased at 1  week in 
neurons, and by 4 weeks the level of trkB expression increased to the same level as in the 
ipsilateral ganglia.
The mRNA for trkC remained at unoperated control levels in ipsilateral ganglia one 
day and one week after sciatic transection and NT-3 treatment, but at 2 weeks had 
significantly increased when compared to unoperated controls (p<0.001, Figure 3.16F and 
3.18C), although it was still significantly lower than in ipsilateral ganglia from vehicle- 
treated animals (p<0.05). In situ hybridisation showed that at 2 weeks trkC mRNA was 
expressed in all sizes of neuron, especially small-to-medium neurons. By 4 weeks trkC 
mRNA levels in ipsilateral ganglia from NT-3-treated animals were elevated three-fold 
over unoperated control levels (p<0.005), and were significantly higher than that in 
ipsilateral ganglia from vehicle-treated animals (p<0.05). NT-3 administration significantly 
increased trkC mRNA expression in contralateral ganglia at 4 weeks only.
p75N TR transcripts decreased markedly after axotomy, but NT-3 administration had 
no effect, compared with vehicle-treated ganglia, on the profile of p75NTR mRNA 
expression in ipsilateral ganglia after sciatic transection (Figure 3.18D). However, in 
complete contrast with the change in ipsilateral ganglia, the p75NTR mRNA level in 
contralateral ganglia was significantly increased by NT-3 treatment at all time points, and 
at 4 weeks was around 2.5-fold higher when compared with unoperated control ganglia. In
140situ hybridisation showed that the increased expression appeared to be due to up-regulation 
in small neurons and satellite cells (Figure 3.17C).
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Figure 3.18: Neurotrophin receptor expression. The expression of mRNA for TrkA (A),
TrkB (B), TrkC (C) and p75MR (D) in rat L4 and L5  DRG after sciatic transection with 
systemic NT-3 or vehicle administration (Mean ± S.E.M.). *  indicates p<0.05 versus 
unoperated control of same side DRG. **  indicates p<0.05 versus vehicle administration of 
the same side DRG; ANOVA with Tukey’s post hoc analysis (Appendix  14,  15,  16 and  17).
3.7  Gene expression  profile in adult rat dorsal  root ganglion after 
axotom y and system ic NT-3 adm inistration
3.7.1  Quality of array hybridisation
A cDNA library was analysed to identify changes in gene expression resulting from 
axotomy and subsequently systemic NT-3 administration; L4 and L5 DRG tissue from 
adult rats was collected 2 weeks after right sciatic nerve transection and ligation with either 
systemic vehicle or NT-3 administration, as well as from unoperated rats. To check the 
quality of total RNA extracted from these ganglia before carrying out further steps of 
microarray analysis, quality of RNA samples were assessed by capillary electrophoresis on 
Bioanalyzer 2100 Agilent to ensure the 28S  :  18S rRNA ratio was >  1.0 for each sample; 
an example was shown in Figure 3.19. All the nine RNA samples passed the requirements.
142For each group (unoperated, axotomy + systemic vehicle administration and 
axotomy + systemic NT-3 administration), three chips were used. Twelve rats were used 
for each group. After target hybridisation and image scanning, a few parameters, such as 
noise factor (Q), scaling and normalisation factors, intensity of background and the 
percentage of present genes in each array, were listed to show the quality of hybridisation 
(Table 3.4). Noise factor is a measure of the pixel-to-pixel variation of probe cells on an 
array. Electrical noise of the scanner leads to a significant portion of Q value. To make it 
possible to compare data from different arrays, average intensities of gene expression were 
normalised to a same value of 100 using a scaling factor before further analysis. Larger 
discrepancies among scaling factors (greater than three-fold) indicate significant assay 
variability or sample degradation. All scaling factors in this study were within a two fold 
change. The percentage of genes present in each array ranged from 27 to 39% of the genes 
included.
A few controls were used, including B2 oligo arranged on the boundaries of the 
probe area to as a positive control, bioB, bioC, bioD and ere as hybridisation controls to 
evaluate sample hybridisation efficiency to gene expression arrays, and actin and GAPDH 
as internal control genes to check degradation by the ratio of the j  probe set to the 5  probe 
set.
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Figure 3.19: RNA quality was assessed by capillary electrophoresis to ensure the 28S : 
18S rRNA ratio was >  1.0 for each sample.
Table 3.4: Details of microarray hybridisation.
Chip
No
Procedure
Q (noise 
factor)
Scaling
Factor
Back­
ground
SD of 
background
Genes 
present (%)
1
Unoperated
1.73 1.27 55.42 0.89 32.10
2 3.51 1.91 134.27 4.66 31.70
3 1.97 0.56 65.9 1.37 39.30
4
Axotomy + 
vehicle
1.58 1.09 49.29 0.67 35.30
5 1.75 0.64 56.67 0.98 38.60
6 3.05 0.86 115.93 6.3 29.10
7
Axotomy + 
NT-3
1.62 1.02 51.84 0.8 33.20
8 2.83 1.73 89.34 4.05 27.50
9 3.28 0.91 124.56 7.28 27.00
SD: Standard deviation
3.7.2  Gene expression profile in adult rat DRG after axotomy
The gene expression profile in vehicle-treated animals was quantitatively compared 
with unoperated controls and NT-3-treated animals to find out the genes regulated by 
axotomy and by systemic NT-3 treatment 2 weeks after injury. Three chips were used for
144each group and cross-comparisons were made between all the chips to generate nine pair­
wise comparisons between unoperated and axotomy + vehicle rats and nine pair-wise 
comparisons between axotomy + vehicle and axotomy + NT-3 rats. The fold changes are 
presented as mean ± standard deviation of the nine pair-wise comparisons.
In addition to the genes already functionally known, the cDNA microarrays used in 
this study include EST sequences. The technology of sequencing expressed sequence tag 
(EST), which is is a short sub-sequence of a protein-coding DNA sequence, offers a 
relatively cheap alternative to whole genome sequencing and has become a valuable 
resource for gene discovery (Lindlof, 2003). Based on the concept that proteins 
participating in similar biological pathways often have similar expression profiles (Hughes 
et al., 2000), the use of a cDNA microarray that includes EST sequences has made it 
possible to obtain interesting functional insights from the temporal expression profiles of 
newly detected genes. To analyse the regulated EST functionally might lead to the 
discovery of novel genes that contribute to nerve regeneration. Of the 1322 known genes 
and ESTs represented on the Rat neurobiology U34 array, 357 (27.0%) genes were 
consistently detected in all arrays. Based on the potential functions of the genes, they were 
categorised into 9 classes (Table 3.5).
Figure 3.20 A, B and C shows a correlation of the signal intensity values of all the 
expressed transcripts between two unoperated chips, two axotomy + vehicle chips and two 
axotomy + NT-3 chips. The signal intensity observed for each expressed transcript was 
very similar between the three chips in each group. The correlation coefficients between 
any two chips in each group were 0.895-0.964 (mean: 0.932) in unoperated group, 0.967- 
0.993 (mean: 0.979) in axotomy + vehicle group, and 0.970-0.983 (mean: 0.975) in
145axotomy + NT-3 group, which confirmed the reproducibility of the three triplicate chips in 
each group.
1.5-fold change in signal intensity was used as a cut-offline to consider the 
differential expression of a gene as significant. Among those genes and ESTs, 69 showed 
an increase in expression greater than  1.5-fold, and 49 a decrease in expression greater than 
1.5-fold when comparing DRG at 2 weeks after axotomy with DRGs from the unoperated 
control animals (Figure 3.21 A). Twenty-nine genes and ESTs increased more than  1.5-fold 
and 15 genes and ESTs decreased more than  1.5-fold in DRGs from NT-3-treated animals 
compared with those from vehicle-treated animals (Figure 3.21B). The coefficient of 
variance (CV= standard deviation/mean) is the degree to which a set of data points varies, 
which is used to to assess the precision of a technique. When assessing precision, the lower 
the coefficient of variance percentage, the better the precision between replicates. Among 
the regulated genes, the CV for  147 of these was less than 0.5; for 14 genes the CV was 
between 0.5 and  1.0, indicating good reproducibility of the three arrays in each group. To 
verify the array results, quantitative real-time PCR was performed to confirm a total of 7 
genes (NF-L, NP-Y, 5HT-3R, p75NTR, HSP70, peripheral-type benzodiazepine receptor, 
glutamate receptor subnit 5-2) and show that our microarray results accurately reflect the 
molecular changes (Table 3.6, Figure 3.22).
The full names and the GenBank accession numbers of the transcripts observed to 
change more than  1.5 fold between unoperated and vehicle-treated samples are given in 
Tables 3.5A and B. The genes regulated by systemic NT-3 by more than  1.5 fold are 
categorised in Table 3.5C and D. There is good correlation between some of the genes in 
the present study and others’ previous observations (Costigan et al., 2002; Xiao et al.,
1462002), substantiating the accuracy of our data. The functional implications of the change in 
genes regulated by axotomy and NT-3 administration will be discussed in Discussion.
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Figure 3.20: The correlation of the hybridisation signal intensity for all the expressed 
genes between two unoperated chips (A), two axotomy + vehicle chips (B), two axotomy + 
NT-3 chips (C), an axotomy + vehicle chip and an unoperated chip (D), an axotomy + 
vehicle chip and an axotomy + NT-3 chip (E), and an unoperated chip and an axotomy + 
vehicle chips (F).
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Figure 3.21 A: Percentage of regulated genes 2 weeks after axotomy + systemic vehicle 
administration (compared with unoperated). “Blue colour” indicates up-regulation; “red 
colour” indicates down-regulation; “white colour” indicates genes detected but not changed.
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Figure 3.21 B: Percentage of regulated genes 2 weeks after axotomy + systemic NT-3 
administration (compared with axotomy + vehicle administration). “Blue colour” indicates 
up-regulation; “red colour” indicates down-regulation; “white colour” indicates genes 
detected but not changed.
149Table 3.5A: Genes, grouped according to functional activity, whose expression was 
increased following 2 week sciatic nerve transection and vehicle administration, compared 
to unoperated animal (Appendix 18).
Group Gene name (Fold change, mean)
Signal transduction 
and regulation gene 
expression
Mothers against dpp  1   homolog (Madl) (4.50); Interferon- 
gamma inducing factor isoform alpha precursor (IGIF) 
(3.44); VGF (3.44); Immediate-early serum-responsive JE 
gene (MCP-1) (2.82); Cytosolic retinol-binding protein 
(CRBP)(1.88); Transferrin (1.70); Guanine nucleotide 
binding protein beta  1   subunit (1.57); Microtubule associated 
protein (MAP2c)(1.56); Janus protein tyrosine kinase  1  
(JAK1)(1.55); G protein betal  subunit (rGbl) (1.55); Ras 
GTPase-activating protein (1.52)
Pain-related genes
Neuropeptide Y(NP-Y)(54.53); Galanin (25.79); 
Corticotropin releasing factor (CRF)(1.92); P2X2-3 receptor 
(P2X2)(1.51)
Receptor and 
membrane protein
Peripheral-type benzodiazepine receptor (PBS)(4.31);
MRC OX-45 surface antigen (2.19); Neuronal high affinity 
glutamate transporter (2.06); Glutamate/aspartate transporter 
protein (1.95); GABA-A receptor a-5 subunit (1.95)
Growth-associated 
protein and growth 
factors
GAP-43 (2.40); Basic fibroblast growth factor (2.00); 
Neurotrophin-3 (NT-3)(1.97); Brain-derived neurotrophic 
factor (BDNF)(1.65); Insulin-like growth factor binding 
protein (rIGFBP-6)(l .63); Insulin-like growth factor II (1.57)
Ion transport
Dihydropyridine-sesitive L-type calcium channel alpha-2 
subunit (CCHL2A)(5.19); Brain sodium channel III (1.98); 
Neuronatin alpha (1.93); Neuron specific calcium-binding 
protein hippocalcin (1.87)
Secreted and 
extracellular 
molecules
Synaptic vesicle protein (SV2)(2.28); Synaptotagmin IV 
homolog (1.73); Syntaxin B (1.53); Synaptotagmin 
associated 35kDa protein (1.52)
Cytoskeleton
Glial fibrillary acidic protein alpha (GFAP)(3.45); 
Microtubule-associated protein (MAP) IB (2.94); 
Cytoplasmic beta-actin (1.95); RBI09 (brain specific 
protein)(1.73); Mu-calpain large subunit (clsl )(1.45)
Apoptosis Calmodulin-dependent protein kinase II-delta (2.27)
150Heat shock protein (Hsp27)(2.97); Monoamine oxidase A
(2.68); Manganese-containing superoxide dismutase
Others (MnSoD)(2.43); A rat novel protein which is expressed with
nerve injury (1.70); Tissue-type plasminogen activator (t-
PA)(1.65); Neural adhesion molecule F3 (1.55)
Table 3.5B: Genes, grouped according to functional activity, whose expression was 
decreased following 2 week sciatic nerve transection and vehicle administration, compared 
to unoperated animal (Appendix  19).
Group Gene name (Fold change, mean)
Signal transduction 
and regulation gene 
expression
Noggin (-1.89); GTP-binding protein (G-alpha-0)(-1.78); 
Phosphodiesterase I (-1.71); Presenilin-2 (-1.54); 
Ca2+/calmodulin-dependent protein kinase IV kinase 
isoform (-1.51)
Pain-related genes
Beta-tachykinin (-2.03); Beta-type calcitonin gene-related 
peptide (CGRP)(-1.80); RET ligand 2 (RETL2)(GDNFR)(- 
1.79); substance P precursor (-1.60); Somatostatin-14 (- 
1.60); Nicotinic acetylcholine receptor alpha 3 subunit (- 
1.57); Nicotinic acetylcholine receptor subunit beta4 (-1.54); 
Somatostatin (-1.52)
Receptor and 
membrane protein
Glutamate receptor subunit 5-2 (GluR5-2)(-2.13);
Neural membrane protein 35 (-1.86); ET-B endothelin 
receptor (-1.83); Fast nerve growth factor receptor (p75NTR)(- 
1.69); Transferrin receptor (-1.65); Meotropic glutamate 
receptor (GLUR4)(-1.63); GABA-B receptor (-1.60)
Ion transport
Potassium channel, alpha subunit (Kv9.3)(-3.81); CLC-5 
chloride channel (-2.62); Voltage-gated Na channel alpha 
subunit NaN (-2.48); Potassium channel (Kv2.2; CDRK)(- 
2.16); Voltage-gated sodium channel (SNS)(-2.00); Na,K- 
ATPase alpha-1   subunit (-1.91); 5HT3 receptor subunit (- 
1.85); 5HT3 receptor (-1.85); Sodium channel I (-1.77); 
Potassium channel, alpha subunit (Kv9.1)(-1.71); Na+,K+- 
ATPase beta-3 subunit (-1.55); Putative chloride channel (- 
1.55); Putative potassium channel TWIK (-1.54); SI00 alpha 
(-1.52); Potassium channel protein (3145 bp)(-1.51)Secreted and 
extracellular 
molecules
Synaptosomal-associated protein 25 (SNAP-25A)(-1.73); 
Ca2+/calmodulin-dependent protein kinase II isoform 
gamma-b (CAMK2)(-1.61); Rat ras-related mRNA rab3 (- 
1.55)
Cyto skeleton
Neurofilament protein-light chain (NF-L)(-2.12); 
Microtubule-associated protein  1A (MAP1A)(-1.55); Heavy 
neurofilament polypeptide NF-H C-terminus (-1.52)
Others Neurodegeneration associated protein  1   (-1.53)
Table 3.5C: Genes, grouped according to functional activity, whose expression was 
increased following 2 week sciatic nerve transection and NT-3 administration, compared to 
vehicle-treated animals (Appendix 20).
/  v  Group Gene name (Fold change, mean)
Signal transduction 
and regulation gene 
expression
Phosphoinositide 3-kinase regulatory subunit p85alpha 
(2.99); Neuron-specific cortexin (1.97); cAMP response 
element binding protein (CREB)(1.67); Mothers against dpp 
1   homolog (Mad 1)( 1.52); GTP-binding protein (G-alpha- 
0)(1.50); Chemokine CX3C(1.50)
Pain-related genes  ,
Major hippocampal somatostatin receptor (SSTR4)(1.69); 
Calcitonin receptor-like receptor (CRLR)(1.67); Muscarinic 
receptor m2 (1.67)
Receptor and 
membrane protein
AMPA-selective glutamate receptor-A (1.92); ET-B 
endothelin receptor (1.50)
Growth-associated 
protein and growth 
factors
Fibroblast growth factor (FGF-18)(1.72)
Ion transport
Potassium channel (1.73); Calcium channel alpha-IS subunit 
(ROBl)(1.51)
Secreted and 
extracellular 
molecules
Syntaxin 4 (1.71)
Cytoskeleton
Cytoplasmic beta-actin (1.67); Glial fibrillary acidic protein 
alpha (GFAP)(1.54)
Others
Phosphoneuroprotein 14 (1.57); Calnexin (1.55); Olfactory 
receptor-like protein (SCR D-8)(l .55)
152Table 3.5D: Genes, grouped according to functional activity, whose expression was 
decreased following 2 week sciatic nerve transection and NT-3 treatment, compared to 
vehicle-treated animals (Appendix 21).
Group Gene name (Fold change, mean)
Signal transduction 
and regulation gene 
expression
Rat immediate-early serum-responsive JE gene (MCP-1)(- 
1.58); G protein betal  subunit (rGb 1)(-1.58)
Receptor and 
membrane protein Beta-arrestin 2 (-1.50)
Ion transport
Sodium/potassium ATPase alpha-1   subunit truncated 
isoform (-1.95); Voltage-dependent sodium channel alpha 
subunit [SS1-SS2 segment, transmembrane segments IVS3- 
IVS6](-1.56)
Secreted and 
extracellular 
molecules
SNAP-25B (-1.68); Synaptojanin (-1.59); Rat ras-related 
mRNA rab3 (-1.58); Synapsin la (-1.54); SNAP-25A (-1.53)
Cytoskeleton Microtubule-associated protein  IB (-2.53)
Others
Tissue-type plasminogen activator (t-PA)(-1.71);
A rat novel protein which is expressed with nerve injury (- 
1.51)
153Table 3.6: Real-time quantitative PCR confirmation on 7 genes selected from microarray 
data (Appendix 22).
Genbank
accession
number
Axotomy + vehicle 
(fold change, compared 
with Unoperated)
Axotomy + NT-3 
(fold change, compared 
with Axotomy + vehicle)
Microarray
Real-time
PCR
Microarray
Real-time
PCR
Neurofilament-
L M25638 -2.12 -2.17 1.15 -1.14
Neuropeptide Y M15880 54.53 180.68 -1.02 -1.08
5HT3 receptor U01227 -1.85 -2.56 1.03 1.06
p75N TR X05137 -1.69 -3.02 1.32 1.31
Heat shock 
protein 70
Z75029 1.05 1.31 -1.14 -1.12
Peripheral-type
benzodiazepine
receptor
J05122 4.31 3.41 1.06 -1.11
Glutamate 
receptor subnit 
5-2
M83561 -2.13 -1.64 -1.37 -1.39
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Figure 3.22: Real-time quantitative PCR confirmation of 7 selected genes from microarray 
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157CHAPTER 4: DISCUSSION
158In this section I will present and discuss the morphological, immunohistochemical 
and molecular results of my work and provide evidence in support of the hypothesis that 
NT-3 enhances neuronal regeneration in DRG after sciatic nerve transection. The results 
will be compared with relevant data from the literature, and the molecular events 
underlying the neuronal response of axotomised DRG after administration of NT-3 will be 
discussed.
4.1 Effects of axotomy and systemic NT-3 administration on neuronal 
number and apoptosis in adult rat dorsal root ganglia
4.1.1  Methodological considerations
Using a stereological method, the physical disector, neuronal loss was established in 
this study by calculating the ratio between neuronal number in the ipsilateral L4 & L5 and 
contralateral DRGs. This approach was based on the finding that neither degenerating or 
apoptotic neurons, nor any indication of neuronophagia, was seen in any section of the 
serially-sectioned contralateral ganglia. The physical disector technique provided unbiased 
estimates of absolute DRG neuronal numbers in unoperated animals comparable to those 
obtained by the optical disector technique (Tandrup,  1993,  1995; McKay Hart et al., 2002). 
My work was carried out on ganglia sectioned at 4 pm and stained with cresyl fast violet, 
using a plane of section parallel to the longitudinal axis of the ganglion; this thickness is 
ideal for distinguishing “tops” of nuclei, which were between  10-18 pm in diameter, in the 
reference sections. Using nucleus as a counting unit which every cell has exactly one, this 
method provided accurate estimates of neuronal numbers when it was compared with a
159serial reconstruction method based on nucleolar counting (Coggeshall et al., 1994). 
Stereology uses geometric probabilities and can provide simple, reliable and efficient 
quantitative methods for assessment of normal quantitative morphology and evaluation of 
degeneration and cell loss in the DRG. Systemic, uniformly random sampling at all levels 
is the principle (see Tandrup, 2004). Because the sample of counting fields should 
represent the whole ganglion cell population and the uneven distribution of DRG neurons, 
which are clustered between the fiber fundles, more fields are necessary than in situations 
with more homogeneous distributions. In addition, a microcator is necessay for 
measurements of section thickness. Because of the variation among ganglia, it is sufficient 
to count 100 cells to obtain a stable number estimate (Gundersen et al.,  1988).
As it was shown that most, if not all, neurons with the morphological features of 
apoptosis could be stained with TUNEL technique in frozen sections (McKay Hart et al., 
2002). Apoptosis is a term originally used to describe a particular morphology related to a 
special condition of the cell, and the use of morphological criteria of apoptosis is now well 
established, especially when applied to well-fixed tissue (Groves et al.,  1997; Portera- 
Cailliau et al.,  1997; Groves et al.,  1999; see Clarke,  1999). In this study, the estimates of 
neuronal numbers were obtained using stereology with the evaluation of neuronal apoptosis 
in the same ganglia, using morphological criteria on cresyl fast violet stained sections. 
Direct observation of apoptotic neurons provides information about the incidence of neuron 
death at a particular time point. All neurons identified as apoptotic by their morphology 
also showed activated caspase-3 immunoreactivity in sections immunostained for it, 
confirming that apoptotic pathways were activated in these cells.
1604.1.2  Neuronal number and apoptosis after sciatic nerve transection and systemic NT-3 
administration
In this study, the ratio of neuron number between right (L4 & L5) and left (L4 & L5) 
DRGs was used to analyse the neuronal loss after axotomy and the effects of NT-3 
treatment. Because I used the rats with the same initial weights for 2-week and 4-week 
study, there was a variation of age (around 2 weeks) when the animals were sacrificed. As 
the postnatal neurogenesis in rat DRG has been observed by some authors (Cecchini et al., 
1995; Popken and Farel,  1997; Farel, 2002, 2003), it is not appropriate to compare 
ipsilateral and contralateral DRGs with those in untreated rats. Contralateral cell increase 
stimulated by NT-3 administration cannot be ruled out, which may lead to the 
underestimation of neuronal replacement in the axotomised ganglia. However, there was no 
evidence of neuron gain in contralateral ganglia from BrdU labelling in our previous study 
(Groves et al., 2003) and nestin immunostaining in this study. The ratios in unoperated rats 
shows a significantly greater number (about 7%) of neurons on the right side than on the 
left. Mid-thigh sciatic nerve transection with ligation induced a similar apoptotic rate in 
both vehicle- and NT-3-treated groups at 2 weeks after axotomy. This resulted in 
approximately 15-20% neuronal loss in injured L4 & L5 DRGs at 4 weeks in rats not 
treated with NT-3 (calculated from the right: left ratio in neuronal numbers of around 0.90 at 4 
weeks after axotomy and 1.07 in unoperated ganglia); at this time the incidence of apoptosis 
stayed at a similar level as at 2 weeks in any of the no treatment, vehicle-treated and NT-3- 
treated groups. An identical lesion has been reported to produce a neuronal loss of around 
14% at 8 weeks and 37% at 32 weeks after injury (Tandrup et al., 2000); in that study 
neuronal loss was estimated by absolute counts in bilateral L5 DRGs which are prone to
161have larger variation than using right: left ratio of neuronal numbers in L4 & L5 DRGs as I 
did in my study.
On the other hand, systemic NT-3 administration for 4 weeks at the dose of 
1.25mg/4 weeks and 5mg/4 weeks prevented the decline of the neuronal number in 
ipsilateral ganglia, although it did not have any effect upon neuronal apoptosis at any of the 
time points studied. However, the absolute number of neurons lost via apoptosis can only 
be calculated if the time taken by the process were known. In this respect, only data from in 
vitro studies are available.
Work done on sympathetic neurons showed that the time taken for cells undergoing 
apoptosis in vitro, induced by NGF withdrawal, to become ‘ghost cells’ and disappear is 
around 2-3 hours after initiation of the process (Edwards and Tolkovsky,  1994); similar 
times were found for other neuron populations (see Clarke,  1999). Although the results of 
in vitro study have to be applied with caution, it is possible to hypothesize that if the time 
of the apoptotic process in vivo is similar to that in vitro, it would lead, over the relatively 
long time periods of my observations, to a significant loss of neurons. Because caspase 
pathway is part of a cascade, it probably does not vary in the time taken to completion once 
started. Indeed, on the basis of 15 apoptotic neurons seen in the ipsilateral DRGs at any 
time and of a duration of apoptosis elimination of 3 hours, it could be calculated that 2 
weeks after axotomy and vehicle administration, the loss could be of at least 100-150 every 
24 hours, resulting in a loss of 1400-2100 neurons between 2 weeks and 4 weeks after 
axotomy. It is known that axotomy-induced apoptosis begins at around  1  week (Groves et 
al.,  1997) or earlier (McKay Hart et al., 2002), therefore the neuronal loss at 4 weeks after 
axotomy would be greater than  1400-2100 neurons. In the group treated with  1.25mg NT-3
162for 4 weeks, around  19 apoptotic neurons were seen in the ipsilateral DRGs at 2 weeks 
after axotomy and  11  apoptotic neurons at 4 weeks. Assuming the absolute number of 
neuronal loss can be calculated on the basis of mean apoptotic neuron number at these two 
time points, similar conclusions can be drawn as those in the vehicle-treated groups.
The finding that apoptotic neurons in both NT-3- and vehicle-treated groups were 
immunoreactive for activated caspase-3, which is one of the final steps in the caspase 
cascade, confirms that caspase-3 was activated throughout the time period when apoptotic 
neurons were morphologically recognisable. This shows that NT-3 treatment did not 
change the apoptotic pathway, and so would not have slowed down the process.
The lack of effect of exogenous NT-3 upon neuronal apoptosis following axotomy 
raises the question of how it prevents the decline in neuronal number in the ipsilateral 
ganglia. The identical incidence of apoptosis at 2 weeks in NT-3- and vehicle-treated 
groups indicates that NT-3 treatment did not delay the onset of neuronal apoptosis, which 
normally starts around  1   week after axotomy (Groves et al.,  1997; McKay Hart et al., 2002). 
It can be concluded that NT-3 does not share the effects of glial-derived neurotrophic factor 
(GDNF), which alone was shown to reduce the number of neurons undergoing apoptosis in 
cultured adult DRG explants whilst NGF, BDNF and NT-3 did not (Edstrom et al.,  1996; 
Leclere et al.,  1997); these results suggest that for most DRG neurons, signalling through 
the neurotrophin receptors does not influence neuronal apoptosis in vitro. My results show 
that NT-3 does not influence neuronal apoptosis in vivo.
As apoptosis persists in NT-3-treated rats at the same rate as in untreated, the 
replacement of dying DRG neurons either by newly-formed or newly differentiated 
neurons must be considered to explain this. Neurogenesis in postnatal DRG has been
163studied by a few researchers; Farel (2002, 2003) reported that the number of rat lumbar 
DRG neurons increased by 20% between postnatal day (P) 11 and PI00, and by 35% 
between PI  and P I00 using counts and 3 dimensional counting. Devor et al. (1985) also 
showed a 50% increase of DRG neurons between 85 and 490 postnatal days using 
corrected profile counts. BrdU, which can incorporate into DNA during S phase in dividing 
cells as a mitotic marker, was used in some studies to observe proliferating precursor cells 
(Ciaroni et al., 2000; Farel, 2003; Groves et al., 2003). BrdU has been shown to be specific 
for neurons that are derived from dividing cells, rather than neurons undergoing DNA 
repair, at the dose used (Cooper-Kuhn and Kuhn, 2002). Ciaroni et al. (2000) found some 
BrdU-positive rounded or bell-shaped cells in L4 DRGs of adult vitamin E-deficient rats 
between 4 and 5 months of age; some of these cells showed neuronal phenotype and were 
suggested to be transitional neuroblasts. However, these cells were scarce and were never 
found to have morphological features of well-differentiated neurons. Others have reported 
an unchanged DRG neuronal number in relation to age (Chimelli and Scaravilli,  1986; 
Pover et al.,  1994; Mohammed and Santer, 2001); an earlier study using [3H] thymidine to 
label dividing cells showed that neurogenesis in DRG is complete by embryonic day 15 
(Lawson et al.,  1974). St. Wecker et al. (1994) reported that the neuronal numbers doubled 
during postnatal life in frog, whereas no neurons were labelled with [3H] thymidine, a 
method which only identifies cells produced from cell division during the period of 
administration. Moreover, the increase of neuronal number in DRG observed by Farel 
(2002) was also suggested to be a result of late differentiation because subcutaneously- 
injected BrdU did not label any DRG neurons between PI  and PI5 when new neurons were 
expected to be added at the greatest rate (Farel, 2003).
164In addition to the possible neurogenesis in normal DRG, we (Groves et al., 2003) 
have recently reported more than  15-20% neuronal loss in DRG, using physical dissector 
technique to count neurons, at 1   month and 2 months after sciatic nerve crush, but no 
significant loss observed at 3 months, suggesting that replacement of lost neurons occurs in 
injured ganglia without any treatment. The small number (0.04%) of neurons in axotomised 
L4 and L5 DRGs labelled with BrdU suggested either that cell proliferation was 
insufficient to explain the neuronal replacement or that the BrdU technique is unsuitable for 
identifying new neurons. Moreover, Ljungberg et al. (1999) found that intrathecal 
administration of NT-3 or NGF following transection of an intercostal nerve resulted in a 
25% increase in the number of DRG neurons that transported a tracer from the injury site. 
These data suggests that neuronal addition may be further stimulated by neurotrophins in 
injured ganglia.
In PNS, neuronal precursors may derive from self-renewing, multipotent neural 
crest stem cells (NCSCs) in the embryo, which then maintain a limited ability to proliferate 
and differentiate into neurons. Indeed these precursors have been extracted from adult 
mouse DRG and found to be capable of differentiating into neurons in vitro when exposed 
to neurotrophic factors including NGF and NT-3 (Namaka et al., 2001). During embryonic 
development of mouse DRG, NT-3 is thought to trigger the final differentiation of sensory 
neuroblasts into post-mitotic neurons (ElShamy et al., 1998). This can be promoted through 
a truncated isoform of trkC that lacks the catalytic kinase domain (known as trkC NC2; 
(Menn et al.,  1998)), in conjunction with p75N TR (Hapner et al., 1998). It is possible that 
NT-3 has similar actions in vivo, under certain conditions, on any sensory neuron precursor 
cells present in adult DRG, such as following peripheral nerve injury. All these data
165indicate that stem cells and precursor cell/undifferentiated neuron type may exist in adult 
rat DRG without undergoing cell division to any significant extent (Farel, 2002, 2003), but 
may undertake the pathway towards final maturation/ differentiation when stimulated by 
certain factors, including peripheral nerve injury alone or, to higher extent, following 
administration of neurotrophic factors.
NGF and NT-3 have previously been shown to prevent the decline in DRG neuronal 
number after peripheral axotomy when administered intrathecally or to the proximal stump 
(Otto et al.,  1987; Rich et al.,  1989; Groves et al.,  1999; Ljungberg et al.,  1999). Among 
these studies, Otto et al., Rich et al., and Ljungberg et al. estimated neuron numbers by 
corrected numbers of neurons from counts of nucleolar profiles; Groves et al. used 
stereological methods. It has been suggested that this effect is mediated through their high 
affinity receptors, trkA and trkC respectively, whose activation has been shown to be 
neuroprotective and prevent neurons from undergoing injury-induced apoptosis after 
axotomy, at least in neonates (Ernfors et al.,  1994; Smeyne et al.,  1994). In contrast, 
Tandrup et al. (1999), using stereological technique, reported that systemic NGF treatment 
by subcutaneous injection for 1   month had no apparent effect on neuronal loss in L5 DRGs 
after spinal nerve transection. Different counting methods may explain the different results 
obtained by systemic and intrathecal NGF application. Systemic NT-3 treatment in my 
study appears to stimulate neuronal replacement instead of affording neuroprotection as 
shown by the unchanged incidence of neuronal apoptosis. It is possible that this may be due 
to different intracellular signalling pathways being activated by axonal and perikaryal trkC 
receptors (Watson et al., 2001)(see 1.2.12), both of which (Erkl/2 and Erk5 pathways) 
were assumed to be activated concurrently by systemic NT-3 administration rather than the
166activation of only one of them by other methods of application such as intrathecal infusion 
and administration to the proximal stump.
4.1.3  Effect of systemic NT-3 administration on nest  in mRNA expression and 
immunoreactivity
Using real-time PCR quantitation and immunohistochemistry for nestin, this study 
showed increased nestin expression in some small neuron-like oval-shaped cells (mean 
diameter: 20-2 lpm) in vehicle-treated injured DRG; there were no neurons expressing 
nestin protein in the contralateral ganglia or ganglia from unoperated rats. Systemic NT-3 
treatment for 4 weeks significantly up-regulated mRNA expression of nestin and increased 
the incidence of nestin-immunoreactive neurons in ipsilateral ganglia. All of these nestin- 
expressing cells are also immunoreactive for a neuronal marker, {3-III tubulin, and some of 
them express trkA, trkC, or CGRP. Nestin immunoreactivity was seen in a large number of 
satellite cells surrounding large neurons in unoperated animals, and no change was 
observed in satellite cell expression of nestin after axotomy or NT-3 treatment.
Nestin is a class of VI intermediate filament protein mainly expressed in 
proliferating progenitor cells, neuron-restricted precursor cells, glial-restricted precursors in 
mammalian and rodent developing CNS and PNS as well as developing muscle and 
myocardial cells (Hockfield and McKay,  1985; Lendahl et al.,  1990; Sjoberg et al.,  1994; 
Dahl strand et al.,  1995). When these precursor cells differentiate into neuronal and glial 
cells, nestin is down-regulated and replaced by cell type-specific intermediate filament, 
such as neurofilaments or GFAP (Frederiksen and McKay,  1988). In the adult brain, nestin 
can be found in cells in restricted areas which exhibit postnatal neuro- or gliogenesis such
167as the hippocampus, subventricular cells and olfactory neuronal progenitor cells (Morshead 
et al., 1994; Doyle et al., 2001). Nestin has also been detected in bone marrow stromal cells 
(BMSC) and in various pathological conditions including CNS tumours, excitotoxic, 
ischaemic and traumatic cerebral injury (Dahlstrand et al., 1992; Li and Chopp,  1999; 
Sanchez-Ramos et al., 2000).
In my study, nestin-immunoreactive cells had a mean diameter of around 20-21  pm, much 
bigger than satellite cells. Co-expression of nestin with (3-III tubulin, which is considered to 
be one of the earliest neuron-associated cytoskeletal marker proteins (see Katsetos et al., 
2003), in these cells can be interpreted as evidence for neuronal replacement after 
peripheral nerve transection. The expression of trkA or trkC in some nestin- 
immunoreactive cells implies that neurotrophins may play a role in these cells, or that these 
cells are responsive to exogenous or endogenous neurotrophins. CGRP is a neuropeptide 
that is synthesised in approximately 50% of the small- and medium-size DRG neurons, 
especially trkA-expressing neurons (Averill et al.,  1995), and is transported along the axon 
to the periphery and dorsal horn to modulate nociception and inflammation (Ju et al.,  1987; 
McNeill et al.,  1988; Heppelmann and Pawlak,  1997). The appearance of nestin- and 
CGRP-expressing cells suggests that intraganglionic sprouting of CGRP axons may 
originate from these neurons and may be implicated in the development of chonic 
neuropathic pain (Hu and McLachlan, 2000).
Because nestin immunoreactivity was not observed in axons in this study, it is not 
known whether nestin-immunoreactive neurons extend axons beyond their immediate 
vicinity to the spinal cord or to the periphery. Unless a specific marker of newly formed
168neurons that is present in axons is discovered, it is very difficult to investigate the sprouting 
of axons from nestin-immunoreactive cells after injury.
4.1.4 Possible source of neuronal replacement
As mentioned in 4.1.2, one possible source of the neuronal replacement observed in 
the present study is the late maturation of immature nerve cells. The lack of difference 
between animals treated with  1.25 and 5mg could reflect the fact that the lower dose of NT- 
3 applied in this study (1.25mg/4 weeks) may be maximal and sufficient to trigger all the 
possible neuronal precursors to leave the cell cycle and differentiate. A more intriguing 
possibility is that the neuronal replacement is related to the number of apoptotic neurons.
The proliferation and activation of satellite cells after nerve injury, as reviewed in 
1.3.5, could also imply their involvement in neuronal replacement after axotomy and NT-3 
treatment. The injury-induced synthesis of neurotrophic factors, such as NGF and NT-3, in 
both neurons and satellite cells (Zhou et al.,  1999b), and the expression of trkA and trkC I 
observed in satellite cells of axotomised ganglia suggest that there may be increased 
communication between neurons and their surrounding satellite cells and satellite cells may 
respond to NT-3 treatment.
Bone marrow is another potential source of neuronal precursors capable of moving 
into adult mouse DRG and differentiating into neurons. Sanchez-Ramos (2002) reviewed 
the literature in which cells from postnatal bone marrow were induced to proliferate and 
differentiate into glial cells and neurons in CNS. Various agents were successfully used to 
induce neural differentiation in vitro, including neurotrophins (NGF, BDNF and NT-3),
169retinoic acid and other neurotrophic factors (Sanchez-Ramos et al., 2000; Reyes and 
Verfaillie, 2001; Koyama et al., 2003). In vivo studies in which adult bone marrow cells 
were transplanted into systemic circulation also showed that the administered bone marrow 
cells could migrate to normal brain and differentiate into neuron-specific antigen- 
expressing cells (Brazelton et al., 2000; Mezey et al., 2000). In rodents, intracerebral 
grafting and intravenous infusion of bone marrow stromal cells (BMSC) might be used to 
facilitate the recovery of neurologic deficits of stroke, CNS trauma and Parkinson Disease 
(Li et al., 2000b; Chen et al., 2001); however, whether the therapeutic benefit comes 
directly from newly-formed neurons with functional activities or indirectly from the trophic 
factors and cytokines elaborated from some of the transplanted cells is unclear. Human 
haematopoietic bone marrow cells have been reported to express trk receptors including the 
catalytic and truncated isoforms of trkC (Labouyrie et al.,  1999), suggesting that NT-3 may 
exert effects on bone marrow cells through trk signalling. Corti et al. (2002) demonstrated 
that numerous transplanted bone marrow cells were seen in adult normal DRGs (around 20 
cells per coronal section of ganglia) at 3 months after transplantation. A small number of 
them were found to express neuronal marker acquired phenotypes, including class III p- 
tubulin, neural-specific nuclear antigen (Neu-N) and neurofilament (NF); these neuronal 
cells were small, round and with short processes (Corti et al., 2002). These results showed 
that bone marrow cells could acquire neuronal phenotypes in uninjured DRG as previously 
shown in brain (Brazelton et al., 2000; Mezey et al., 2000). Taken together, bone marrow 
could be a potential source of neuronal replacement in axotomised DRG in my study, and 
NT-3 may be an enhancing factor.The functional aspects of DRG neuronal replacement are unknown. Because nestin 
immunoreactivity was not observed in axons in this study, it is not known whether nestin- 
immunoreactive neurons extend axons beyond their immediate vicinity to the spinal cord or 
to the periphery. Unless a specific marker of newly formed neurons that is present in axons 
is discovered, it is very difficult to investigate the sprouting of axons from nestin- 
immunoreactive cells after injury. However, retrograde tracing and confocal microscopy 
may be helpful in investigating whether nestin immunoreactive neurons extend axons and 
where these axons project to.  If there is any axonal sprouting from nestin-immunoreactive 
neurons within DRG, they may be relevant to the development of neuropathic pain 
associated with nerve injury (see Ramer et al.  1999).
4.2  Effects of axotomy and systemic NT-3 administration on neuron size 
and gene expression of neurofilaments
4.2.1  Methodological considerations
Profiles of around 600 neurons were measured in each ganglion examined. Cell 
sizes in wax-embedded ganglia are reduced compared with those in frozen sections 
(McCarthy and Lawson,  1990), but the overall profile of sizes is unaffected (Lawson and 
Harper,  1985). Because of the bimodal distribution of neuron size, I used a non-parametric 
test to compare the size profiles of neurons between ipsilateral L4 & L5 DRGs and 
contralateral ganglia. A previous study has shown that axotomy has no detectable 
contralateral effect on the neuronal volume from 4 days to 45 days after spinal nerve 
transection (Vestergaard et al.,  1997).
171The general decrease in neuron size may mask selective increases or decreases 
among particular size categories. To examine this possibility, Farel. (2002) presented the 
disproportionate increase in small neurons in L4 DRGs between postnatal day 1  (PI) and 
postnatal day 100 (PI00) rats by normalising his data by the mean and analysing the 
absolute number of neurons below the mean. I used the same method to see whether 
axotomy and NT-3 administration produce effects on the proportion of a specific 
subpopulation of neurons.
4.2.2  Neuron size profile and neurofilament mRNA in axotomised DRG
It has been reported that rat DRG cells continue to increase in diameter in 
proportion to the increase in body surface area for at least 100 days after birth (Donaldson 
and Nagasaka,  1918; Lawson et al.,  1974). In addition to the general increase of neuronal 
size, Farel (2002) noted increased number of neurons in L4-6 DRG between PI  and PI 00 
and the added neurons fell disproportionately into the population below that of the mean 
size within the ganglion.
My results of neuron size distribution showed a shrinkage of neurons of all sizes in 
the ipsilateral ganglia since 2 weeks after axotomy. Previous reports showed a 15-30% 
decrease in cell volume in neurons of all sizes from one to 3 weeks after the same 
procedure, and a 33% decrease 4 days after spinal nerve transection (Rich et al.,  1987; 
Vestergaard et al.,  1997; Bergman et al.,  1999). The neuron size distribution was shown to 
shift to the left 2 weeks and 4 weeks after sciatic nerve transection.
Moreover, Vestergaard et al. (1997) not only reported shrinkage of DRG neurons at 
4, 8 and  15 days after spinal nerve axotomy, but also observed a partial restoration of mean
172volume at 45 days; the disappearance of some small neurons was one possible explanation. 
Rich et al. (1989) found that neuronal death was greatest among smaller neurons with 
diameters between  16 and 28 pm following sciatic nerve transection.
Concomitantly, the mRNA expression of neurofilament-light chain (NF-L) 
examined by microarray analysis and real-time PCR confirmation also revealed a more 
than 2 fold decrease at 2 weeks after axotomy. The expression of mRNA for neurofi lament, 
which is a major determinant of the size of the neuronal perikaryon and axon (Friede and 
Samorajski,  1970; Portier et al.,  1983; Hoffman et al.,  1987), has already been reported to 
be down-regulated in DRG neurons after transection of either central or peripheral branch 
axons of DRG neurons (Greenberg and Lasek,  1988; Wong and Oblinger,  1990a). Since 
NF-L is a neuron-specific protein, axotomy-induced alterations in the levels of the mRNAs 
encoding this protein reflect corresponding changes in its expression by DRG neurons.
4.2.3  Effects of systemic NT-3 administration on neuron size and neurofilament mRNA
It has been shown that NGF from target organs plays an important role in 
determining neuronal size; NGF administration for 3 months to the proximal stump of the 
transected sciatic nerve significantly decreased the degree of neuronal atrophy from 28% to 
13% (Rich et al.,  1987). Whether any of the other neurotrophins, including NT-3, could 
rescue the axotomy-induced neuronal atrophy was not clear. In my study, systemic NT-3 
administration at either dosage did not produce any significant effect on the shrinkage of 
neurons, and the NT-3 treatment for 2 weeks did not significantly regulate the transcripts of 
NF-L and NF-H, which were examined by microarray. Therefore, I suggest that systemic 
NT-3 administration does not significantly rescue the axotomy-induce neuronal atrophy, at
173morphological or molecular levels. Although NT-3 may interact with trkA in addition to its 
preferred receptor, trkC, it still cannot replace the rescue effect that NGF has on neuronal 
atrophy.
4.3  Effects of systemic NT-3 administration on the mRNA expression of 
neurotrophin and neurotrophin receptors
The results discussed in section 4.1  and 4.2 show that NT-3 may stimulate neuronal 
replacement in DRG after sciatic nerve transection; however they do not provide 
information about the molecular mechanisms activated by this neurotrophin. In particular, 
it is not clear whether NT-3 acts through its high-affinity receptor, trkC, and low-affinity 
receptor, p75NTR and the extent of the contribution by other neurotrophins. This section of 
the discussion will analyse my data on the expression of three main neurotrophins, NGF, 
BDNF and NT-3, and their receptors after axotomy and systemic NT-3 administration.
4.3.1  Methodological considerations on real-time PCR
Compared with conventional PCR, real-time quantitative PCR has some advantages: 
(1) increased speed due to the reduced cycle times, removal of separate post-amplification 
manipulation and detection procedures; (2) increased sensitivity because of the use of 
sensitive fluorescence (SYBR in this study) detection equipment; (3) good reproducibility.
Successful quantitative RT-PCR is mainly dependent on the quality of RNA. In this 
study, RNA was extracted from whole ganglia which contained different cell types 
including sensory neurons, satellite cells, Schwann cells, mast cells, fibroblasts, perineurial 
and endothelial cells. RNA samples were purified using Qiagen RNeasy columns, which
174are supposed to isolate pure RNA but were shown to have DNA contamination to some 
degree (Bustin, 2002). For preventing the inaccurate quantification resulting from DNA 
contamination, DNase was routinely applied during RNA extraction in this study and 
removed during the subsequent wash steps. In order to decrease the variations due to 
mispriming and primer dimerisation, thermostable polymerases, requiring heat activation at 
95 °C before the first cycle of RNA, were used.
Using any quantitative RT-PCR method inevitably results in averaging the 
expression of all cell types and masking the minor change of the expression profile of a 
specific cell type. Laser capture microdissection (LCM) should be introduced to select 
individual cells by directing a brief laser pulse at desired cells within a formalin-fixed 
paraffin-embedded tissue section on a glass slide, followed by RNA extraction and 
quantification analysis. However, even this method could not avoid contamination by 
satellite cell cytoplasm. I overcame this limitation by adding to real-time quantitative PCR 
in situ hybridisation to identify the cell type responsible.
Data normalisation is an important process to make samples from different 
experimental animals comparable. GAPDH was shown to be expressed at a constant level 
in DRG after sciatic nerve injury (Gallinat et al.,  1998; Araki et al., 2001; Macdonald et al.,
2001), and my data from microarray study also demonstrated that GAPDH did not change 
its mRNA expression in injured state, validating the use of GAPDH as a housekeeping 
gene in real-time PCR data analysis.
4.3.2  mRNA expression of neurotrophins after axotomy
175In my study, the mRNAs for NGF, BDNF and NT-3 were detected by real-time 
PCR and in situ hybridisation in DRG neurons, but not in satellite cells, from unoperated 
animals, as reported by others using in situ hybridisation, RT-PCR and northern blot 
analysis (Sebert and Shooter,  1993; Zhou et al.,  1999b). However, Shen et al. (1999) failed 
to detect NT-3 mRNA in normal or axotomised DRG by ribonuclease protection assay. In 
other earlier literatures using in situ hybridisation, RT-PCR and northern blot analysis, 
neither NGF nor NT-3 mRNA was shown to be present in a detectable amount in normal 
DRG (Davis et al.,  1987; Emfors et al.,  1990; Wetmore and Olson,  1995). Different 
methodologies which have different sensitivities may explain the different results.
Concomitantly with the expression of the high-affinity receptors, trkC and trkA, 
in specific subpopulations of DRG neurons, NT-3 appears to have a greater effect on 
myelinated sensory axon regeneration than NGF, whereas NGF seems to stimulate 
unmyelinated axon regeneration (Bradbury et al.,  1999; Romero et al., 2001). As 
expression of mRNA for trkA and trkC was occasionally seen in satellite cells in 
unoperated DRG, it could be proposed that these locally-synthesised neurotrophins may be 
related to trophic support to normal DRG neurons and satellite cells.
My data show that the expression of mRNA for NGF increased at 1  day and 1  week 
after axotomy in vehicle-treated ipsilateral ganglia, which was consistent with previous 
results (Sebert and Shooter,  1993; Zhou et al.,  1999b). The up-regulation of NGF in 
axotomised DRG, was reported to be largely due to increased synthesis in satellite cells, 
which did not express detectable levels in uninjured ganglia (Zhou et al.,  1999b). However, 
using in situ hybridisation, I found increased expression of NT-3 and NGF in small-to- 
medium neurons in addition to some satellite cells. The injury-induced increase in mRNA
176expression of neurotrophins implies the importance of local neurotrophin synthesis within 
DRG, which may provide autocrine and paracrine effects, instead of target-derived trophic 
support from the periphery in injured DRG.
Lee et al. (1998) reported that the NGF protein level was decreased at 6 hours after 
tight ligation of spinal nerves, but recovered to almost normal levels at 2 days, suggesting 
that the increased synthesis of NGF within the injured DRG contributes to the recovery; 
another potential source of endogenous NGF synthesis is the proximal stump of transected 
sciatic nerve (Heumann et al.,  1987).
My data show that BDNF mRNA expression increases in neurons of various sizes 
at 1  day after axotomy, but not in satellite cells, which is in keeping with other researchers’ 
results (Michael et al.,  1999; Karchewski et al., 2002). This increase lasted for less than one 
week. In uninjured ganglia, BDNF is expressed in a number of trkA-expressing nociceptive 
sensory neurons and is transported anterogradely to the dorsal horn of the spinal cord where 
it is located in C-fibre terminals (Michael et al.,  1999). The increase in BDNF mRNA and 
protein in trkB- and trkC- expressing neurons in axotomised ganglia and the enhanced 
anterograde transport of BDNF to the spinal cord following sciatic nerve injury may 
contribute to increased synaptic transmission and modulates somatosensory pathways 
(Tonra et al.,  1998; Michael et al.,  1999; Thompson et al.,  1999). In contrast to the 
increased levels of BDNF mRNA, the mRNA expression of its preferred receptor, trkB, 
was down-regulated 2 weeks after axotomy. This suggests that the increased synthesis of 
BDNF in injured ganglia may play a more important role in spinal cord than in the 
axotomised DRG.In my study, mRNA levels of NT-3 increased only at 1  day after axotomy; in situ 
hybridisation localised its expression mainly in small and some large neurons as well as 
satellite cells. Because of its relatively low expression in normal DRG, only Zhou et al. 
(1995,  1999b), using RT-PCR, in situ hybridisation and immunohistochemistry, reported a 
detectable level of NT-3 mRNA and protein in normal small and large DRG neurons and 
an up-regulation of NT-3 synthesis mostly in satellite cells at 2 days after sciatic nerve 
transection, which lasted for 2 months. The satellite cell-derived NGF and NT-3 may 
contribute to the trophic support for regenerating neurons as well as those trkA- and trkC- 
expressing satellite cells. Compared to the down-regulation of trkA and trkB mRNA 
following axotomy, the up-regulation of trkC mRNA in DRG neurons of all sizes for 2 
weeks and its expression in satellite cells in uninjured ganglia suggests the importance of 
trkC signalling in axotomised ganglia.
The axotomy-induced synthesis of NGF and NT-3 in DRG has also been implicated 
in the formation of sympathetic nerve sproutings in the axotomised DRG from 2 weeks 
after injury (Zhou et al.,  1999b; Deng et al., 2000). These grow around large diameter 
neurons, and have been linked to the development and maintenance of neuropathic pain 
after nerve injury (Frostick et al.,  1998; Zhou et al.,  1999b). Sympathetic neurons express 
both trkA and trkC, and require NGF and NT-3 for neuronal survival and differentiation 
during their development (Farinas et al.,  1994; Zhou and Rush,  1995). Zhou et al. (2000) 
showed systemic administration of NGF and NT-3 antisera prevented sympathetic nerve 
sprouting and attenuated allodynia as assessed by foot withdrawal responses evoked by von 
Frey hairs (Zhou et al., 2000).
1784.3.3 mRNA expression of neurotrophin receptors after axotomy
My finding that axotomy decreases the mRNA expression of trkA is in keeping 
with reports by previous authors using Northern blotting, RNase protection assays, in situ 
hybridisation, microarray and immunohistochemistry after sciatic nerve or spinal nerve 
transection (Krekoski et al.,  1996; Bergman et al.,  1999; Shen et al., 1999a; Xiao et al.,
2002); however, some studies in which only crush injury was applied found no change in 
trkA mRNA expression (Ernfors et al.,  1993; Sebert and Shooter,  1993). In normal DRG, 
trkA-expressing sensory neurons are mainly small-sized (McMahon et al.,  1994). Shen et al. 
(1999) reported that the increased amount of NGF protein synthesis did not correlate well 
with the recovery of trkA mRNA expression in the DRG after axotomy (Lee et al.,  1998; 
Shen et al.,  1999b), suggesting that NGF signal transduction through the soma membrane is 
different from that taking place through axon terminals at the periphery in intact state, or 
that some other factors in addition to NGF may also regulate trkA mRNA levels. It has 
recently been reported that different mitogen-activated protein kinase (MAPK) signalling 
pathways are activated by NGF during retrograde signalling and direct stimulation of the 
cell soma (Watson et al., 2001). An in vivo study showed that intrathecal NGF 
administration partly rescued the axotomy-induced decrease of trkA mRNA (Verge et al., 
1992). The transient elevation of BDNF and NT-3 mRNA expression in axotomised DRG 
may not contribute much to the late recovery of trkA levels.
In this study, trkB mRNA was down-regulated at 2 weeks after axotomy and 
returned to control levels by 4 weeks, which is consistent with the study by Bergman et al. 
(1999) using in situ hybridisation and immunohistochemistry. Using Northern blotting, 
others have reported increased trkB mRNA  1   week after crushing the sciatic nerve (Ernfors
179et al.,  1993). The difference could derive from variations in the sciatic nerve lesions used 
and the quantitative methods. The primers for PCR and oligonucleotide probes for in situ 
hybridisation were designed from sequences of catalytic isoforms of trkB and trkC (see 
2.3.5), which have tyrosine kinase domains and display tyrosine phorphorylation in 
response to BDNF and NT-3 respectively. The mechanism of trkB regulation is not known, 
although local neuronal synthesis of BDNF is known to be the main source of this 
neurotrophin. This is in contrast to the synthesis in target organs of NGF and NT-3; this 
may explain why the axotomy did not initiate the change of trkB mRNA at earlier time 
points, as did trkA and trkC.
My results found a large increase in ipsilateral trkC mRNA expression in neurons of 
all sizes, as well as satellite cells, within 24 hours of axotomy. This increase was sustained 
for at least 2 weeks, which is consistent with the findings by Ernfors et al. (1993), but at 
variance with another study which used in situ hybridisation with probes for all isoforms of 
trkC and found decreased trkC expression in neurons at 7 days after mid-thigh sciatic nerve 
transection (Bergman et al.,  1999). Different methods of mRNA detection and different 
targets of examination (catalytic or non-catalytic isoforms) may explain the contradictory 
results. In normal DRG, my study and those of others showed that trkC was expressed in 
medium-to-large neurons; the changed pattern of its mRNA expression in axotomised 
ganglia would imply that trkC signalling may have effects on different subsets of sensory 
neurons with passing time after peripheral injury.
I found that satellite cells expressed trkA or trkC in both unoperated and injured 
ganglia; trkA receptor expression has recently been reported in satellite cells of normal 
DRG (Pannese et al., 2003), but trkC has not. The function of perineuronal satellite cells in
180both normal or axotomised DRG is not well studied, and it has been proposed that satellite 
cells could regulate ion concentration in the microenvironment of DRG neurons (see 
Pannese,  1994). A recent study discovered the formation of new gap junctions between 
satellite cells in injured ganglia (Pannese et al., 2003), showing that responses of satellite 
cells could be triggered by unknown mechanisms after axotomy. The expression of trkA 
and trkC in satellite cells implies the existence of neuron-satellite cell interactions in intact 
and axotomised ganglia. The expression of these neurotrophin receptors in some satellite 
cells also suggests that they have partly neuronal phenotype and may be able to 
differentiate into neurons.
In the current study, the expression of p75N TR mRNA was decreased in neurons and 
up-regulated in satellite cells surrounding large diameter neurons in ipsilateral ganglia after 
sciatic nerve transection, resulting in a marked decrease ofp75N TR mRNA in the whole 
ganglia from  1   day to  1  week after axotomy, as reported by other researchers after the same 
injury (Krekoski et al.,  1996; Zhou et al.,  1996; Bergman et al.,  1999). p75NTR, the 
prototypic member of the tumour necrosis factor receptor family, is known to be capable of 
both signalling independently and modifying the binding and signalling capabilities of trk 
receptors (Hempstead, 2002). In normal lumbar DRG, the p75NTR receptor is co-expressed 
with most trkA- and trkB-expressing DRG neurons, as well as with half of the trkC- 
expressing neurons (Wright and Snider,  1995), where it may enhance the binding affinity 
and neurotrophin selectivity of trk receptors and facilitate the retrograde transport of 
neurotrophins (Hempstead et al.,  1991; Benedetti et al.,  1993). The regulating signals are 
not known, but intrathecal NGF administration was reported to exert a role by partially 
preventing the decrease of p75 mRNA in axotomised ganglia and increasing the p75NTR
181transcripts in normal ganglia (Verge et al.,  1992). In my study, the up-regulation of 
neurotrophin mRNA in DRG neurons and satellite cells, particularly NGF mRNA, whose 
increased expression lasted more than one week, may contribute to the recovery of p75 
mRNA seen at 2 weeks after transection. Moreover, down-regulation of p75N TR mRNA 
expression in injured ganglia after peripheral axotomy may result in a partial loss of 
specificity for the ligands for trkA and trkB (Bibel et al.,  1999; Mischel et al., 2001). This 
suggests that the responsiveness of trkA- and trkB-expressing neurons to NT-3 may 
increase in axotomised DRG.
The altered expression of all trk receptors was observed to return to control levels 
over time after axotomy. Complete recovery of neurotrophin levels by increased local 
synthesis in DRG may contribute to this on the basis that the elevated endogenous NGF 
synthesis in the axotomised DRG can fully replace in quantity the decrease of retrograde- 
transported NGF (Lee et al.,  1998). As well as being a result of a deprivation of 
neurotrophins from target organs, the injury-induced change in trk receptor and p75N TR 
mRNA could be triggered by other signals being mediated either by neuronal activity or by 
retrograde transport (Sebert and Shooter,  1993).
4.3.4  Contralateral effects
I found an increased expression of BDNF mRNA and trkA mRNA at 1  day and 
trkC mRNA at 1   day and 4 weeks, and decreased expression of p75N TR mRNA at 1  day and 
1   week in the contralateral DRGs following sciatic nerve transection. Only a limited 
number of studies on neurotrophins and their receptors have examined contralateral ganglia; 
they show increased level of NGF mRNA in contralateral DRG at 1   and 4 days after sciatic
182nerve crush and decreased trkA-immunoreactive neurons in uninjured DRG at 1  week after 
spinal nerve transection (Wells et al.,  1994; Li et al., 2000a). Unilateral sciatic nerve 
transection has been shown to produce changes in the contralateral nerve, affecting growth 
associated protein-43 (Booth and Brown,  1993), structural proteins (neurofilament- 
L)(Wong and Oblinger,  1990a), and others (e.g. interleukin-1(3 and transforming growth 
factor-pl) (Ryoke et al., 2000). It is unclear whether these adaptive reactions in 
contralateral uninjured DRG serve any functional purpose, but they imply the presence of 
as yet unidentified communication between the two sides of the body (see Koltzenburg et 
al.,  1999). Possible mechanisms include the delivery of neurotrophic cytokines or stress- 
related hormones through the general circulation, which has been demonstrated by the 
increase in NGF mRNA in contralateral cervical ganglia at 3 days after sciatic nerve crush 
(Fitzgerald,  1983; see Koltzenburg et al.,  1999; see Lowrie, 1999). Local bilateral synaptic 
communication between bilateral motor neurons has been suggested by an experiment 
which showed that 4 days after injections of the Bartha strain of pseudorabies virus into the 
medial gastrocnemius muscle of a normal rat or in rats with unilateral L3-L6 dorsal 
rhizotomies, transneuronally labelled neurons were seen in the ipsilateral L5 spinal laminae 
I and II and bilaterally in spinal laminae IV-VIII, and X (Rotto-Percelay et al., 1992). 
Whether local synaptic communication between bilateral sensory neurons exists is not 
understood.
4.3.5  Effect of systemic NT-3 administration on mRNA expression of neurotrophins
Local and intrathecal administration of NT-3 has been proven to modulate the 
expression of neuropeptide Y and pituitary adenylate cyclase-activating polypeptide
183(PACAP) in DRG neurons after sciatic nerve and spinal nerve injury (Sterne et al.,  1998; 
Jongsma Wallin et al., 2001); however, there are no reports addressing whether systemic 
NT-3 administration would regulate mRNA expression of neurotrophins, including NT-3 
itself, and neurotrophin receptors in axotomised DRG.
Using real-time quantitative PCR, my results showed a temporary increase of 
mRNA expression of NGF, BDNF and NT-3 in vehicle-treated DRG after mid-thigh sciatic 
nerve transection as discussed in 4.3.1  and 4.3.2; systemic NT-3 treatment at the dose of 
5mg/4 weeks prolonged the up-regulation of these neurotrophins but not of NT-3 itself. In 
situ hybridisation showed the increased expression of NGF to be localised predominantly in 
small- and medium-sized neuron and some satellite cells around large neurons, and that 
BDNF was expressed in neurons of all sizes in ipsilateral ganglia following axotomy and 
NT-3 administration.
Whether NT-3 can regulate the expression of NGF in DRG cells in vivo has never 
been studied. A previous study showed that a single subcutaneous injection of NT-3 at dose 
of 1  mg/kg had no effect on BDNF expression in intact DRG using ribonuclease protection 
assay (Apfel et al.,  1996). My finding that NT-3 administration prolonged the ipsilateral 
up-regulation in BDNF mRNA appears to be at variance with work by Karchewski et al. 
(2002) who showed instead that it produced a down-regulation of BDNF. However, these 
authors transected the right sciatic nerve at its origin from the L4 and L5 spinal nerves and 
used in situ hybridisation to quantify mRNA levels and intrathecal administration of NT-3 
at different dose, which may activate different intracellular pathways and produce different 
effects (Watson et al., 2001)(see  1.2.12), whereas I used real-time quantitative PCR and 
applied NT-3 systemically.
184Only a few studies have examined the interactions between members of 
neurotrophin family. An in vitro study, using transfected PC 12 cells, which express trkA 
and p75NTR, but not trkB or trkC, has shown that exogenous NGF can induce release of 
BDNF, NT-3 and NT-4/5, mediated by both trkA and p75NTR; exogenous BDNF induces 
NT-3 release, via p75NTR; and exogenous NT-3 induced secretion of BDNF and NT-3 itself, 
probably via p75NTR but not trkA (Kruttgen et al.,  1998). With regard to the possible 
mechanisms responsible for the neurotrophin-induced neurotrophin release, increasing 
intracellular calcium mediated by p75 and/or trk receptors through PLC-y and PI-3 kinase 
pathways were proposed; an indirect pathway suggested triggering of neurotransmitter 
release which then causes depolarization and neurotrophin release (Kruttgen et al., 1998). 
However, the question of whether NT-3 can affect the secretion of NGF in vitro was not 
addressed in that study, although an in vivo study also described an up-regulation of BDNF 
mRNA expression in response to intrathecal administration of NGF, mostly in trkA- 
expressing DRG neurons (Michael et al., 1997).
On the basis of my results, I suggest that the NT-3-induced early up-regulation of 
NGF and BDNF levels in this study could be secondary to the activation of trkC or p75N TR 
signalling in DRG neurons and satellite cells. Signal transduction through the increased 
cross-activation between NT-3 and trkA or trkB in injured state due to the depressed 
p75NTR mRNA expression cannot be excluded. The NT-3-stimulated up-regulation of NGF 
mRNA in axotomised ganglia may have an effect on pain processing, and the up-regulation 
of BDNF may be anterogradely transported to dorsal horn and modulate the activity of 
trkB-expressing neurons in the spinal cord (Michael et al.,  1997; McMahon, 1996; Woolf, 
1996). However, systemic NT-3 treatment did not seem to exacerbate autonomy or change
185the pain behaviour of rats, when compared with vehicle treatment. The increased BDNF 
may act through p75NTR on Schwann cells to stimulate remyelination (Notterpek, 2003), 
and the further up-regulated NGF may be involved in the formation of sympathetic nerve 
sproutings in the axotomised DRG (Zhou et al.,  1999b; Deng et al., 2000).
4.3.6  Effect of  systemic NT-3 administration on mRNA expression of neurotrophin 
receptors
It has been shown that 7-day intrathecal NT-3 administration caused the down- 
regulation of trkA but not trkC in uninjured DRG, using in situ hybridization (Gratto and 
Verge, 2003). Although these results are not really comparable to injury studies, they were 
to some degree in agree with my results of trkA and trkC expression in the contralateral 
ganglia of NT-3 treated rats at earlier time points.
The expression of neurotrophin receptors in axotomised ganglia after NT-3 
administration has never been examined in vivo before. The present study showed that 
systemic NT-3 has effects on the expression of mRNA for all trk receptors. The decrease of 
trkA mRNA expression in axotomised DRG was counteracted by NT-3 from two weeks 
after injury; trkB mRNA was up-regulated by NT-3 treatment from 2 weeks following 
injury; the increase in mRNA expression of trkC in axotomised ganglia was totally 
counteracted by exogenous NT-3 until one week and then remained only slowly elevated 
but still at levels lower than vehicle-treated DRG for another week. At the last time point 
examined, 4 weeks, all three trk receptors were up-regulated by NT-3 administration, 
compared with either unoperated levels or vehicle-treated ganglia.
186Because the early decrease of trkA mRNA in vehicle-treated axotomised ganglia is 
at least partly due to a decrease of target-derived NGF (as discussed in 4.3.2), the rebound 
of trkA transcripts in NT-3-treated ganglia, which were expressed in many neurons of all 
sizes, from 2 weeks implies that exogenous NT-3 may act directly via trkA or p75NTR, or 
indirectly via other signalling pathways or by the up-regulation of NGF mRNA.
In a previous study using BDNF null mutant mice, it has been shown that 
endogenous BDNF is not required for the developmental induction of trkB expression or 
for the onset of BDNF dependence in sensory neurons (Huber et al., 2000). As BDNF is 
mainly synthesised in normal DRG and its expression increases in injured ganglia (Michael 
et al.,  1999; Karchewski et al., 2002), the delayed decline of this receptor after axotomy 
suggests that BDNF itself does not regulate trkB mRNA expression. The increased 
expression of trkB mRNAby NT-3 treatment could be due to signal transduction initiated 
by NT-3 stimulation of trkB or p75NTR.
The early counteraction of the increased expression of trkC mRNA by NT-3 
treatment in injured DRG suggests that NT-3 from target organs is a major factor in 
regulating trkC expression in adult DRG. As systemic NT-3 administration has no effect on 
p75NTR mRNA expression in injured ganglia, in contrast to the complete recovery of 
p75NTR mRNA by intrathecal NGF infusion (Verge et al., 1992), it is assumed that target- 
derived NT-3 is not the main factor regulating p75 expression in adult DRG.
All together these results show that systemic NT-3 administration up-regulates 
mRNA expression of neurotrophins except NT-3 itself and counteracts, albeit only 
temporarily for trkC, the axotomy-induced changes of trk mRNA in DRG. NT-3 
administration is likely to enhance the responsiveness of trkA- and trkB-expressing neurons
187to their ligands by increasing the mRNA levels of both receptors and ligands in axotomised 
DRG.
NT-3 is known to be capable of activating all trk receptors (Cordon-Cardo et al., 
1991; Lamballe et al.,  1991; Soppet et al.,  1991), although whether this happens in vivo is 
not clear. As the markedly decreased level of p75NTR mRNA after axotomy was proposed 
to result in at least partial loss of specificity to their ligands for trkA and trkB, these two trk 
receptors, even when down-regulated, may be more responsive to exogenous NT-3 than in 
intact state. In contrast, lower p75NTR co-expression with trkC may increase its specificity 
for NT-3 (Bibel et al.,  1999; Vesa et al., 2000; Mischel et al., 2001). NT-3 at a normal 
physiological concentration has no effect on other trk receptors (Ip et al.,  1993); however it 
may be possible for exogenous and injury-induced endogenous NT-3 to activate tyrosine 
phosphorylation via some or all trk receptors under these circumstances.
4.3.7  Developmental similarities
In order to ascertain whether the results of morphological and genetic study in 
axotomised DRG support the hypothesis of nerve cell replacement, I have compared them 
with known events during DRG development, although I am fully aware of the 
considerable differences between the two conditions.
During mouse development, DRG neurogenesis begins shortly before E10 with a 
burst between E l2 and E l3 (Lawson and Biscoe,  1979; Farinas et al., 1996); trk proteins 
start to be expressed concomitantly with neuronal differentiation (Klein et al., 1990b; 
Tessarollo et al.,  1994). At El 0.5-El 1   in mice, when more than 60% of the DRG cells are
188still at a precursor cell stage, most DRG neurons express trkC protein, whereas trkB is 
present in a modest subpopulation of cells and only low levels of trkA are present (Farinas 
et al.,  1998). During that early stage, it has been suggested that NT-3 can directly activate 
trkB as well as trkC in vivo (Farinas et al.,  1998). From El 1-13.5, when trkA-expressing 
axons start penetrating into the proximal hindlimb and approach cutaneous targets, trkA 
expression increases steadily to appear in the majority of cells; on the other hand trkC 
decreases, to be expressed only in a subpopulation of DRG cells and persists into adulthood 
(White et al.,  1996; Farinas et al.,  1998). On the other hand, trkB expression undergoes no 
obvious changes during this period. In the present study, the mRNA expression of trk 
receptors during the 2 weeks after sciatic nerve axotomy parallels the events during 
embryonic neurogenesis, when trkA expression is low and most neurons express trkC.
In mice, NGF mRNA starts to be detectable in the surface ectoderm of the 
developing hindlimb at El 1.5 and its expression increases from E13.5 to E15.5 when NGF 
is strongly expressed in the epithelium of the hindlimb epidermis and subjacent 
mesenchyme instead of the skin as a main source of synthesis in adult (Schecterson and 
Bothwell,  1992; White et al.,  1996). NT-3 mRNA is expressed in mesenchymal cells in the 
dermamyotome immediately adjacent to the DRG and in muscle precursors in the proximal 
limb bud between E10 and E l2 before their axons have reached their peripheral targets 
(Farinas et al.,  1996; White et al.,  1996). In my study, the NGF and NT-3 mRNA 
expression was increased in neurons and induced in satellite cells after axotomy, which is 
to some degree similar to the scenario during embryogenesis when the tissue adjacent to 
DRG releases neurotrophins and plays important roles.
189These changes described may reflect an adaptive response to injury but whether the 
tissue would revert to a less differentiated state (de-differentiation) after peripheral nerve 
injury is questionable; increased local synthesis of neurotrophins or subsequent external 
stimuli (e.g. exogenous neurotrophins) may stimulate regeneration, or even neuronal 
replacement.
4.4  Gene expression profile in adult rat dorsal root ganglion after 
axotomy and systemic NT-3 administration
This section will discuss the data of microarray, which was performed to screen 
1322 genes relevant to neurobiology in unoperated rats and at 2 weeks after mid-thigh 
sciatic nerve transection with and without systemic NT-3 treatment. The main emphasis 
will be on how axotomy and exogenous NT-3 regulate signalling pathways, growth 
associated proteins and other important genes and how this technique assists us to better 
understand the molecular mechanisms of morphological findings from axotomised ganglia.
4.4.1  Time point of microarray study and technical considerations
In this study, microarray was used to screen mRNA expression of more than one 
thousand genes. The transcription of genomic DNA into mRNA is the first step in the 
process of protein synthesis; alteration in mRNA expression reflects the intracellular 
responses to external stimuli, such as administration of neurotrophic factors and sciatic 
nerve injury. Although only the mRNA, which is an intermediate molecule in protein 
synthesis, can be studied, mRNAs for most genes are regarded as good indicators of
190corresponding protein levels. However, in some conditions mRNA levels may not reflect 
the levels of protein, because regulation may occur at the post-transcription stage (Gygi et 
al.,  1999).
There are mainly two types of array: oligonucleotide arrays and cDNA arrays. Each 
gene included in an oligonucleotide array is represented by one set of 16 different ‘probe 
pairs.’ Each probe pair consists of a 25-base-pair (bp) ‘match’ probe and a 25-bp 
‘mismatch’ probe, in which the 13th base does not match the target sequence. After 
hybridisation, the probe pair saturation is detected and analysed to generate a Detection p- 
value and assign a Present (P), Marginal (M) or Absent (A) call
(http://www.affymetrix.com). Instead of using 25-bp probes, a cDNA array is produced by 
spotting PCR products of around 0.6-2.4kb, either full-length cDNAs or partially 
sequenced cDNAs. The disadvantage of cDNA arrays is that cDNA is deposited in a 
double-stranded form and tends to have intra-strand cross-link or some constraining 
contacts with the matrix (membrane or glass) along its length, which can be avoided in 
oligonucleotide arrays. One more advantage for using an oligonucleotide array is that each 
sample is hybridised onto a separate array, which allows independent repeated experiments 
with multiple samples without pairing or matching groups beforehand. However, using 
oligonucleotide arrays may have the disadvantages of the reduction of specificity and 
variations in melting temperature due to AT-CG composition (Duggan et al.,  1999).
Although microarray accelerates the study of known or novel genes, it cannot 
totally replace other quantitative methods, including northern blots, RT-PCR, nuclease 
protection assays, and in situ hybridisation, which target on specific genes, and are able to 
quantify smaller changes in transcripts and confirm or extend microarray results. One more
191limitation of this technique is that the starting amount and quality of total RNA is also an 
important factor. If microarray is to be applied to cases where only limited starting 
materials can be yielded, for example the LCM-selected cells, RNA amplification or 
multiple rounds of linear amplification based on cDNA synthesis and template-directed in 
vitro transcription might be required (Eberwine et al.,  1992; Spirin et al., 1999). In addition, 
RNA was extracted from whole ganglia which contained different cell types including 
sensory neurons, satellite cells, Schwann cells, mast cells, fibroblasts, perineurial and 
endothelial cells; different regulation of genes in various cells should be considered.
To make it possible to compare data from different arrays that had been hybridised 
at the same time in this study, average intensities of gene expression were normalised (or 
scaled) to a value of 100. In other researchers’ experience of using the array chips including 
more than thousands of genes in different experimental groups, only a small portion of 
present genes changed, being either up-regulated or down-regulated. Normalising (or 
scaling) the mean intensities in each array to a value of 100 for the majority of experiments 
seemed to be a reasonable and feasible method before further statistical analysis. Although 
a few potential “housekeeping control genes”, including GAPDH, actin and hexokinase, are 
included in these arrays, it is not appropriate to use just one of them to normalise the data 
before confirming that a proposed “ housekeeping gene” does not change under the 
experimental circumstances (sciatic nerve transection in my study) using other quantitative 
methods. In these microarray data, there was no significant difference in expression of 
GAPDH between the three groups, which is consistent with previous studies (Fan et al., 
2001; Kim et al., 2001; Kubo et al., 2002; Xiao et al., 2002). These results support the
192reliability of the data analysis of my real-time PCR study in section 2.4.10 in which 
GAPDH was used to normalise all the examined genes.
In my study, Rat Neurobiology U34 arrays from Affymetrix were used, which are a 
type of oligonucleotide array with a sophisticated internal control.  1322 sequences relevant 
to neurobiology research are included in each array chip. In view of the variability between 
animals, reproducibility and false positive detection, ganglia from 4 rats were pooled before 
hybridising onto an array and triplicate experiments in each group were performed. 
According to the data yielded from the study of neuronal number and apoptosis, which 
support the existence of newly-formed neurons in NT-3-treated axotomised DRG, and my 
data showing that systemic NT-3 can regulate the mRNA of all of the trk receptors, as well 
as that for NGF and BDNF in injured DRG, simple knowledge of the preferred pathway for 
NT-3 via trkC is not enough to explain the complexity of events triggered by nerve injury.
In addition, my results also show that neurotrophin mRNAs were up-regulated, especially 
NGF, whose up-regulation lasted for more than  1  week, and some neurotrophic factors 
(such as glial-derived neurotrophic factor, transforming growth factor, ciliary neurotrophic 
factor and bFGF) have been reported to be up-regulated in axotomised DRG without 
treatment (Costigan et al., 2002; Xiao et al., 2002), finding out the signalling pathways 
which are regulated by axotomy may help to explain the mechanism of post-axotomy 
changes in ganglia. Moreover, these results may be derived from interactions of multiple 
pathways and proteins in DRG cells and neurons.
On the basis of these data I chose to examine gene expression patterns using the 
U34 Neurobiology to identify some of the genes implicated in development, regeneration 
and adaptive responses in axotomised DRG following vehicle or NT-3 treatment. The time
193point of 14 days after sciatic nerve transection was chosen in this study because it is the 
time when neuronal apoptosis begins to be observed and the changes of neurotrophin 
/receptor mRNA are significant.
The results show altered mRNA transcripts (> 1.5-fold) of 118 genes, including 
known genes and ESTs, 2 weeks after mid-thigh sciatic nerve transection with vehicle 
administration compared to sham operation. Microarray analysis of the alterations in gene 
expression caused by the injury demonstrates the response in DRG cells, which include 
sensory neurons that have been deprived of part of the axon and peripheral synaptic 
contacts. Real-time quantitative PCR were used to confirm 7 genes and validated my 
choice of 1.5-fold change to be a significant change. On the basis of my above 
considerations, I am confident that the method 1  apply is appropriate and adequate to find 
out which genes are involved in the process leading to the morphological changes I 
observed, and provides reasonable explanations of the NT-3-stimulated effects in 
axotomised DRG.
4.4.2  Gene expression profile in adult rat DRG after axotomy and systemic NT-3 
admin istration
Three chips were used for each group and cross-comparisons were made between 
all the chips generating nine pair-wise sets of data; the regulated genes were categorised 
into 9 classes and selected genes were discussed to link their function to the reaction of 
neurons in injured state or after systemic NT-3 administration.
4.4.2.1  Signal transduction and cell regulation gene expression
194In  this  study,  expression  of  a  few  genes  of  signalling  pathway  involved  in 
regeneration and neural development was regulated by axotomy and NT-3 treatment.
Mothers  against  decapentapleic  (dpp)  (Mad)  is  a  mediator  of  the  signal 
transduction  pathways  of transforming  growth  factor  beta  (TGF-{3)  superfamily,  which 
includes TGF-(3s, activins and bone morphogenetic proteins (BMPs). Madl  was reported to 
mediate BMP  signalling (Hoodless  et al.,  1996), which  instructs the maturation of neural 
crest-derived  progenitor  cells  to  neuronal  lineage  and  regulate  subsequent  neuronal 
differentiation in peripheral nervous system (Shah et al.,  1996; Zhang et al.,  1998); BMP-2 
signalling  has  been  shown  to  induce  trkC  expression  and  NT-3  responsiveness  in 
sympathetic  neurons  (Zhang  et  al.,  1998).  BMP  receptors  are  expressed  in  adult  DRG, 
mainly  in  large  sensory  neurons,  which  also  express  trkC  (Zhang  et  al.,  1998).  The 
significant  increase  of  Madl  transcripts  (4.50-fold)  after  axotomy  in  the  present  study 
follows the  activation  of this  pathway  after peripheral  nerve transection  and  supports the 
idea  that  peripheral  nerve  transection  initiates  the  processes  associated  with  neural 
differentiation and up-regulates trkC expression in DRG. As a result, the axotomised DRG 
neurons are likely to become more responsive to either endogenous or exogenous NT-3. In 
addition,  axotomy-induced  increase of Madl  was further up-regulated by NT-3 treatment, 
suggesting  that  the  signalling  pathways  initiated  by  the  activation  of the  BMP  receptors 
were stimulated by NT-3 either directly or indirectly.
Noggin,  which  is widely  distributed  and  secreted  as  a  homodimeric  glycoprotein, 
acts  by  binding  and  limiting  BMP  actions  (Zimmerman  et  al.,  1996),  and  plays  an 
important  role  in  neural  tube  development  (McMahon  et  al.,  1998).  After  sciatic  nerve 
transection, Noggin  mRNA was decreased by  1.89-fold, which would also facilitate BMP
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effect on the expression of this gene.
Janus  protein  tyrosine  kinases  (JAKs)  are  important  components  of  signal 
transduction pathways activated by a variety of growth factors and most cytokines (Ihle et 
al.,  1995).  JAK  signalling  pathway  has  cross-talk  with  other  neurotrophin-activated 
signalling  pathways,  such  as  MAP  kinase  pathway  and  PI-3  kinase  pathway  (Rane  and 
Reddy,  2000).  However,  whether  JAKs  are  implicated  in  signal  transduction  processes 
initiated by NT-3 or other neurotrophins or neurotrophic factors is not clear. The growth of 
regenerating axons  in  cultures of DRG neurons,  2 weeks after a “conditioning” lesion on 
the sciatic nerve,  depends on the JAK signalling pathway instead of the MAP kinase and 
PI-3 kinase pathways, both of which are crucial during development (Liu and Snider, 2001). 
My  data  show  increased  JAK1  mRNA  expression,  which  is  consistent with  its persistent 
up-regulation observed by Rane et al. (2000) in axotomised DRG, implying the importance 
of  the  JAK  pathway  in  enabling  neurons  to  survive  the  loss  or  depression  of  other 
signalling  pathways  (Rane  and  Reddy,  2000).  The  mRNA  expression  of JAK1  was  not 
affected by NT-3 treatment.
At  least  three  intracellular  pathways  are  known  to  be  important  mediators  of 
survival,  differentiation  and  neurite  growth  of  sensory  neurons:  the  ras/raf/mitogen- 
activated  protein  (MAP)  kinase  pathway,  the  phosphatidylinositol  3’-kinase  (PI-3) 
kinase/Akt  pathways  and  the  phospholipase  C-y  (PLCy)  pathway  after  activation  of trk 
receptors  (Vetter  et  al.,  1991;  Obermeier  et  al.,  1993;  Baxter et  al.,  1995;  Goldberg  and 
Barres, 2000). In this study, none of the genes relevant to these pathways were significantly
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signalling and JAK pathway.
In neurons, Ras GTPase-activating protein (SynGAP) is enriched at excitatory 
synapses in brain and may be coupled to NMDA receptor function, negatively regulating 
Ras activity and playing a role in synaptic plasticity (Kim et al., 2003). The SynGAP 
knockout mice have smaller brains and die perinatally, showing its importance during early 
postnatal development (Kim et al., 2003). In my study, the increased SynGAP transcripts 
after axotomy may result in the inactivation of Ras, which is downstream of the MAP 
kinase pathway and which is normally initiated by neurotrophins or Ca2+ (Fukunaga and 
Miyamoto,  1998), inhibiting signal transduction through this pathway in axotomised 
neurons. SynGAP mRNA was not regulated by NT-3 administration.
Interestingly,  systemic NT-3  treatment for 2 weeks  after axotomy up-regulated  3- 
fold  PI-3  kinase  regulatory  subunit  p85a  mRNA  levels,  which  controls  sequential 
activation  of PI-3  kinase  (Jimenez  et  al.,  2002).  The  cAMP  response  element  binding 
protein  (CREB), which  is a known  regulator of genes required  for neuron  survival  and  is 
involved  in the PI-3  kinase and  PLCy pathways (Riccio et al.,  1997; Johnson et al., 2000), 
was  also  increased  by  1.7-fold  after  NT-3  administration,  compared  to  vehicle-treated 
ganglia. In vitro studies showed that the transcription of bcl-2, which is known to suppress 
apoptosis, was induced in neurons through CREB by insulin-like growth factor-a (IGF-1), 
NGF  and  BDNF  (Pugazhenthi  et  al.,  1999;  Riccio  et  al.,  1999);  whether  NT-3  also 
regulates bcl-2 through CREB and then promotes DRG neuronal survival is not known, but 
my  morphological  results  implied  that  NT-3  had  no  anti-apoptotic  effects  in  vivo.  This 
result  indicates  that  of  the  three  main  signalling  pathways  for  NT-3,  the  PI-3  kinase
197pathway  is  activated  by  systemic  administration  of this  neurotrophin at 2 weeks and  may 
play a crucial  role in neuronal regeneration and replacement of dying neurons. PI-3  kinase 
pathway also affects calcium homeostasis in cells, which is critical to survival (Tong et al., 
1996).
In  addition,  a  few  genes  related  to  neuronal  development  were  regulated  by 
axotomy and/or NT-3 administration. VGF, a secretory peptide precursor, widely expressed 
by  neurons  and  neuroendocrine  cells  throughout  the  nervous  system,  plays  an  important 
role in developing neurons when they complete migration and begin to differentiate, and is 
involved in energy metabolism  in adult CNS. VGF synthesis in DRG was first observed at 
embryonic  day  13.5,  but  its  exact  function  in  DRG  is  not  known  (Snyder  et  al.,  1998; 
Salton et al.,  2000).  In this  study,  VGF  increased  by 3.4-fold after axotomy;  however, 2- 
week NT-3 administration did not significantly regulate its expression in DRG as NGF did 
in PC 12 cells and NT-3 did in primary culture of cortical or hippocampal neurons (Hawley 
et al., 1992; Bonni et al.,  1995). Its cell type-restricted regulation of transcription may be an 
explanation.
Monocyte  chemoattractant  protein-1   (MCP-1)  was  observed  to  increase  in 
experimental  stroke models (Kim  et al.,  1995;  Yamagami  et al.,  1999), and contributes to 
recruitment of neutrophils,  lymphocytes and  monocytes  into the damaged tissue (Ousman 
and David, 2001).  MCP-1  levels were significantly increased in  ischaemic brain and were 
also  involved  in  the  migration  of bone  marrow  stromal  cells  (MSCs)  in  vitro  using  a 
microchemotaxis chamber (Wang et al., 2002b). MCP-1 was also shown to inhibit neuronal 
and astrocyte apoptosis in the CNS (Eugenin et al., 2003). The 2.8-fold increase of MCP-1 
expression  in  axotomised  ganglia  in  my  arrays  supports  the  idea  that  MSCs  can  be
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and get ready for further signals (e.g. NT-3) to differentiate. MCP-1  up-regulation may also 
explain  the  lymphocyte  and  macrophage  invasion  of  DRG  after  axotomy  (Hu  and 
McLachlan,  2002).  However,  NT-3  treatment  partly  counteracted  the  injury-induced 
increase of MCP-1.
Chemokines are a superfamily of chemoattractant proteins, mainly functioning in 
control of leukocyte trafficking, and recruitment and activation of inflammatory cells. 
Chemokine CX3C, which exists as either a membrane-anchored protein or a secreted 
chemokine, is expressed in neurons, microglia and astrocytes, together with its G-protein- 
coupled receptor CX3CR1, in brain (Mizuno et al., 2003). This chemokine participates in 
the attraction and activation of microglia after brain ischaemia (Tarozzo et al., 2002). 
Chemokine CX3C can provide neuroprotective effects to hippocampal neurons in vitro by 
activation of Akt/PI-3 kinase pathway (Meucci et al., 2000; Mizuno et al., 2003), whereas 
its distribution and function in DRG is not clear, except for being expressed in neonatal 
DRG neurons (Oh et al., 2001). In my work, the presence and levels of chemokine CX3C 
mRNA in unoperated DRG indicated its activity also in normal adult DRG; the NT-3- 
induced up-regulation of this chemokine raises the possibility that it is involved in the 
activation of the PI-3 kinase pathway as well as the recruitment of certain types of cells 
which may be important for neuroprotection or neuronal replacement.
Cytosolic retinol-binding protein  (CRBP)  is  involved  in the oxidation  of retinol to 
retinal  and  retinal  to retinoic acid  (RA), which  initiates the differentiation of neurons and 
glial  cells  and  induces  early  apoptosis;  RA  also  stimulates neurite outgrowth  from  DRG 
neurons  during  embryonic  development  via  nuclear  receptors  and  modulates  gene
199transcription  (Quinn  and  De Boni,  1991; Ross et al., 2000;  Sarkar and  Sharma, 2002).  In 
cell cultures of stem cells from adult rat hippocampus, exposure to RA caused cell division, 
initiation  of differentiation  into  immature  neurons  and  up-regulation  of trkB,  trkC  and 
p75NTR;  subsequent  application  of  either  NGF,  BDNF  or  NT-3  enhanced  neuronal 
maturation  (Takahashi  et  al.,  1999).  In  this  work,  the  1.9-fold  increase  of CRBP-I  after 
axotomy  suggests  that  the  retinoid  signalling  is  activated  in  injured  ganglia  and  may 
contribute to the post-axotomy  regulation  of trk receptors, especially the up-regulation of 
trkC,  and  the  differentiation  of  cells  into  Schwann  cells,  satellite  cells  and  neurons. 
Although NT-3 did not significantly affect the levels of CRBP-I transcripts, it is proposed 
that  NT-3,  or  other  NT-3-stimulated  neurotrophins,  may  subsequently  enhance  any 
neuronal maturation by way of RA-dependent expression of the Trk receptors (Takahashi et 
al.,  1999).
Interferon-gamma inducing factor (IGIF), also named interleukin-18 (IL-18), is a 
relatively newly found cytokine and has been shown to be induced in macrophages during 
axotomy-induced Wallerian degeneration to modulate immune reactions after peripheral 
axonal injury (Menge et al., 2001). The expression of IGIF/IL-18 was reported to be 
increased in RA-treated mouse embryonic stem cell culture during neural differentiation 
(Sarkar and Sharma, 2002). Its increased mRNA expression in injured DRG shown here, 
which was not affected by exogenous NT-3, may be implicated in the post-axotomy 
inflammatory reactions, apoptosis of neurons and satellite cells and neuronal differentiation.
2004.4.2.2  Growth-associated proteins and growth factors
Axotomy induced the up-regulation of growth associated protein 43 (GAP-43) by 
2.4-fold, bFGF by 2-fold, NT-3 by 2-fold, BDNF by 1.7-fold, insulin-like growth factor 
(IGF)-2 by 1.6-fold and insulin-like growth factor binding protein (IGFBP)-6 by 1.6-fold. 
NGF is not included in the design of these commercial arrays.
In previous studies, these neurotrophic factors and their receptors have been 
demonstrated to play critical roles during nervous system development, and increased 
expression of some of these factors in DRG after axotomy, including NGF, BDNF, NT-3 
and FGF-2, have been reported in the present study using real-time PCR and in previous 
papers (Sebert and Shooter,  1993; Grothe et al., 1997; Michael et al.,  1999; Zhou et al., 
1999; Karchewski et al., 2002).
GAP-43, a rapidly transported axonal protein localised primarily in the axonal 
growth cone, is strongly expressed during axonal outgrowth period of embryonic 
development. Its up-regulation by trauma has been shown to correlate with substantial 
functional recovery after axonal injury (Skene and Willard,  1981; Katz et al.,  1985; 
Hoffman,  1989; Gispen et al.,  1991; Fu and Gordon,  1997); although the rats in my study 
did not get any functional recovery or any growth cones after sciatic nerve transection and 
ligation for 4 weeks, the marked elevation of GAP-43 mRNA found in them suggested the 
potential of axonal regeneration, in keeping with previous studies (Costigan et al., 2002; 
Xiao et al., 2002).
Insulin-like growth factor II (IGF-II) has been reported to be expressed by Schwann 
cells after injury and to be involved in Schwann cell proliferation during peripheral nerve
201regeneration (Svenningsen and Kanje,  1996); its receptor is expressed in a subset of DRG 
neurons of all sizes (Hawkes and Kar, 2002). Insulin-like growth factor binding proteins 
(IGFBP) modulate IGF actions in an autocrine or paracrine setting (D'Ercole et al., 1996). 
The up-regulation of IGF-II and IGFBP-6 in axotomised ganglia in this study implies that 
they may contribute to neuronal and non-neuronal adaptive reactions after axotomy.
Up-regulation of these growth-associated factors and growth factos may participate 
in the protection of neurons from death, in nerve regeneration and in modulation of some 
receptors and ion channels after axotomy (Doster et al.,  1991; Fu and Gordon,  1997; Sterne 
et al.,  1997; Bennett et al.,  1998; Boucher et al., 2000). This provides a possible 
explanation for the survival of the majority of axotomised DRG neurons after sciatic nerve 
transection. However, these factors may be expressed in Schwann cells and satellite cells.
The above axotomy-induced potentially neuroprotective or regenerative factors 
were not up- or down-regulated by systemic NT-3 treatment. The only factor that was up- 
regulated by NT-3 treatment in injured ganglia in this category is fibroblast growth factor- 
18 (FGF-18), which is expressed in brain neurons during postnatal development and 
stimulates formation of glial cells in CNS (Hoshikawa et al., 2002). It was shown to be a 
neuroprotective agent in brain (Ellsworth et al., 2003); however the distribution and 
function of FGF-18 in DRG has not been studied before.
4.4.2.3  Apoptosis-related genes
The period of neuronal apoptosis in DRG following sciatic nerve transection has 
been reported to continue for at least 6 months after injury (Groves et al., 1997; McKay 
Hart et al., 2002). Although neuronal apoptosis was observed in the present study, no genes
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in any arrays, except a 2.3-fold increase of calmodulin-dependent protein kinase II 
(CaMK2).
Calmodulin (CaM) is a Ca2+-binding protein involved in a variety of cell functions; 
CaMK2 is one of the CaM-dependent enzymes, which is known to be activated by the 
injury-induced Ca2+ overload and mediates the depolarisation-induced neuronal cell death 
in primary cortical neuron culture (Takano et al., 2003). However, the role of CaMK2 in 
neuronal damage in vivo is controversial (Takano et al., 2003). All the apoptotic neurons 
were immunoreactive for active caspase-3 in sections stained for it, indicating that this 
protease cascade is the main pathway of axotomy-induced neuronal death. CaM/CaMK2 
signalling pathway may to some extent regulate the axotomy-induced neuronal death in 
DRG.
As the RNA used in this study was prepared from the pooled L4 and L5 DRGs, the 
contribution from apoptotic cells, approximately 0.04-0.07% of all neurons at a time point, 
is likely to be below the threshold applied in this study (>1.5-fold change). Although a 
study showed that axotomy-induced cell death might be related to their low ratio of cell 
death repressor bcl-2 and bcl-x to cell death promotor Bax expression in small-sized DRG 
neurons (Gillardon et al.,  1996), in my data there was no significant up- or down-regulation 
of any of these genes.
In the present study systemic NT-3 administration did not affect any of the genes 
relevant to apoptosis; this is consistent with the morphological findings that there was no 
significant difference in the apoptotic rate between any operated groups. My results
203confirm that systemic NT-3 treatment seemed to provide no neuroprotective effect against 
apoptosis in axotomised ganglia.
4.4.2.4  Cytoskeleton
The decrease in neuronal diameter in axotomised ganglia suggests that genes 
relevant to cytoskeleton are affected by axotomy and/or NT-3 treatment. The three major 
components of neuronal cytoskeleton are: (1) actin, which is particularly important in the 
structure of the growth cone; (2) microtubules, which regulate the movement of the growth 
cone; (3) intermediate filaments such as neurofilament proteins. A common feature of both 
development and regeneration after axotomy is the up-regulation of actin and tubulin, a 
component of microtubules, and the down-regulation of neurofilament (Wong and Oblinger, 
1990b; Moskowitz and Oblinger,  1995).
The increase in mRNA for cytoplasmic p-actin I observed after axotomy is 
consistent with the increase of p-actin protein expression in DRG neurons reported 
following sciatic nerve crush and transection (Lund et al., 2002). p-actin is involved in the 
transport of cytoplasmic vesicles and is a limiting factor in the speed of axonal outgrowth 
during regeneration (Lund et al., 2002). The rapid induction of the mRNA expression of p- 
actin under the stimulation by NGF in PC  12 cells in vitro has been considered one of the 
general early gene responses to growth or differentiation factors (Greenberg et al.,  1985; 
Chao,  1992). My data showed that the expression of p-actin was further up-regulated by 
systemic NT-3 administration, suggesting that exogenous NT-3 may stimulate axon growth 
after axotomy (Young et al., 2001). In some studies, p-actin, proposed to be expressed 
consistently, is often used as a housekeeping gene to normalise mRNA expression of a
204gene examined by RT-PCR (Yun et al., 2002; Gnoatto et al., 2003). On the basis of my
findings, it is not appropriate to use P-actin as an internal control for the mRNA
quantification, especially when it is used in studies of the development and regeneration of 
the nervous system.
Microtubule-associated protein  IB (MAPIB) is expressed at high levels during 
development of the nervous system and is localised primarily in neurons and growing 
axons; on the other hand, MAPI A is not expressed during embryogenesis (Fawcett et al., 
1994). Both MAPI A and IB are expressed in adult DRG neurons and their axons, and are 
involved in the dynamics of microtubules in intact and regenerating axons (Fawcett et al., 
1994; Ma et al.,  1999). In the present work, MAP IB mRNA was increased after axotomy 
with a nearly complete counteraction by NT-3 treatment; MAPI A was down-regulated 
following axotomy, but was not affected by NT-3 treatment. The changes in mRNA 
encoding MAPs in axotomised DRG I found seem to recapitulate a developmental pattern, 
and this suggestion is supported by a previous report that the expression of MAP IB mRNA 
and protein are expressed in Schwann cells during both development and axonal 
regeneration (Ma et al.,  1999). Taken together, the findings regarding p-actin and MAPs 
show that the injured DRG neurons try to regenerate axons, even with a tight ligation of the 
proximal nerve stump. The NT-3-regulated changes in their mRNA expression may induce 
the reorganization of the cytoskeleton to alter the speed of axonal growth and axonal 
transport velocity in regenerating neurons (see Young et al., 2001).
My results show a down-regulation of neurofilament protein light subunit (NF-L) 
and neurofilament protein heavy subunit (NF-H) mRNA expression after axotomy, which 
is compatible with previous observations after sciatic nerve injury (Wong and Oblinger,
2051987,  1990a). Systemic NT-3 treatment provided no significant effects on the mRNA 
expression of these two neurofilaments. The down-regulation of neurofilaments is a general 
trend during both development and regeneration (Muma et al., 1990; Troy et al.,  1990; 
Wong and Oblinger,  1990b). As neurofilament content is a major determinant of axonal 
calibre and perikaryal diameter (Friede and Samorajski,  1970; Lawson and Waddell, 1991), 
the decrease in NF-L and NF-H expression probably underlies the decreases in perikaryal 
volume of DRG neurons seen 2 and 4 weeks after axotomy in my study.
The regulation of MAPs and neurofilaments by axotomy supports the notion that 
developmental processes are to some degree being recruited after peripheral nerve injury. 
Another protein required during axonal development, GAP-43, was up-regulated in DRG 
after axotomy in this study, in keeping with results by others (Hoffman and Cleveland, 
1988; Meiri etal.,  1988).
The mRNA levels of glial fibrillary acidic protein (GFAP) alpha, which is a major 
glial cytoskeletal protein (intermediate filament), were increased by 3.5-fold after axotomy 
in the present study and were consistent with the activation and proliferation of satellite 
cells in PNS reported following injury (Woodham et al.,  1989; Fenzi et al., 2001).  In CNS, 
astrocytes are also activated by motor axon injury, resulting in molecular changes including 
increased levels of GFAP (see Aldskogius and Kozlova,  1998). Although the functional 
implications of the glial cell responses in injured ganglia are unclear, these findings support 
the possibility that there could be some intercellular neuron-glia signals playing a role in 
satellite cells in response to peripheral nerve injury. The activated satellite cells may 
modulate the attempts of injured DRG neurons to survive and achieve functional repair. 
Systemic NT-3 treatment in my study further up-regulated GFAP mRNA, indicating that
206NT-3 may stimulate glial cell proliferation in axotomised ganglia. This possibility is 
supported by the presence of a number of trkC-expressing satellite cells in unoperated and 
injured DRG using in situ hybridisation.
4.4.2.5  Pain-related genes
Neuropathic pain is induced by injury to the nervous system. To understand the 
complex molecular pathophysiology of neuropathic pain following nerve trauma, previous 
studies have focused on a few known genes and signalling pathways in DRG neurons. 
Recently, cDNA microarrays were used to identify additional genes which may contribute 
to the generation and maintenance of neuropathic pain after sciatic nerve transection or 
spinal nerve ligation (Wang et al., 2002a; Xiao et al., 2002).
In my study, galanin and NPY are up-regulated after sciatic nerve transection; in 
contrast, somatostatin (SST), calcitonin gene-related peptide (CGRP), substance P, RET 
ligand 2 (RETL2),'preprotachykinin (PPT) and nicotinic acetylcholine receptor mRNAs are 
down-regulated.
NPY, acting as a transmitter within the nervous system through G-protein-coupled 
receptors, showed a marked 55-fold increase after sciatic nerve transection, which is 
consistent with previous reports (Wakisaka et al.,  1991; Sterne et al.,  1998). Systemic NT-3 
treatment for 2 weeks did not affect the mRNA expression of NPY, a result that contradicts 
the finding that exogenous NT- 3 delivered by grafting impregnated fibronectin for 30 days 
attenuated the up-regulation of NPY (Sterne et al., 1998). However, the different methods 
of delivery, dose and duration of exposure to NT-3 used in the studies may results in 
activation of different pathways or other trk receptors (Watson et al., 2001)(see 1.2.12).
207Increased amounts of the transcripts for NPY in injured ganglia may produce an anti­
nociceptive effect (Hua et al.,  1991; Bannon et al., 2000)
Galanin, a neuropeptide acting via G-protein-coupled receptors and ion channels, 
was up-regulated by 26-fold in axotomised DRG; similar results were reported before using 
immunohistochemistry, in situ hybridisation and microarray (Villar et al.,  1989; Xiao et al., 
2002). NT-3 administration made no significant effects on the mRNA expression of this 
neuropeptide. Galanin is involved in the normal growth and development of the nervous 
system (Ubink et al., 2003); increased transcripts for galanin may also produce an anti­
nociceptive effect in the injured spinal cord (Bannon et al., 2000).
Somatostatin (SST) mRNA expression was reduced by 1.5-fold following axotomy 
and NT-3 treatment had no effect on this. SST, a non-opioid neuropeptide, is transiently 
expressed in most rat DRG neurons during the early development, but its mRNA is only 
detected again from postnatal week 2 in small DRG neurons. It is involved in pain 
transmission as an inhibitory neuromodulator (Maubert et al.,  1994). In DRG neurons, SST 
was shown to be colocalised with RET, which is a functional receptor component of glial- 
derived neurotrophic factor (GDNF) (Baloh et al., 2000). The down-regulation of SST after 
axotomy could be rescued by GDNF administration to provide anti-inflammatory and anti- 
hyperalgesic effects (Bennett et al.,  1998; Kashiba and Senba, 2000).
I found that RETL2 mRNA was decreased by 1.8-fold after axotomy, and that this 
was not affected by NT-3 administration. RETL2 interacts with the extracellular domain of 
RET, is a key component of the RET signalling pathway for GDNF and can only bind 
GDNF with high affinity in the presence of RET (Sanicola et al.,  1997). Decreased 
expression of RETL2 in axotomised DRG may result in decreased GDNF signalling and be
208related to the generation of neuropathic pain and neuronal death (Leclere et al., 1998). 
GDNF administration can reverse down-regulation of GDNF receptor components after 
axotomy (Bennett et al.,  1998, 2000).
A  1.8-fold decrease in CGRPmRNA was shown by microarrays at 2 weeks after 
sciatic nerve transection; no effect of NT-3 on this decrease was observed which is in 
agreement with other work (Steme et al.,  1998). CGRP is a neuropeptide that is synthesised 
in approximately 50% of the small- and medium-size DRG neurons, especially trkA- 
expressing neurons (Averill et al., 1995), and is transported along the axon to the periphery 
and dorsal horn to modulate nociception (Ju et al.,  1987; McNeill et al.,  1988; Heppelmann 
and Pawlak,  1997). Depressed levels of CGRP mRNA were reported to last for up to 45 
days after axotomy (Dumoulin et al.,  1991; Sterne et al.,  1998); it was suggested that this 
be due to decreased target-derived NGF (Verge et al.,  1995; Shadiack et al., 2001); and 
NGF administration increases CGRP expression (McMahon et al.,  1995).
My study showed that SP mRNA expression decreased by 1.6-fold after axotomy, 
as reported in a previous study at the same time point (Ma and Bisby,  1998); this decrease 
was also not affected by systemic NT-3, in keeping with previous observations. Similar to 
CGRP, SP is also released from both the peripheral and central terminals of nociceptive 
afferents into the periphery and dorsal hom to modulate nociception (Malmberg and Yaksh, 
1992). The decline was probably due to decreased retrograde transport of NGF, and 
exogenous NGF was reported to up-regulate SP expression in DRG neurons in vitro 
(Lindsay and Harmar,  1989). Removal of NGF with antisera reduces SP and CGRP levels 
in vivo (Shadiack et al., 2001).
209In my study, nicotinic acetylcholine receptor subunits were down-regulated 
following sciatic nerve transection, but were not further regulated by NT-3; in contrast, 
acetylcholine muscarinic receptor mRNA remained at ‘unoperated’ level after axotomy, 
and was up-regulated by NT-3 treatment. Normal rat DRG neurons are able to synthesise 
acetylcholine (Ach) and also express cholinergic receptors of both muscarinic and nicotinic 
type (Tata et al., 2000; Genzen et al., 2001). Muscarinic receptor subtypes are preferentially 
expressed in small-medium sensory neurons and satellite cells in DRG, indicating their 
association with nociception and possible cross-talk between neurons and satellite cells 
(Tata et al., 2000). Nicotinic receptors are also expressed by a majority of large DRG 
neurons and some small neurons (Genzen et al., 2001), both at cell soma and nerve 
terminals, to modulate somatic sensory transmission including nociception (Damaj et al., 
1998). The regulation of these two types of Ach receptors shown here suggests a possible 
mechanism of neuropathic pain which may be regulated by exogenous NT-3.
In the current study, P2X2 receptor mRNA was increased by 1.5-fold in DRG 
following sciatic nerve transection. P2X2 receptor, which is a ligand-gated ion channel 
mainly expressed in small neurons of DRG, is known to mediate the action of extracellular 
ATP and plays a role, together with other P2X receptors, in nociceptive signalling (Ding et 
al., 2000).  Its increase in injured DRG suggests extracellular ATP and this receptor could 
also be involved in the chronic neuropathic pain after nerve injury. NT-3 administration did 
not affect mRNA expression of this receptor.
In addition to muscarinic receptor, somatostatin receptor 4 (SSTR4) and calcitonin 
receptor-like receptor (CRLR) were the only two transcripts which were up-regulated by 
NT-3 administration in this category. SSTR4 is a subtype of the receptors for somatostatin,
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in rat, suggesting a role during neurogenesis (Maubert et al., 1994). After brain injury, 
SSTR4 is up-regulated in glial cells and down-regulated in neurons (Schreff et al., 2000). 
Taken together the depressed SST and elevated SSTR4 levels indicate that somatostatin- 
induced signal transduction may play an important role in NT-3-treated DRG neurons to 
modulate pain transduction.
Calcitonin receptor-like receptor (CRLR), coupled with a receptor component 
protein (RCP) and a receptor activity-modifying protein (RAMP1), functions as a 
nociceptive CGRP receptor (Juaneda et al., 2000). CRLR has also been found to be present 
in bone marrow-derived macrophages, and interleukin-6 synthesis was stimulated by 
CGRP in these cells (Fernandez et al., 2001). Whether CRLR is expressed in DRG neurons 
or satellite cells or other cell type is unclear. The up-regulation of CRLR mRNA by NT-3 
indicates either that systemic NT-3 administration may modulate nociception after axotomy, 
whist CGRP is still at a lower level than normal, or that it acts on macrophages in injured 
DRG to control cytokine secretion.
The complex regulation of pain-related genes after sciatic nerve transection, as 
discussed in the paragraphs above, shows that some of them may stimulate neuropathic 
pain whilst others may inhibit it. However, neuropathic pain mechanisms involve adaptive 
reactions in the periphery and also in the dorsal horn of spinal cord. As SP and CGRP 
expression are known to be regulated by NGF (Lindsay and Harmar, 1989), and NT-3 can 
activate trkA, NT-3 administration might be expected to up-regulate CGRP expression (Ip 
et al.,  1993; Farinas et al.,  1998). My results demonstrated that systemic NT-3 
administration for 2 weeks did not significantly affect either CGRP or SP transcripts,
211showing that NT-3 at this concentration does not produce similar effects on nociception as 
NGF, acting via the trkA receptor.
4.4.2.6  Proteins related to synaptic transmission
The expression of mRNA for the glutamate/aspartate transporter was increased by 
1.9-fold following axotomy; but expression of mRNA for the glutamate receptor subunit 5- 
2 (GIuR5-2) was decreased by 2.1-fold. NT-3 treatment up-regulated the mRNA encoding 
for the AMPA-selective glutamate receptor 1.9-fold in ipsilateral DRGs.
Glutamate is a major excitatory neurotransmitter in CNS, and can activate both ion- 
channel-forming (ionotropic) and G-protein-coupled (metabotropic) glutamate receptors 
(GluRs) to initiate its biological effects. The expression of these receptors at both protein 
and mRNA levels in DRG was investigated by Sato et al. (1993). Glutamate transporters, 
which are responsible for concentrating glutamate in synaptic vesicles and for controlling 
its concentration m the extracellular space after its release into the synaptic cleft, are 
expressed in large, CGRP-negative DRG neurons with transporter-containing nerve 
terminals in the spinal cord (Oliveira et al., 2003). The increased mRNA transcripts for 
glutamate transporter in injured DRG presented in this study imply that the release of 
glutamate from central terminals of glutamatergic DRG neurons may be involved in the 
adaptation of sensory processing after nerve injury. Although the distribution of glutamate 
transporter in large DRG neurons implies its colocalisation with trkC, NT-3 did not 
regulate the expression of this transporter.
In the present study the ligand-gated receptor GluR5 is down-regulated in the 
injured DRGs. GluR5 has been found to be expressed specifically in the presynaptic
212terminals of C-fibres, especially in neurons that innervate the inner layer of lamina II in the 
dorsal spinal cord, and to have an inhibitory role in the regulation of neurotransmission in 
presynaptic cells (Hwang et al., 2001; Kerchner et al., 2001). It may be the case that the 
decreased mRNA expression of this receptor in my study could correlate with the 
disappearance of presynaptic inhibition of neurotransmission from primary sensory neurons, 
resulting in the increased activity of these neurons projecting to the dorsal hom of the 
spinal cord.
AMPA receptor is an inotropic receptor of glutamate; its mRNA and protein 
expression in DRG have been described in adult rat (Sato et al.,  1993). The increased levels 
of AMPA have been linked to the long-term functional impairment after spinal cord injury 
(Grossman et al.,  1999); however its function in normal and injured DRG is not clear. The 
NT-3-stimulated expression of AMPA shown here may alter the response of DRG neurons 
to glutamate if the up-regulation is in neurons. However, satellite cells have also been 
reported to express AMPA receptors (Tachibana et al.,  1994).
My microarray data also showed that gamma-aminobutyric acid (GABA)-A 
receptor a5 subunit mRNA was up-regulated after axotomy, whereas GABA-B was down- 
regulated. Its receptors are divided into two classes, ionotropic (GABA-A) and 
metabotropic (GABA-B) receptors, both of which are expressed in DRG neurons (Maddox 
et al., 2004); GABA-B predominates within the dorsal horn of the spinal cord (Towers et 
al., 2000). Activation of presynaptic GABA-B receptor decreases the release of 
neuropeptides and excitatory amino acids; the activation of postsynaptic GABA-B 
receptors located on ascending second-order neurons may inhibit the response to noxious 
stimuli (see Towers et al., 2000). The combined effects of the injury-induced regulation of
213these two receptors may lead to the change of presynaptic inhibition at the central terminal 
of the injured primary afferent and modulate the activation of dorsal horn neurons during 
nociception. The mRNA expression of GABA was not affected by systemic NT-3 
administration.
Transferrin mRNA increased by  1.7-fold following axotomy in this study; NT-3 
administration had no influence on its mRNA expression. Transferrin is the iron- 
transporting glycoprotein found in plasma; it can be detected as early as E l8 in rat DRG 
neurons (Dion et al.,  1988). The two main sources of transferrin in adult brain are 
oligodendrocytes and the choroid plexuses; CNS neurons also express transferrin mRNA in 
vitro; transferrin would bind with any extracellular iron to decrease oxidative injury to 
myelin (see Wagner et al., 2003). Increased synthesis of transferrin was seen in brain 
following a variety of brain injury (see Wagner et al., 2003).
Transferrin receptor mRNA in DRG was decreased after axotomy, and it was not 
regulated by NT-3 administration. Iron is required for many metabolic processes in the 
nervous system, including the formation of myelin, and the uptake, packaging and 
degradation of neurotransmitters (Beard et al.,  1993). Iron-bound transferrin is taken up as 
an endosome into the cells expressing transferrin receptors. As damage to tissues and cells 
may result in release of iron, the decreased transcripts of transferrin receptor shown in the 
present study may provide some degree of neuroprotection.
4.4.2.7  Secreted and extracellular molecules
The transmission of nerve impulses across synapses is accomplished through the 
release of neurotransmitters from synaptic vesicles during calcium-regulated exocytosis.
214these two receptors may lead to the change of presynaptic inhibition at the central terminal 
of the injured primary afferent and modulate the activation of dorsal horn neurons during 
nociception. The mRNA expression of GABA was not affected by systemic NT-3 
administration.
Transferrin mRNA increased by  1.7-fold following axotomy in this study; NT-3 
administration had no influence on its mRNA expression. Transferrin is the iron- 
transporting glycoprotein found in plasma; it can be detected as early as E l8 in rat DRG 
neurons (Dion et al.,  1988). The two main sources of transferrin in adult brain are 
oligodendrocytes and the choroid plexuses; CNS neurons also express transferrin mRNA in 
vitro; transferrin would bind with any extracellular iron to decrease oxidative injury to 
myelin (see Wagner et al., 2003). Increased synthesis of transferrin was seen in brain 
following a variety of brain injury (see Wagner et al., 2003).
Transferrin receptor mRNA in DRG was decreased after axotomy, and it was not 
regulated by NT:3 administration. Iron is required for many metabolic processes in the 
nervous system, including the formation of myelin, and the uptake, packaging and 
degradation of neurotransmitters (Beard et al.,  1993). Iron-bound transferrin is taken up as 
an endosome into the cells expressing transferrin receptors. As damage to tissues and cells 
may result in release of iron, the decreased transcripts of transferrin receptor shown in the 
present study may provide some degree of neuroprotection.
4.4.2.7Secreted and extracellular molecules
The transmission of nerve impulses across synapses is accomplished through the 
release of neurotransmitters from synaptic vesicles during calcium-regulated exocytosis.
214(Bark et al.,  1995; Boschert et al.,  1996). My study showed increased mRNA of synaptic 
vesicle protein (SV2), Synaptotagmin IV and syntaxin B, and a decreased abundance of 
SNAP25A at 2 weeks after axotomy. Systemic NT-3 administration for 2 weeks in 
axotomised DRG up-regulated syntaxin 4, and down-regulated SNAP-25A and 25B, ras- 
related mRNA (rab3), synaptojanin and synapsin la.
Rab2, 25 kDa synaptosomal associated protein (SNAP-25A), SNAP-25B, synapsin 
2a and 2b, ras-related rab3, and neurexin-lp are the main components of synaptic secretory 
apparatus, and participate in vesicle docking, fusion, neurotransmitter release and 
neuroplasticity, such as neurite outgrowth and synaptogenesis (Grabs et al.,  1996; Porton et 
al.,  1999; Brunger, 2000).
Down-regulation of any components of synaptic secretory apparatus may hinder the 
functions relevant to neurotransmitters. For example, SNAP-25 has two isoforms: SNAP- 
25A, which is the major isoform expressed during embryogenesis; SNAP-25B, which 
increases during synaptogenesis in the post-natal period and predominates in the adult brain 
(Boschert et al.,  1996). Decreased expression of SNAP-25A in injured ganglia may to some 
degree impair the release of neurotransmitter from central terminals of DRG neurons. NT-3 
treatment further down-regulated the expression of mRNAs for SNAP-25 A and SNAP-25B.
Synaptotagmin is a family of vesicle membrane proteins, involved in Ca2+- 
regulated exocytosis in neurons (Mikoshiba et al.,  1999). Increased synaptotagmin IV in 
this study may decrease evoked synaptic transmission by decreasing efficiency at coupling 
Ca2+ to secretion (Littleton et al.,  1999).
Two more synaptic vesicle-associated proteins were down-regulated by NT-3 
administration: (1) Synaptojanin, which is a polyphosphoinositide phosphatase, playing
215roles in clathrin-mediated synaptic vesicle endocytosis in CNS (Stenmark, 2000). (2) 
Synapsins, a family of phosphoproteins mainly expressed in neurons in CNS, which plays 
roles in controlling the number of vesicles available for release at the nerve terminus and 
neurite elongation and synapse formation during development (Ferreira and Rapoport, 
2002).
Syntaxins are synaptic proteins implicated in docking of synaptic vesicles with the 
presynaptic cellular membrane (Rizo and Sudhof, 2002). Syntaxin 4 was up-regulated by 
NT-3 treatment in my study.
My data are consistent with the loss of synaptic terminals and reinforce the idea that 
nerve injury causes the down-regulation of genes associated with neurotransmission. The 
reduced levels of some synaptic vesicle-associated proteins after NT-3 treatment indicate 
that the docking and fusion of synaptic vesicles may be attenuated which may result in 
reduced signalling from injured neurons and act as a protective mechanism when axonal 
regeneration was impeded by permanent transection, and may represent increased resources 
going to axonal regeneration and less resources to synaptic transmission.
4.4.2.8  Others
A few genes not categorised in the above groups were also regulated by axotomy 
with or without NT-3 treatment.
In this study, neuronatin-alpha was increased by 1.9-fold following axotomy and 
was unaffected by NT-3 treatment. Neuronatin is a protein expressed primarily in the 
central and peripheral nervous systems with a proposed function in neuronal maturation 
and maintenance. In the fetus and neonatal stages, it is expressed at a higher level than in
216adulthood and is down-regulated in PC 12 cells upon NGF-induced differentiation 
(Wijnholds et al.,  1995; Joseph et al.,  1996). An in vitro study demonstrated that neuronatin 
protected differentiated PC 12 cells against some toxic insults (Zheng et al., 2002). The 
increased transcripts of this gene suggest its implication on neuroprotection or regeneration 
after axotomy.
Sciatic transection also increased transcripts of tissue plasminogen activator (t-PA) 
mRNA, which was completely counteracted by systemic NT-3 treatment. The induction of 
this gene by sciatic nerve axotomy has been shown in another in vivo study (Siconolfi and 
Seeds, 2001). tPA, a secreted serine protease, is able to cleave plasminogen to produce the 
active protease plasmin (Vassalli et al.,  1991), and to play important roles in tissue 
remodelling and dissolving the extracellular matrix to assist axonal regeneration (Siconolfi 
and Seeds, 2001). The mRNA for t-PA was up-regulated following axotomy, although 
axonal regeneration could not take place because of nerve transection and ligation. The 
prevention of up-regulation by NT-3 treatment implies that the involvement of NT-3- 
induced signalling in t-PA regulation and NT-3 may prevent the optimal environment for 
axonal regrowth to be established.
Neural adhesion molecule F3 mRNA was up-regulated in DRG after sciatic nerve 
transection, but was not further regulated by NT-3 treatment. Neural adhesion molecule F3 
is an axonal adhesion molecule, which mediates bidirectional exchange of information 
between neurons and glial cells and stimulates Schwann cell migration during development 
and regeneration by binding to its receptors on Schwann cells (Xiao et al.,  1997; 
Thomaidou et al., 2001). The change shown on the arrays is consistent with increased
217neurite growth after axotomy regardless of the ligation of proximal stump of transected 
nerve.
Cortexin is expressed in adult DRG, and its levels do not change after axotomy, but 
are 2-fold up-regulated by NT-3 administration. Cortexin was shown to stimulate neurite 
growth in E l0-11  chick DRG culture (Chalisova and Khavinson, 2000). These results 
further suggest that NT-3 may stimulate axonal regeneration.
In this study, heat shock protein 27 (HSP27) is up-regulated in axotomised DRG, 
but is unaffected by NT-3 administration. This is consistent with previous reports that 
HSP27, a chaperone protein thought to protect cellular macromolecules from damage, was 
up-regulated in DRG neurons within 48 hours after sciatic transection at mid-thigh level 
(Costigan et al.,  1998; Lewis et al.,  1999). HSP27 was shown to protect neonatal DRG 
neurons from axotomy- or NGF withdrawal-induced apoptosis (Lewis et al.,  1999; 
Wagstaff et al.,  1999). My results of increased HSP27 mRNA expression for more than 2 
weeks, when neurons were dying at a steady rate, suggest that it may provide some 
protective effects and explain the survival of most DRG neurons after axotomy. NT-3 
treatment provided no further effects on HSP27 mRNA expression, further indicating a 
lack of neuroprotective effects.
4.4.3  Summary
The results obtained show that sciatic nerve transection altered the expression of 88 
genes and 30 ESTs in the DRG at 2 weeks following injury. Systemic NT-3 administration 
for 2 weeks after axotomy up- and down-regulated 33 genes and  11 ESTs. The changes in
218the expression of these genes give some general insights into the events that occur at 2 
weeks following peripheral injury.
In vehicle-treated axotomised DRG, BMP and JAK signalling pathways are 
activated. The up-regulated growth-associated proteins, transferrin, neuronatin and HSP27, 
and decreased transferrin receptor mRNA may provide neuroprotective functions. The 
changes of cytoskeleton proteins and up-regulated neural adhesion molecule F3 may reflect 
the continuing attempts of neurites to grow despite the presence of a tightly ligated 
transected stump. Neurotransmission from central terminals of DRG neurons tends to be 
impaired. The increased levels of MCP-1, NGF, CRBP, IL-18 could be relevant to the 
neuronal lineage commitment of progenitor cells, which are a potential source of replacing 
cells and neurons (Corti et al., 2002).
Systemic NT-3 treatment is likely to act through PI-3 kinase and BMP pathways. 
The proposed complex interactions between these signal transduction pathways may be 
involved in the pathological changes in DRG neurons after axotomy, and any neuronal 
replacement mechanism stimulated by NT-3 administration. By up-regulating p-actin and 
cortexin, NT-3 appears to be capable of further stimulating axonal regeneration after 
axotomy. Satellite cells in injured ganglia appear to be activated by exogenous NT-3, 
resulting in increased levels of mRNA for GFAP.
219CHAPTER 5: CONCIJTSIQIV
220This study used an animal model to investigate the morphological and molecular 
events following peripheral nerve injury, and first time to examine the effects of systemic 
NT-3 administration on neuron number, neuronal apoptosis, expression of neurotrophins, 
neurotrophin receptors and neurofilaments, and the gene expression profile in axotomised 
DRG. NT-3 was suggested to support survival of embryonic sensory neurons via trkA or 
trkB signalling rather than through its preferred receptor trkC; therefore NT-3 treatment 
may produce broader effects than any other single neurotrophin.
My results show that a shift to the left in neuronal size distribution (atrophy) with 
no significant neuronal loss is evident at 2 weeks after mid-thigh transection and ligation of 
sciatic nerve, when 0.057% of DRG neurons were observed to be apoptotic and were also 
activated caspase-3-immunoreactive; at 4 weeks following axotomy, when the incidence of 
neuronal apoptosis was around 0.04-0.059%, around 16% DRG neurons appeared to be lost 
in the ipsilateral ganglia. Furthermore, some small-sized (mean diameter: 20pm) nestin- 
immunoreactive neuron-like cells appeared in the injured ganglia at 4 weeks, which were 
not seen in any sections from normal or contralateral ganglia, showing the appearance of a 
marker for neuronal or glial progenitors.
Systemic administration of NT-3 for 4 weeks via subcutaneous micro-osmotic 
pump at the dose of 1.25 and 5 mg/4 weeks is effective in preserving neuron numbers after 
axotomy, but it does not prevent or delay neuronal apoptosis; the incidence of nestin- 
expressing cells in injured DRG was further increased to 3.89 % by systemic NT-3 
treatment for 4 weeks. I suggest that the preservation of neuronal numbers takes place 
through stimulated neurogenesis or neuronal maturation from either the precursor cells in 
adult DRG or bone marrow, and the nestin-immunoreactive cells are candidates for the
221replaced neurons. Neuronal precursors have been obtained from adult mouse DRG by 
Namaka et al. (2001) and found to be capable of differentiating into neurons in vitro when 
exposed to neurotrophic factors, including NT-3. However, our previous study, showing 
that BrdU labelling of few proliferating cells in DRG after sciatic nerve crush, in which 
model neuronal replacement was also proposed, suggested that cell proliferation was 
insufficient to explain the neuronal replacement. New neuron formation from neuronal 
precursor cells which may undertake the pathway towards final maturation/ differentiation 
when stimulated by NT-3 is preferred.
Another finding by real-time quantitative PCR and in situ hybridisation is that the 
mRNA expression of neurotrophins in DRG neurons and satellite cells increases in 
response to peripheral axotomy, suggesting that the up-regulation of endogenous 
neurotrophins may at least in part replace the interrupted retrograde transport of periphery- 
synthesised neurotrophins after sciatic nerve transection. The existence of different 
intracellular signalling pathways for neurotrophins activated by axonal and perikaryal trk 
receptors may affect the compensatory functions of axotomy-stimulated neurotrophin 
synthesis in DRG cells and the effects of exogenous neurotrophins applied locally, 
intrathecally or systemiclly. The decreased expression of mRNAs for trkA and trkB, and 
the increased expression of trkC mRNA in neurons of all sizes in axotomised ganglia 
suggest a higher overall responsiveness of DRG neurons to NT-3 after axotomy, in contrast 
to a decreased responsiveness to NGF and BDNF, and could have synergistic effects on 
regeneration when administered with other neurotrophins. Moreover, systemic NT-3 
administration is demonstrated to increase trkA and trkB responsiveness in axotomised 
neurons by up-regulating both these receptors and their ligands, at various time points.
222Although systemic NT-3 administration alone has successfully prevented axotomy-induced 
neuronal loss in the present study, combinations of neurotrophic factors, which act through 
the up-regulated receptors, may appear promising. Different neurotrophic factors might 
selectively enhance the protective or reparative mechanisms, act at different stages of the 
degenerative process or influence distinct subpopulations of DRG sensory neurons or non­
neuronal cells.
My subsequent microarray study revealed that BMP and JAK signalling pathways, 
instead of MAP kinase, PI-3 kinase and PLCy pathways for neurotrophins, are activated in 
axotomised DRG, suggesting the importance of other neurotrophic factors in post-axotomy 
adaptive reaction of DRG cells in addition to the locally synthesised neurotrophins. 
Systemic NT-3 treatment activates signal transduction through PI-3 kinase and BMP 
pathways, highlighting the involvement of these two pathways directly or indirectly in the 
effects of NT-3 treatment on neuronal replacement in DRG and regulation of the 
expression of associated genes after sciatic nerve transection. Combining the findings of 
the appearance of 1.6% small nestin-immunoreactive neuron-like cells in the axotomised 
ganglia and the up-regulation of a few genes relevant to neuronal differentiation after 
axotomy, I suggest that a neuronal replacement mechanism is initiated 2 weeks after 
axotomy in untreated animals and that this process can be further stimulated by systemic 
NT-3 treatment, leading to the final differentiation of neurons. A more unexpected 
influence of NT-3 on genes controlling various cellular functions, including pain-related 
genes, growth factors, secreted and extracellular molecules and cytoskelton, was found in 
this study. These show that developmental processes are to some degree being recruited 
after peripheral nerve injury, and NT-3 appears to be capable of further stimulating axonal
223regeneration after nerve injury, of activating satellite cells in injured ganglia, and of 
attenuating the docking and fusion of synaptic vesicles as a protective mechanism. 
Examining a large number of genes simultaneously by microarray analysis is clearly an 
important step in elucidating their functional role and provides a good opportunity to serve 
as a baseline for evaluating the efficacy of treatments aimed at regulating the injury-related 
changes in gene expression. However, it should be considered that the other cells in 
addition to neurons, such as satellite cells, Schwann cells, fibroblasts and blood vessels, 
may also play a role in the changes of gene expression detected in this study. Further 
studies will address the functional properties of these genes, which will clarify the 
pathways involved in nerve regeneration and neuronal replacement and find effective 
therapies to ameliorate the effects of peripheral nerve injury and stimulate neurogenesis or 
inhibit neurogenesis.
It is still an open question whether there are either stem cells or any postmitotic 
cells in adult DRG which can contribute to the neuronal replacement which appears to take 
place as my results suggest in injured states after systemic NT-3 administration. Detection 
of BrdU incorporation in combination with sequential markers for progenitor cells and new 
neurons or using retroviral infection, which can only integrate into dividing cells, will help 
to understand the characteristics of these new neurons. Moreover, transplantation of green 
fluorescent protein (GFP)-expressing bone marrow into mice or rats before carrying out 
sciatic nerve transection and systemic NT-3 administration will help to confirm and 
identify the origins of these new neurons in the future.
224Appendices
225Appendix 1: Estimated numbers of neurons  and apoptotic neurons in the ipsi- and 
contralateral L4 and L5 DRGs after transection and ligation of the right sciatic nerve 
with no treatment, systemic saline administration or systemic NT-3 administration , 
using a physical disector technique and morphological criteria.
Time/treatment
/
Animal
Neurons in left 
L4/L5 ganglia
Neurons in 
right L4/L5 
ganglia
Mean R:L ratio 
in neuronal 
number (± SD)
Number of 
apoptotic 
neurons in ipsi- 
lateral L4/L5
Unoperated
3486 29062 29669 1.021 0
3534 25913 28399 1.100 0
3535 25048 25877 1.033 0
3536 22499 24354 1.082 0
4025 27394 31321 1.143 0
4119 26072 27180 1.042 0
Mean ± S.E.M. 25998 ± 904 27800± 1036 1.070 ±0.019 0
2 weeks 
/vehicle
3963 24423 26187 1.072 16
3974 27970 26142 0.935 19
3975 26802 30558 1.140 20
3976 28107 25623 0.912 7
Mean ± S.E.M. 26826 ± 853 271281 1151 1.01510.055 15.513.0
2weeks
/0.625mg NT-3
3959 30920 28240 0.913 2
3960 30462 26250 0.862 22
3961 25474 27832 1.093 28
3964 33723 28817 0.855 28
3965 26094 25309 0.967 17
Mean ± S.E.M. 29335 11556 272901653 0.938 10.044 19.414.8
4 weeks
/axotomy only
3420 34410 29035 0.843 18
3419 25994 25860 0.995 24
3142 28744 24700 0.859 10
3141 27961 26669 0.954 10
3418 27769 23709 0.854 18
Mean ± S.E.M. 289761 1431 259951912 0.898 10.030 16.012.7
4 weeks
/vehicle
3698 26266 23380 0.890 13
3703 26048 26280 1.009 23
3704 24263 24580 1.013 14
2263705
3706
25097
27934
20070
23728
0.800
0.849
3
19
Mean ± S.E.M. 25922 ±617 23608 ±1017 0.912 ±0.043 14.4 ±3.4
4 weeks
/1.25mg NT-3
3699 25019 27310 1.092 7
3700 25070 27437 1.094 15
3701 27608 25549 0.925 21
3702 28622 25552 0.893 4
3697 25617 27939 1.091 6
Mean ± S.E.M. 26387 ±731 26757 ± 504 1.019 ±0.045 10.6 ±3.2
4 weeks 
/5mg NT-3
4043 28485 29103 1.022 12
4090 29673 32221 1.086 8
4091 27824 26262 0.944 22
4092 24413 27184 1.114 10
Mean ± S.E.M. 27599 ± 1129 28693 ± 1317 1.042 ±0.038 13.0 ± 3.1
227Appendix 2: Total number of neurons measured in L4&L5 DRG.
Unoperated
3535 3536 3707
L R L R L R
Total 598 619 614 620 606 658
2 week axotomy + 
vehicle
3974 3975 3976
L R L R L R
Total 640 620 659 655 647 583
2 week axotomy + NT- 
3 (1.25mg/4 weeks)
3961 3964 3965
L R L R L R
Total 644 678 650 626 637 664
4 week axotomy + 
vehicle
3698 3703 3705
L R L R L R
Total 601 618 595 625 689 657
4 week axotomy + NT- 
3 (1.25mg/4 weeks)
3697 3699 3701
L R L R L R
Total 628 621 662 607 624 622
4 week axotomy + NT- 
3 (5mg/4 weeks)
4043 4091 4092
L R L R L R
Total 553 597 661 487 625 654
228Appendix 3: Profiles of neuronal size— Unoperated
1 2 3
Animal 3536 3707 3535
% L R L R L R
<10 0 0 0 0 0 0
10  12 0 0 0 0 0 0
12  14 0 0 0.165017 0 0.167224 0
14  16 0.325733 0.322581 0.660066 1.367781 0.167224 0
16  18 1.954397 2.419355 2.145215 2.431611 0.334448 1.615509
18  20 5.04886 4.032258 4.290429 6.382979 2.341137 1.938611
20  22 8.143322 9.032258 9.570957 8.81459 5.518395 4.038772
22  24 12.37785 11.93548 10.39604 11.39818 7.525084 6.623586
24  26 13.35505 14.51613 12.0462 11.39818 11.53846 11.14701
26  28 11.07492 11.12903 11.71617 10.94225 13.8796 12.27787
28  30 9.446254 7.903226 9.570957 7.294833 10.53512 10.17771
30  32 '  6.026059 6.451613 6.765677 5.6231 7.023411 9.208401
32  34 4.723127 3.548387 4.125413 5.015198 6.020067 6.300485
34  36 3.745928 3.064516 3.30033 4.103343 5.016722 2.261712
36  38 2.28013 5.16129 2.805281 3.951368 3.010033 3.392569
38  40 2.28013 3.709677 5.280528 5.167173 2.675585 4.523425
40  42 2.605863 3.064516 2.145215 4.863222 4.180602 5.169628
42  44 2.931596 3.870968 3.30033 2.735562 3.344482 2.584814
44  46 3.420195 3.225806 3.30033 2.12766 2.842809 3.877221
46  48 2.931596 2.258065 1.485149 2.735562 3.344482 3.231018
48  50 2.76873 1.774194 2.475248 1.519757 1.839465 3.392569
50  52 0.977199 0.645161 1.980198 0.759878 1.672241 3.71567
52  54  1 1.302932 0.645161 0.49505 0.303951 1.839465 1.77706
54  56 0.814332 0.483871 1.485149 0.303951 1.839465 1.453958
56  58 0.814332 0.483871 0.330033 0.455927 1.505017 0.646204
58  60 0.488599 0.322581 0.165017 0.151976 1.337793 0.323102
>60 0.162866 0 0 0.151976 0.501672 0.323102
No. of 
neurons 
examined
606 658 614 620 598 619
229Appendix 4: Profiles of neuronal size— 2 week axotomy + vehicle
1 2 3
Animal 3975 3976 3974
% L R L R L R
<10 0 0 0 0 0 0
10  12 0.151745 0 0 0.171527 0 0.16129
12  14 0.151745 0.763359 0.618238 0 0 0
14  16 1.669196 3.358779 0.927357 3.087479 0.3125 1.290323
16  18 2.579666 6.259542 3.554869 7.718696 2.03125 5.967742
18  20 6.980273 13.43511 5.873261 11.14923 4.375 10.80645
20  22 11.22914 14.65649 13.60124 13.37907 7.03125 13.22581
22  24 14.56753 9.312977 12.36476 8.747856 12.03125 9.516129
24  26 12.13961 8.854962 15.76507 5.317324 12.03125 9.677419
26  28 11.38088 7.022901 10.20093 8.404803 13.59375 8.387097
28  30 7.435508 5.496183 6.33694 5.831904 8.28125 7.096774
30  32 4.855842 3.053435 3.554869 4.631218 5.78125 4.83871
32  34 2.427921 5.038168 3.400309 3.945111 4.21875 5.483871
34  36 3.490137 5.648855 2.782071 5.145798 2.65625 3.548387
36  38 1.972686 4.427481 2.009274 4.459691 3.125 3.548387
38  40 2.427921 3.51145 2.318393 4.459691 2.96875 4.677419
40  42 3.490137 3.816794 2.009274 4.116638 3.75 3.387097
42  44 2.731411 1.832061 3.400309 2.915952 3.59375 2.419355
44  46 3.186646 1.984733 2.163833 2.058319 3.28125 2.096774
46  48 2.427921 0.763359 3.24575 1.543739 2.96875 1.451613
48  50 1.972686 0.305344 2.009274 1.200686 1.40625 0.806452
50  52 1.062215 0.305344 1.700155 0.857633 1.5625 0.967742
52  54 0.91047 0 1.081917 0.343053 1.25 0.322581
54  56 0.151745 0 0.463679 0 1.5625 0.322581
56  58 0.30349 0.152672 0.309119 0.171527 1.25 0
58  60 0.30349 0 0.15456 0.171527 0.46875 0
>60- 0 0 0.15456 0.171527 0.46875 0
No. of 
neurons 
examined
640 620 659 655 647 583
230Appendix 5: Profiles of neuronal size— 4 week axotomy + vehicle
1 2 3
Animal 3698 3705 3703
% L R L R L R
<10 0 0 0 0 0 0
10  12 0 0 0 0 0 0
12  14 0 0.161812 0.145138 0 0.168067 0.64
14  16 0.998336 1.294498 1.161103 2.435312 0.168067 0.48
16  18 2.66223 2.10356 2.902758 4.718417 1.344538 2.72
18  20 4.991681 5.177994 4.644412 8.371385 3.02521 6.56
20  22 8.319468 7.928803 7.692308 12.48097 7.89916 8.96
22  24 11.14809 12.78317 9.869376 8.371385 10.58824 10.08
24  26 12.31281 9.546926 12.77213 12.32877 12.26891 7.2
26  28 12.81198 9.708738 9.143687 8.371385 13.44538 8.48
28  30 9.151414 7.443366 8.272859 6.240487 7.563025 8.96
30  32 5.15807 6.472492 6.095791 6.392694 6.386555 8.48
32  34 4.492512 4.20712 5.370102 5.936073 4.369748 9.6
34  36 3.161398 5.177994 4.499274 5.631659 3.02521 4.8
36  38 1.331115 4.045307 3.918723 5.175038 3.02521 5.76
38  40 2.66223 4.692557 4.644412 2.130898 2.857143 4.96
40  42 1.663894 4.20712 3.483309 3.348554 2.352941 4.32
42  44 1.830283 3.883495 3.773585 3.348554 3.529412 2.88
44  46 4.159734 4.045307 2.75762 2.130898 4.705882 1.6
46  48 3.161398 2.588997 3.193033 1.065449 2.857143 1.76
48  50 2.995008 1.941748 1.886792 0.761035 3.02521 0.16
50  52 2.163062 0.809061 1.886792 0.304414 2.857143 1.12
52  54 1.331115 0.647249 0.725689 0.152207 1.512605 0.16
54  56 1.331115 0.323625 0.580552 0.152207 2.016807 0.16
56  58 1.164725 0.323625 0.290276 0 0.504202 0.16
58  60 0.332779 0.323625 0.145138 0.152207 0.336134 0
>60 0.665557 0.161812 0.145138 0 0.168067 0
No. of 
neurons 
examined
601 618 689 657 595 625
231Appendix 6: Profiles of neuronal size— 2 week axotomy + 0.625mg NT-3
1 2 3
Animal 3961 3965 3964
% L R L R L R
<10 0 0 0 0 0 0
10  12 0 0 0 0 0 0
12  14 0 0 0 0.215517 0.181818 0.5703422
14  16 0.310559 0.737463 0.457666 2.155172 1.636364 2.0912547
16  18 0.931677 2.507375 2.517162 2.586207 3.636364 8.7452471
18  20 2.484472 6.489676 5.949657 9.051724 9.090909 11.596958
20  22 4.503106 12.24189 8.695652 12.06897 9.818182 9.5057034
22  24 9.627329 14.45428 9.610984 10.34483 12.18182 10.076045
24  26 14.59627 11.35693 9.839817 9.913793 13.09091 8.7452471
26  28 11.02484 7.522124 10.29748 7.112069 8 7.2243346
28  30 10.71429 5.752212 6.864989 7.758621 8 5.1330798
30  32 6.832298 3.244838 6.17849 5.603448 4.181818 4.9429657
32  34 4.192547 3.982301 5.491991 5.172414 2.545455 4.3726235
34  36 3.416149 2.359882 5.949657 4.310345 3.272727 5.5133079
36  38 1.708075 4.572271 4.576659 5.818966 2.909091 4.5627376
38  40 1.863354 3.834808 3.203661 3.663793 2.909091 4.3726235
40  42 3.726708 4.129794 5.034325 5.172414 4 2.6615969
42  44 3.416149 4.719764 3.203661 3.232759 2.545455 3.9923954
44  46 2.018634 3.687316 2.28833 3.448276 4.545455 1.7110266
46  48 2.950311 2.507375 3.661327 1.077586 1.818182 1.3307984
48  50 2.950311 2.212389 2.059497 0.431034 2.363636 0.9505703
50  52  1 3.416149 1.327434 1.372998 0.215517 1.272727 0.7604562
52  54 3.26087 1.917404 1.372998 0.431034 0.727273 0.3802281
54  56 2.484472 0.294985 0.686499 0 0.181818 0.3802281
56  58 1.552795 0 0.457666 0 0.727273 0.3802281
58  60 1.242236 0 0.228833 0 0 0
>60 0.776398 0.147493 0 0.215517 0.363636 0
No. of 
neurons 
examined
644 678 650 626 637 664
232Appendix 7: Profiles of neuronal size— 4 week axotomy + 1.25mg NT-3
1 2 3
Animal 3697 3699 3701
% L R L R L R
<10 0 0 0 0 0 0
10  12 0 0 0.151057 0 0 0
12  14 0.477707 0.575816 0.151057 0.329489 0.320513 0.643086
14  16 1.11465 1.535509 1.057402 1.482702 0.160256 2.250803
16  18 2.866242 3.262956 2.114804 4.283361 1.121795 3.054662
18  20 7.324841 6.333973 3.172205 7.413509 3.365385 7.71704
20  22 9.076433 11.70825 5.287009 8.566722 7.051282 13.66559
22  24 9.872611 14.39539 9.063444 11.69687 9.455128 13.82636
24  26 10.03185 8.253359 11.93353 10.54366 13.30128 8.199356
26  28 6.369427 9.213052 12.68882 7.248764 10.89744 9.163987
28  30 7.802548 8.06142 11.48036 7.413509 9.294872 4.662379
30  32 5.573248 3.838772 4.380665 7.248764 4.967949 5.948553
32  34 5.095541 3.838772 4.07855 6.095552 3.044872 4.662379
34  36 4.936306 3.262956 2.265861 5.107084 2.403846 4.662379
36  38 5.254777 3.454894 2.719033 3.459638 2.403846 4.823151
38  40 6.369427 3.646833 2.567976 6.425041 3.365385 4.823151
40  42 5.095541 4.03071 3.625378 2.635914 3.205128 3.376205
42  44 3.343949 3.454894^ 2.567976 3.789127 3.205128 2.411575
44  46 5.573248 4.606526 3.776435 1.812191 5.288462 1.286173
46  48 1.910828 2.495202 3.927492 1.647446 4.326923 1.286173
48  50 1.11465 2.111324 2.719033 0.823723 3.846154 1.607717
50  52 0.318471 0.767754 2.870091 0.494234 3.205128 1.286173
52  54 0.318471 0.383877 2.719033 0.494234 2.724359 0.482315
54  56 0.159236 0.191939 2.265861 0.494234 1.602564 0.1607717
56  58 0 0.191939 1.057402 0.164745 0.801282 0
58  60 0 0.383877 0.906344 0.329489 0.160256 0
>60 0 0 0.453172 0 0.480769 0
No. of 
neurons 
examined
628 621 662 607 624 622
233Appendix 8: Profiles of neuronal size— axotomy + 5mg NT-3
1 2 3
Animal 4043 4092 4091
% L R L R L R
<10 0 0 0 0.152905 0 0
10  12 0 0 0 0 0 0.205339
12  14 0.329489 0.167504 0.16 0.458716 0 0.616016
14  16 1.482702 1.005025 0.48 1.834862 0.453858 1.848049
16  18 4.283361 2.680067 3.68 7.492355 1.966717 6.570842
18  20 7.413509 6.030151 7.2 13.45566 4.689864 8.62423
20  22 8.566722 9.21273 11.84 14.52599 8.774584 10.47228
22  24 11.69687 12.0603 12.16 11.6208 13.01059 9.445585
24  26 10.54366 11.22278 14.88 8.103976 14.37216 9.856263
26  28 7.248764 9.380235 10.56 8.409786 10.28744 8.829569
28  30 7.413509 7.705193 8.48 7.186544 5.295008 6.365503
30  32 7.248764 6.197655 4.64 5.045872 5.748865 5.544148
32  34 6.095552 4.187605 2.88 2.905199 4.08472 4.312115
34  36 5.107084 4.355109 2.08 3.669725 4.08472 4.928131
36  38 3.459638 3.852596 3.36 4.740061 3.025719 5.954825
38  40 6.425041 2.680067 3.68 2.599388 4.84115 5.13347
40  42 2.635914 3.852596 3.52 2.752294 3.933434 2.258727
42  44 3.789127 3.685092 2.72 2.293578 2.723147 2.874743
44  46 1.812191 3.18258 2.72 1.834862 2.723147 1.64271
46  48 1.647446 4.187605 1.44 0.458716 3.782148 1.437372
48  50 0.823723 1.842546 1.76 0.152905 2.118003 1.232033
50  52 0.494234 1.172529 0.16 0.152905 1.664145 1.232033
52  54 0.494234 0.502513 0.48 0 1.059002 0.410678
54  56 0.494234 0.335008 0.64 0 0.75643 0
56  58 0.164745 0.335008 0.16 0.152905 0.302572 0
58  60 0.329489 0.167504 0.16 0 0.151286 0.205339
>60 0 0 0.16 0 0.151286 0
No. of 
neurons 
examined
553 597 661 587 625 654
234Appendix 9: Percentage of immunoreactive neurons in the ipsi- and contralateral L4
and L5 DRGs after transection and ligation of the right sciatic nerve.
Time/treatment
/
Animal
% of nestin-IR neurons in % of nestin-IR neurons in
ipsilateral L4/L5 ganglia contralateral L4/L5 ganglia
Unoperated
3535 0 0
3536 0 0
4025 0 0
4119 0 0
Mean ± S.E.M. 0 0
4 weeks
/axotomy only 
4011 1.64 0
4012 1.5 0
4098 0.98 0
4099 2.27 0
Mean ± S.E.M. 1.60 ±0.46 0
4 weeks
/5mg NT-3 
4043 3.44 0
4090 2.54 0
4091 3.06 0
4092 5.48 0
Mean ± S.E.M. 3.73 ±1.28 0
8 weeks o
/axotomy only 
4020 0.45 0
4021 5.37 0
4094 3.08 0
4093 5.67 0
Mean ± S.E.M. 3.64 ± 1.21 0
235Appendix 10: Nestin mRNA, examined by real-time PCR (copies/10000 copies
GAPDH)
Group Unoperated 1   day 1   week 2 weeks 4 weeks
0.30 0.92 1.54 2.74 6.30
Right DRG 0.28 1.60 0.80 1.38 0.35
0.26 1.35 1.18 2.59 0.66
VT  W l
0.31 0.72 0.76 3.70 4.60
0.25 0.78 0.52 3.01 4.10
Mean 0.28 1.07 0.96 2.68 3.20
SEM 0.01 0.17 0.18 0.38 1.16
0.80 0.33 5.84 0.21
Right DRG 
(NT-3)
0.16 6.86 5.00 12.90
1.69 1.74 4.66 6.87
1.14 3.97 10.34 8.98
1.27 1.98 6.77 4.35
- s iW r ~ ------------------
1.01
0.26 ------U3------ ]
6.52
1.02 ..  2.14  "
..............  <bc, 0.38 0.25 0.40 0.21
Left DRG 
(vehicle)
0.38 0.50 0.42 0.31 0.24
0.26 0.25 0.28 0.56 0.36
0.37 0.37 0.36 0.37 0.36
0.29 0.27 0.18 0.24 0.31
W r ~ — o £ —
0.35
0.04
0.30
0.04
0.38 0.30
0.03
0.42 0.18 0.51 0.27
T r \ n  o 0.36 0.37 0.35 0.38
Jbeil uinaj
(NT-3)
0.33 0.50 0.30 0.25
0.30 0.46 0.41 0.31
0.26 0.37 0.37 0.42
” 1
ean
2M
0.33
0.03
0.38 ........-..- ■  ■
0.06 0.04
0.33
0.03
236Appendix 11: NGF mRNA, examined by real-time PCR (copies/10000 copies GAPDH)
Group Unoperated 1   day 1  week 2 weeks 4 weeks
Right DRG 
(vehicle)
6.06 17.68 8.14 16.41 11.21
2.80 13.17 9.77 7.73 7.34
2.65 15.16 7.24 5.96 6.42
2.20 21.07 9.67 4.33 10.76
4.32 17.73 11.44 11.36 10.13
Mean
SEM
3.61
0.71
16.96
1.34
9.25
0.72
9.16
2.16 .........0 %   ....
Right DRG 
(NT-3)
16.28 9.44 14.97 2.46
6.27 16.68 16.65 21.32
12.96 13.08 15.40 12.26
7.08 18.87 9.23 14.39
13.05 10.98 4.35 4.11
Mean 11.13 13.81 12.12 10.91
SEM 1.92 1.75 3.20 3.46
Left DRG 
(vehicle)
3.96 4.35 5.48 3.55 3.09
3.48 6.01 7.26 3.64 3.28
3.47 2.60 0.80 2.60 1.77
2.90 1.45 2.19 1.39 1.20
2.35 3.46 4.46 4.31
Mean
SEM
. 3.45
aW o.zz
3.35
0.81
.........3„.84_____
1   15
3.13
0.52
2.73
Left DRG 
(NT-3)
3.07 4.05 4.14 2.15
0.80 2.08 5.76 4.57
2.80 4.97 4.14 2.07
1.77 4.80 2.13 5.56
1.36 2.84 1.19 2.32
Mean 1.96 3.48 3.48 3.33
SEM 0.43 0.56 0.81 0.72
237Appendix 12: BDNF mRNA, examined by real-time PCR (copies/10000 copies
GAPDH)
Group Un operated 1   day 1  week 2 weeks 4 weeks
Right DRG 
(vehicle)
141.32 475.69 215.07 304.69 192.84
156.66 592.61 154.56 316.73 240.54
110.05 411.70 250.21 132.57 184.00
163.49 535.05 543.91 188.82 154.07
165.77 1077.07 331.23 125.02 210.78
Mean 147.46
10.28
618.42
118.50
299.00
67.57
213.57
41.21
196.45
14.34
Right DRG 
(NT-3)
1181.70 543.30 423.26 302.17
827.22 1287.38 403.92 280.35
1596.70 847.73 277.75 482.77
542.11 965.11 459.55 200.19
1264.70 1064.60 323.14 376.01
Mean
SEM
1082.49
182.29
941.62
123.02
377.52
33.49
328.30
47.71
Left DRG 
(vehicle)
115.48 286.74 337.00 237.85 209.96
138.64 377.28 256.71 94.70 160.53
130.63 262.12 108.79 145.27 131.13
161.06 188.84 70.02 156.59 156.60
314.96 245.06 156.00 130.79
Mean 136.46 285.99 203.52 158.08 157.80
SEM
....  ...... ..............
9.50 30.97 49.58 22.97 14.44
Left DRG 
(NT-3)
71.67 91.86 165.11 63.89
146.58 81.41 144.04 108.20
143.06 103.90 153.43 49.14
51.44 109.22 104.78 189.59
119.51 153.65 140.20 89.66
Mean
— — — 106.45
19.18
108.01......
12.39
141.51
10.14
100.10
24.59
238Appendix 13: NT-3 mRNA, examined by real-time PCR (copies/10000 copies GAPDH)
Group Unoperated 1  day 1  week 2 weeks 4 weeks
Right DRG 
(vehicle)
14.92 30.57 29.51 22.12 15.90
9.85 19.78 11.93 4.68 8.92
7.39 14.65 8.89 13.25 10.48
9.98 23.46 7.19 7.15 17.88
13.45 19.13 15.62 9.74
SEM
11.12
1.35
22.11
3.35
15.33
4.09
12.57
3.10
12.59
1.80
Right DRG 
(NT-3)
28.32 5.64 11.84 9.88
21.75 8.29 19.00 13.87
24.90 76.55 2.96 10.86
31.32 37.85 16.24 17.38
19.86 40.38 8.00 7.51
SEM
.....- ...................... 25.23
2.09
33.74
12.91
11.61
2.86
11.90 
1.71
Left DRG 
(vehicle)
6.57 13.00 10.22 20.25 13.89
8.34 18.24 8.44 4.11 10.27
14.72 9.21 15.99 12.55 6.23
19.57 10.37 19.25 9.19 15.00
17.24 13.09 11.50 13.62
Mean
SEM
12.30 ---------------------
2.99
13.61
1.80
13.40
1.95
11.52 
2.62 ".60
Left DRG 
(NT-3)
9.11 10.32 3.22 10.79
14.32 5.23 5.89 13.43
15.52 8.28 12.37 6.34
5.92 15.90 15.27 14.38
17.60 16.66 27.73 14.52
Mean 
v-..  _ - ...................... 12.50 
2.16
11.28 ..........1 12.90
4.29
11.89
1.54
239Appendix 14: TrkA mRNA, examined  by real-time PCR (copies/10000 copies GAPDH)
Group Unoperated 1   day 1   week 2 weeks 4 weeks
Right DRG 
(vehicle)
539.57 367.39 180.64 209.15 383.08
458.67 469.45 339.72 332.35 270.42
500.53 297.77 245.76 102.81 208.30
520.59 301.49 315.72 256.64 302.96
485.66 475.73 490.42 250.73 255.19
SEM
501.00
13.96
382.37
38.87
314.45
35.53
230.34
37.57
283.99
29.09
Right DRG 
(NT-3)
445.98 224.45 377.37 320.42
404.57 182.71 321.93 1145.61
164.96 271.64 492.98 1438.5
443.56 242.9 435.98 960.43
431.65 252.14 362.72 943.00
Mean 378.14 234.77 398.20 961.59
SEM 53.80 15.07 29.93 183.41
Left DRG 
(vehicle)
478.75 717.30 280.52 744.74 780.06
546.51 647.69 506.14 426.51 680.99
625.00 551.83 786.26 1107.44 604.03
406.20 862.03 673.92 564.91 729.03
329.03 809.65 1119.22 712.00 791.53
Mean
SEM
477.10
51.79
717.70
55.54
673.21
140.32
711.12
114.15 34.45
Left DRG 
(NT-3)
517.39 482.32 380.42 360.25
229.37 219.82 500.98 220.51
159.82 376.11 419.07 128.12
338.00 408.98 198.35 706.56
357.68 545.00 500.21 294.52
Mean
SEM
320.45
61.06
406.44
55.10
399.81
55.52
341.99
98.99 ..................
240Appendix 15: TrkB mRNA, examined by real-time PCR (copies/10000 copies GAPDH)
Group Unoperated 1   day 1   week 2 weeks 4 weeks
Right DRG 
(vehicle)
4.03 8.54 2.52 2.28 4.22
8.60 3.23 3.8 1.30 4.33
2.63 9.58 3.04 1.08 5.19
3.12 3.39 1.70 0.88 6.56
5.87 8.19 5.34 1.69 5.63
Mean
|  AO
6.59
1.36
3.29
0.62
1.45
0.25
5.19
0.43
Right DRG 
(NT-3)
6.83 3.63 23.05 23.77
2.30 2.06 17.96 21.69
5.34 5.15 6.61 11.48
8.82 4.99 16.01 22.58
7.19 4.67 13.50 15.13
S E M
6.09
1.10
4.10
0.57
15.43
2.70
18.93
2.39
Left DRG 
(vehicle)
3.59 5.27 4.08 5.14 6 .1 0
6.28 2.10 2.35 6.61 10.19
5.24 12.95 2.66 6.91 10.97
5.50 4.73 2.93 6.54 11.20
1.70 2.56 8.23 2.27
Mean
~ ~   O'T'TV A  ~ ~ S KM
■
c   1 9
-------203-------
2 91 
0 30
6.69 8.15
Left DRG 
(NT-3)
14.83 7.31 9.79 5.64
12.33 21.71 8.79 21.69
2.81 12.85 9.23 26.53
8.99 15.02 24.82 14.41
10.32 18.07 35.72 21.03
S
9.85  14.98
5.43
17 85
241Appendix 16: TrkC mRNA, examined by real-time PCR (copies/10000 copies GAPDH)
Group Unoperate
d
1   day 1  week 2 weeks 4 weeks
Right DRG 
(vehicle)
126.61 91.29 526.69 474.48 181.56
61.53 473.75 388.30 445.88 137.95
66.68 586.65 141.63 372.58 127.41
108.32 536.28 677.51 327.72 260.72
106.56 1031.52 155.33 465.92 207.1
Mean
1270
543.90
149.90
377.89
104.25
417.32
28.70
182.95
24.23
Right DRG 
(NT-3)
116.97 252.99 260.96 390.83
32.07 147.17 348.66 355.24
149.30 249.76 256.95 257.20
59.72 126.85 364.95 142.76
116.15 227.45 336.33 338.35
Mean
SEM
94.84
21.31
200.84
26.62
313.57
22.76
296.88
44.32
Left DRG 
(vehicle)
109.91 305.42 390.20 154.24 173.10
51.51 389.30 300.42 266.44 266.59
90.46 358.42 127.65 241.77 197.87
116.06 290.45 182.49 39.41 249.35
186.96 103.39 210.83 212.31
.....
91  99 
14.55
306.28
34.71
177.16 182.54
40.40
219.84
i n   a   a   1  /. U U
Left DRG 
(NT-3)
266.90 65.59 329.10 185.18
217.90 406.00 270.75 383.65
106.09 348.38 93.40 403.62
68.16 241.68 187.59 253.57
271.63 304.97 175.41 245.98
SEM
... 186.13
41.93
273.32
rn  a  n 58.48
211.25
40.72
294.40
42.33
242Appendix 17: p75N TR mRNA, examined by real-time PCR (copies/10000 copies
GAPDH)
Group Unoperated 1   day 1  week 2 weeks 4 weeks
Right DRG 
(vehicle)
181.20 7.67 8.96 7.25 144.32
351.57 11.95 12.14 6.80 229.96
45.35 18.45 13.16 13.31 214.70
96.22 23.97 16.69 194.88 59.98
235.70 19.98 10.42 78.79 219.96
Mean
SEM
182.00
53.70
16.40
2.92
12.28
1.32
60.20
36.29
173.78
32.23
Right DRG 
(NT-3)
6.45 29.62 88.64 4.39
6.48 8.83 108.51 208.12
6.87 22.95 40.06 446.66
24.58 30.45 99.40 80.04
15.58 27.97 58.12 235.61
A ivicdii 11.99
3.60 4.00
78.94 
12 91 795 J936
Left DRG 
(vehicle)
182.01 7.49 ........3.5 1 ..........j 103.45 180.07
223.54 3.24 3.20 273.42 54.03
138.14 13.86 10.00 96.87 388.01
46.50 8.34 8.97 10.38 116.97
160.46 4.58 5.53 150.25 3.38
Mean 150.13 7.50 6.24 126.87 148.49
SEM 29.49 1.84 1.39 43.04 66.84
Left DRG 
(NT-3)
461.72 442.51 332.77 296.64
288.27 783.95 152.47 420.63
2.47 473.71 483.79 900.00
344.57 521.67 816.58 499.24
238.82 377.62 439.62 368.94
Mean
SEM 70.03
'  ,.... 445r°4  ....
109.03
1
1
243Appendix 18: Genes, grouped according to functional activity, whose expression was
increased following sciatic nerve axotomy, compared to unoperated animal.
Group Gene name Accession number 
(GenBank)
Fold change 
(Mean ± SD)
Signal
transduction and 
regulation gene 
expression
Mothers against 
dpp  1   homolog 
(Mad 1)
U66478 4.50 + 2.15
Interferon-gamma 
inducing factor 
isoform alpha 
precursor (IGIF)
U77777 3.44+1.01
VGF M74223 3.44+ 1.41
Immediate-early 
serum-responsive 
JE gene (MCP-1)
X I7053 2.82 + 0.29
Cytosolic retinol- 
binding protein 
(CRBP)
Ml 9257 1.88 + 0.67
Transferrin D38380 1.70 + 0.26
-
Guanine nucleotide 
binding protein 
beta  1   subunit
AF022083 1.57 + 0.68
Microtubule 
associated protein 
2c (MAP2c)
X I7682 1.56 + 0.16
Janus protein 
tyrosine kinase 1, 
JAK1
AJ000556 1.55 + 0.30
G protein betal 
subunit (rGbl)
U88324 1.55+0.46
Ras GTPase- 
activating protein
D30734 1.52 + 0.30
Pain-related genes
Neuropeptide Y M15880 54.53 + 18.61
Galanin J03624 25.79 + 7.51
Corticotropin 
releasing factor 
(CRF)
M54987 1.92 + 0.74
P2X2-3 receptor 
(P2X2)
AF020756 1.51 ±0.31
Receptor and
244membrane protein
Peripheral-type 
benzodiazepine 
receptor (PKBS)
J05122 4.31 ±0.67
MRC OX-45 
surface antigen
X13016 2.19 ±1.98
Neuronal high 
affinity glutamate 
transporter
D63772 2.06 ± 0.86
Glutamate/aspartat 
e transporter 
protein
X63744 1.95 ±0.29
GABA-A receptor 
alpha-5 subunit
X51992 1.95 ±0.62
Growth-
associated protein 
and growth 
factors
GAP-43 gene L21192 2.40 ±0.56
Basic fibroblast 
growth factor
X07285 2.00 ±0.55
Neurotrophin-3 M34643 1.97 ±0.51
Brain-derived 
neurotrophic factor 
(BDNF)
S76758 1.65 ±0.42
Insulin-like growth 
factor binding 
protein (IGFBP-6)
M69055 1.63 ±0.48
Insulin-like growth 
factor II
X17012 1.57 ±0.68
Ion transport
Dihydropyridine- 
sesitive L-type 
calcium channel 
alpha-2 subunit 
(CCHL2A) gene
M86621 5.19 ± 1.98
Brain sodium 
channel III
Y00766 1.98 ±0.73
Neuronatin alpha U08290 1.93 ±0.44
Neuron specific 
calcium-binding 
protein hippocalcin
D 12573 1.87 ± 1.23
Secreted and 
extracellular 
molecules
245Synaptic vesicle 
protein (SV2)
L05435 2.28 ± 1.14
Synaptotagmin IV 
homolog
U14398 1.73 ±0.47
Syntax in B M95735 1.53 ±0.47
Synaptotagmin 
associated 35kDa 
protein
D 12519 1.52 ±0.28
Cytoskeleton
Glial fibrillary 
acidic protein alpha 
(GFAP) gene
AF028784 3.45 ±1.41
Microtubule- 
associated protein 
IB
U52950 2.94 ±2.83
Gene encoding 
cytoplasmic beta- 
actin
1.95 ± 1.20
RBI09 (brain 
specific protein)
D26154 1.73 ±0.56
Mu-calpain large 
subunit (els 1)
U53858 1.45 ±0.69
Apoptosis
Calmodulin- 
dependent protein 
kinase II-delta
J05072 2.27 ± 1.13
Others
Heat shock protein 
(Hsp27)
M86389 2.97 ± 0.65
Monoamine 
oxidase A
S45812 2.68 ±0.21
Manganese-
containing
superoxide
dismutase
(MnSoD)
Y00497 2.43 ±0.78
A rat novel protein 
which is expressed 
with nerve injury
E l2625 1.70 ±0.52
Tissue-type 
plasminogen 
activator (t-PA)
M23697 1.65 ±0.63
Neural adhesion 
molecule F3
D38492 1.55 ±0.47
EST
Rc  AI101255 2.63 ±0.96
246EST210544
rc  A ll05223 
EST214512
2.45 ± 0.76
rc  AI237836 
EST234398
2.17 ±0.98
rc_AA900476 EST 2.14 ±0.56
rc  AA894330 
EST198133
2.12 ±0.86
rc  AA892559 
EST196362
1.98 ± 1.24
rc_AA925248 EST 1.97 ±0.93
rc  AI008639 
EST203090
1.82 ±0.76
rc  A ll76658 
EST220250
1.76 ±0.41
rc  AI232379 
EST229067
1.75 ±0.52
rc  AA892801 
EST 196604
1.70 ±0.47
rc_AI044610 EST 1.68 ±0.94
rc  AI171319 
EST217274
1.61 ±0.49
rc  AA817892 EST 1.59 ± 1.04
rc  AI009268 
EST203719
1.58 ±0.05
rc  AA998683 EST 1.57 ±0.37
rc  A ll45494 EST 1.55 ±0.87
rc  AI 145494 EST 1.54 ±0.65
rc  AA925495 EST 1.54 ± 0.18
rc  AA892814 
EST 196617
1.54 ±0.83
rc  AI029920 EST  1 1.54 ±0.46
rc  AI009405  ^  
EST203856
1.51 ±0.66
rc  AI072770 EST 1.51  ±0.51
247Appendix 19: Genes, grouped according to functional activity, whose expression was
decreased following sciatic nerve axotomy, compared to unoperated animal.
Group Gene name Accession number 
(GenBank)
Fold change 
(Mean ± SD)
Signal
transduction and 
regulation gene 
expression
Noggin U31203 -1.89 ±0.26
GTP-binding 
protein (G-alpha-0)
M17526 -1.78 ±0.23
Phosphodiesterase I D28560 -1.71 ±0.35
Presenilin-2 X99267 -1.54 ± 0.15
Ca2+/calmodul in­
dependent protein 
kinase IV kinase 
isoform
S83194 -1.51 ±0.31
Pain-related genes
Beta-tachykinin M15191 -2.03 ± 0.73
Beta-type 
calcitonin gene- 
related peptide 
(CGRP)
Ml 1596 -1.80 ±0.32
RET ligand 2 
(RETL2)(GDNFR)
U97143 -1.79 ± 0.51
substance P 
precursor
X56306 -1.60 ± 0.17
Somatostatin-14 K02248 -1.60 ±0.39
Nicotinic 
acetylcholine 
receptor alpha 3 
subunit
L31621 -1.57 ±0.31
Neuronal nicotinic 
acetylcholine 
receptor subunit 
beta4
U42976 -1.54 ± 0.13
Somatostatin M25890 -1.52 ±0.23
Receptor and 
membrane protein
Glutamate receptor 
subunit 5-2 
(GluR5-2)
M83561 -2.13 ±0.45
Neural membrane 
protein 35
AF044201 -1.86 ±0.62
248ET-B endothelin 
receptor
X57764 -1.83 ±0.79
Fast nerve growth 
factor receptor 
(p75NTR)
X05137 -1.69 ±0.12
Transferrin
receptor
M58040 -1.65 ±0.26
Meotropic 
glutamate receptor 
(GLUR4)
M90518 -1.63 ±0.31
GABA-B receptor 
gb2
Af058795 -1.60 ±0.34
Ion transport
Potassium channel, 
alpha subunit 
(Kv9.3)
Y17607 -3.81  ±0.78
CLC-5 chloride 
channel
Z56277 -2.62 ± 0.92
Voltage-gated Na 
channel alpha 
subunit NaN
AF059030 -2.48 ± 0.64
Potassium channel 
(Kv2.2; CDRK)
M77482 -2.16 ±0.38
Voltage-gated 
sodium channel 
(SNS)
X92184 -2.00 ± 0.89
Na,K-ATPase 
alpha-1  subunit
M28647 -1.91 ±0.31
5HT3 receptor 
subunit
U01227 -1.85 ±0.32
5HT3 receptor U59672 -1.85 ±0.66
Sodium channel I M22253 -1.77 ±0.46
Potassium channel, 
alpha subunit 
(Kv9.1)
Y 17606 -1.71 ±0.35
Na+,K+-ATPase 
beta-3 subunit
D84450 -1.55 ±0.09
Putative chloride 
channel
Z36944 -1.55 ±0.26
Putative potassium 
channel TWIK
AF022819 -1.54 ±0.29
S100 alpha S68809 -1.52 ±0.23
Potassium channel 
protein (3145 bp)
X62840 -1.51  ±0.12
Secreted and
249extracellular
molecules
SNAP-25A 
synaptosomal- 
associated protein 
25
AB003991 -1.73 ±0.72
Ca2+/calmodulin- 
dependent protein 
kinase II isoform 
gamma-b 
(CAMK2)
S71570 -1.61 ±0.14
Rat ras-related 
mRNA rab3
X06889 -1.55 ±0.41
Cytoskeleton
Neuro filament 
protein- light chain 
(NF-L) mRNA
M25638 -2.12 ± 0.15
Microtubule- 
associated protein 
1A (MAPIA)
M83196 -1.55 ±0.29
Heavy
neurofilament 
polypeptide NF-H 
C-terminus
X13804 -1.52 ±0.48
Others
Neurodegeneration 
associated protein 1
D32249 -1.53 ±0.33
EST
Rc  AI230211  
EST226906s
-2.53 ± 0.60
Rc  AI072060 EST -2.38 ±0.61
Rc  AI228113 
EST224808
-2.10 ±0.76
Rc  AA924772 
EST
-1.81 ±0.36
Rc  AI013765 
EST208440
-1.74 ±0.54
Rc  A ll36564 EST -1.54 ±0.24
Rc  AI059948 EST -1.52 ±0.26
250Appendix 20: Genes, grouped according to functional activity, whose expression was 
increased following sciatic nerve axotomy and NT-3 treatment compared to vehicle 
treatment.
Group Gene name Accession number 
(GenBank)
Fold change 
(Mean ± SD)
Signal
transduction and 
regulation gene 
expression
Phosphoinositide 3- 
kinase regulatory 
subunit p85alpha
U50412 2.99 ± 0.44
Neuron-specific
cortexin
L15011 1.97 ±0.74
CAMP response 
element binding 
protein (CREB)
X14788 1.67 ±0.32
Mothers against 
dpp  1   homolog 
(Mad 1)
U66478 1.52 ±0.47
GTP-binding 
protein (G-alpha-0)
M17526 1.50 ±0.40
Pain-related genes
'
Major hippocampal 
somatostatin 
receptor (SSTR4)
U04738 1.69 ±0.41
Calcitonin 
receptor-like 
receptor (CRLR)
L27487 1.67 ±0.32
Muscarinic 
receptor m2
ABO 17655 1.67 ±0.49
Receptor and 
membrane protein
AMPA-selective 
glutamate receptor- 
A
S56679 1.92 ± 1.23
ET-B endothelin 
receptor
X57764 1.50 ±0.36
Chemokine CX3C AF030358 1.50 ±0.26
Growth-
associated protein 
and growth 
factors
Fibroblast growth 
factor (FGF-18)
AB004638 1.72 ±0.90
251Ion transport
Potassium channel M77482 1.73 ±0.30
Calcium channel 
alpha-IS subunit 
(ROB1)
U31816 1.51 ±0.78
Secreted and 
extracellular 
molecules
Syntax in 4 L20821 1.71  ± 1.03
Cytoskeleton
Cytoplasmic beta- 
actin
1.67 ±0.34
Glial fibrillary 
acidic protein alpha 
(GFAP)
AF028784 1.54 ±0.40
Others
Phosphoneuroprote 
in  14
D17764 1.57 ±0.29
Calnexin L18889 1.55 ±0.25
Olfactory receptor­
like protein (SCR 
D-8)
AF034896 1.55 ± 0.51
EST
Rc  A ll46214 EST 1.94 ±0.74
Rc  AA893870 
EST 197673
1.88 ± 0.87
Rc  A ll03671 
EST212960
1.72 ±0.80
Rc  AI030286 EST 1.70 ±0.54
Rc  AI008865 
EST203316
1.61 ±0.49
Rc  AI029920 EST 1.56 ±0.29
Rc  AI228113 
EST224808
1.53 ±0.83
Rc  AA900476 
EST
1.51 ±0.24
Rc  AI232379 
EST229067
1.50 ±0.26
252Appendix 21: Genes, grouped according to functional activity, whose expression was 
decreased following sciatic nerve axotomy and NT-3 treatment compared to vehicle 
treatment.
Group Gene name Accession number 
(GenBank)
Fold change 
(Mean ± SD)
Signal
transduction and 
regulation gene 
expression
Rat immediate- 
early serum- 
responsive JE gene 
(MCP-1)
X I7053 -1.58 ±0.16
G protein betal 
subunit (rGbl)
U88324 -1.58 ± 0.12
Receptor and 
membrane protein
Beta-arrestin 2 M91590 -1.50 ±0.26
Ion transport
Sodium/potassium 
ATPase alpha-1  
subunit truncated 
iso form
M74494 -1.95 ±0.31
V o ltage-dependent 
sodium channel 
alpha subunit [SS1  - 
SS2 segment, 
transmembrane 
segments IVS3- 
IVS6]
S75991 -1.56 ±0.57
Secreted and 
extracellular 
molecules
SNAP-25B AB003992 -1.68 ±0.58
Synaptojanin AJ006855 -1.59 ±0.40
Rat ras-related 
mRNA rab3
X06889 -1.58 ±0.46
Synapsin la M27812 -1.54 ±0.37
SNAP-25A AB003991 -1.53 ±0.53
Cytoskeleton
Microtubule- 
associated protein 
IB
U52950 -2.53 ±0.83
Others
253Tissue-type 
plasminogen 
activator (t-PA)
M23697 -1.71 ±0.50
A rat novel protein 
which is expressed 
with nerve  injury
E l2625 -1.51 ±0.44
EST
Rc  AA892801 
EST 196604
-1.92 ± 1.01
Rc  AA943304 
EST198803
-1.50 ± 0.16
254Appendix 22: Real-time PCR confirmation of microarray data.
Unoperated 2-week axotomy + 
vehicle
2-week axotomy + 
NT-3
Neurofllament-
L
8599.21744 522.1465077 217.2373692
9162.292448 1954.931973 2481.935924
6467.584369 3382.137628 3506.772908
1426.287051 4670.017741 2885.790885
4130.503145 3837.445573
S.E.M. 1760 881367
2931.947399
755.7048071
2585.836532
637.4040691
Neuropeptide Y
8.747903857 5438.67121 4524.615583
81.46759507 7827.380952 7791.411043
35.53499598 16442.16691 9290.836653
46.81172291 2933.175636 9461.662198
38.33658346 5463.050314 3926.70537
Mean
S.E.M.
42.17976026
11.7081189
7620.889005
2337.205401
6999.04617
1172.746949
5HT-3R
56.7803242 58.13458262 31.52345264
185.8596679 28.7414966 66.13496933
107.4818986 57.86237189 104.1434263
178.9076377 79.24305145 47.20643432
114.5865835 29.5990566 20.86357039
Mean
S.E.M.
128.7232224
24.09343058
50.71611183
9.614319429
53.97437059
14.68160087
P 7 5 n t r
181.20 7.25 88.64
351.57 6.80 108.51
45.35 13.31 40.06
96.22 194.88 99.40
235.70 78.79 58.12
S.E.M.
182.00
53.70 36.29
78.94
12.91
Heat shock 
protein 70
21.92286193 40.58773424 25.34177542
41.31203931 44.43027211 25.28289025
35.67176187 91.06881406 55.70517928
47.06927176 24.95564755 68.86863271
25.85803432 23.66352201 24.81132075
Mean
S.E.M.
34.36679384
4.682642156 12.24567756
40.00195968
9.333283012
Peripheral-type
benzodiazepine
receptor
41.74399106 280.9625213 241.2197958
176.9683985 355.4421769 304.2944785
96.05792438 445.9736457 245.2589641
54.55150977 168.361916 417.2654155
76.09204368 268.0031447 153.0478955
Mean 89.08277348 303.7486809 272.2173099
255^ .h T  (V j T 23.84812715 46.38247873 43.56423149
Glutamate 
receptor subnit 
5-2
32.2861934 21.61839864 4.155059133
31.96572041 16.59651361 3.646216769
7.682220434 2.045095168 7.688446215
26.67184725 5.441159077 22.69168901
18.66029641 25.38522013 12.95355588
S.E.M.
23.45325558
4.650484854
14.21727732
4.529583746
10.2269934
3.531444522
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